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Dendritic cells: the sentinels of the immune system.
Our immune system consists of cells belonging to the innate immune system and the 
adaptive immune system. Dendritic cells (DCs) are a family of antigen presenting cells 
(APCs) that bridge these two systems1. They scan the internal milieu for self and foreign 
antigens and present these to T cells of the adaptive immune system through a process 
termed ‘antigen presentation’ (Figure 1). T cells express a T cell receptor (TCR) that can 
specifically recognize a particular antigen in the form of a short peptide bound to major 
histocompatibility complex (MHC) molecules on APCs. Whereas CD8+ T cells recognize 
antigens bound to MHC class I molecules, MHC-II is used to present antigens to CD4+ T 
cells (Figure 1). While exogenous antigens, in contrast to intracellular antigens, are nor-
mally presented to CD4+ T cells, cross-presentation enables presentation of exogenous 
antigens onto MHC-I and thereby activation of CD8+ T cells2 (Figure 2).
ready, set, go: 3 signals necessary for complete T cell activation.
Antigen presentation resulting in TCR stimulation, is a first signal, but it does not auto-
matically result in activation of the receiving T cell. Three signals are necessary in total 
to achieve full T cell activation5. Based on the expressed co-stimulatory molecules or 
co-inhibitory molecules (Figure 3) on the surface of DCs, an activating or inhibiting 
response is mediated6, 7, which is known as the second signal. Besides engagement of 
TCR, the signal via CD28 on T cells which binds CD86 on DCs is crucial for T cells, because 
without this interaction a T cell will become anergic8. Positive stimulation can further be 
induced by inducible costimulator (ICOS) that binds ICOS-ligand (ICOS-L) (in Figure 3 as 
‘B7c’)9. Inhibitory signals can be mediated via PD-1 and CTLA-4, which can bind PD-L1/
PD-L2 or CD80/CD86, respectively. CTLA-4 binds CD80/CD86 with greater affinity and 
avidity than CD28, thus enabling it to outcompete CD28 for its ligands. Cytokines, either 
produced by DCs or already available in the milieu, are the third signal, and can further 
define the T cell response e.g. differentiating them into T helper cell subsets or unlocking 
their full potential.
Dc subsets
Four types of DCs can be distinguished: Conventional type 1 or 2 DCs (cDC1s and 
cDC2s), plasmacytoid DCs (pDCs)6 and inflammatory monocyte derived DCs (Mo-DCs)11. 
The functions of DCs are different during steady state or during inflammation. In steady 
state, cDC1s and cDC2s are primarily involved in peripheral tolerance as they can pres-
ent tissue-associated self-antigens and effectively induce regulatory T cells (Tregs) and 
CD4+ and CD8+ T cell tolerance2, 12-14. During activation, however, primarily (but not 
exclusively) CD8+ T cells are activated by cDC1s, and CD4+ T cells by cDC2s14-16. pDCs can 
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also activate both T cell types, but in addition are known for their high type 1 interferon 
signature17. During inflammation, Mo-DCs arise from a monocyte precursor and their 
functions overlap with dendritic cells11. The most used markers to identify DC subsets 
are listed in Table 1.
TAP1
MHC c lass  I  MHC c lass  I I  
Figure 1: Antigen presentation to cD8+ and cD4+ T cells using mHc-I and mHc-II, respectively (a) Vi-
rus antigens or tumor antigens are primarily intracellular antigens and are commonly presented on major 
histocompatibility complex (MHC) class I complex molecules. Proteasomes are large proteins that degrade 
proteins, such as viral or tumor antigens into smaller peptides. Transporter associated with antigen pro-
cessing (TAP) 1 and TAP2, carry antigen peptides into the endoplasmic reticulum (ER). Here, antigens are 
placed onto the presenting groove of MHC-I, which then leave the ER (and are transported via Golgi/secre-
tory vesicles; not shown in figure) to the surface of the cell to present antigen to CD8+ T cells on their T cell 
receptor (TCR). (b) Extracellular antigens, such as bacteria, are commonly presented on MHC-II molecules. 
The extracellular antigens are processed by endolysosomal enzymes into peptides. The presenting groove 
of MHC-II first contains Class II-associated invariant chain peptide (CLIP), which is derived from MHC class II-
associated invariant chain (Ii). CLIP is displaced by the bacterial peptide and the MHC-II molecule is brought 
to the surface of the cell in order to present antigens to CD4+ T cells. Adapted from Kobayashi et al3.
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effector adaptive immune cells in autoimmunity
DCs are central orchestrators of the immune response: they activate T cells and - besides 
antigen presentation and co-stimulation - produce cytokines to direct naïve T cells into 
a particular differentiation pathway (Figure 4). T helper subsets produce different cyto-
kines (Figure 4) and thus have different functions. For a long time, the T helper 1 cell (Th1 
cell) and Th2 cell paradigm dominated our understanding of (auto)immune diseases 
versus allergic diseases, respectively19, 20. The Th1 subset is important in host defenses to 
Figure 2: Processing exogenous antigens onto mHc-I molecules within antigen presenting cells in 
order to cross-present.
Exogenous antigens can be placed onto MHC-I molecules via 2 pathways: the cytosolic pathway or the 
vacuolar pathway. Within the cytosolic pathway (left), phagocytosed exogenous antigens are processed 
in an engulfed vesicle called phagosome, then released into cytosol where they can further be degraded 
by proteasomes. After this, they can be re-transported into the phagosomes, where they can be loaded on 
available MHC-I molecules and expressed on the cell surface. Alternatively, anitgens can be transported 
into the ER and loaded on MHC-I molecules there. The ER contains the transporter protein TAP, which is 
located to phagosomes with the help of other proteins such as the SNARE protein SEC22B and Syntaxin 4. 
ER-Golgi intermediate compartment (ERGIC) is where SEC22B interacts with Syntaxin 4. The vacuolar path-
way (right) allows phagosome-degraded exogenous antigens to be directly loaded on MHC-I molecules 
and then go to the cell surface for antigen presentation. From Joffre et al4
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Figure 3: co-stimulatory and co-inhibitory molecules set thresholds for T cell activation
A selection of common co-stimulatory and co-inhibitory molecules are depicted, that results in positive 
(+ve) or inhibitory (-ve) effects on T cell activation. The most important co-stimulation for activation is CD28 
interaction on T cells with CD80 or CD86 on APCs. Classic interactions are bold arrows, while dashed arrows 
















Figure 4: Differentiation of helper T cell (Th) subsets.. Naïve T cells can differentiate into various T helper 
cell (Th) subsets under influence of differentiating cytokines, that are shown adjacent to the dashed arrows. 
Responsible key transcription factors (green) and primary cytokines are listed per Th cell subset on the right 
side. Adapted from Zou et al Nat Rev Immunol 201036
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intracellular bacteria and is involved in autoimmune diseases such as multiple sclerosis 
and diabetes mellitus. Their development is dependent on transcription factor T-bet, 
and can be induced by cytokine IL-1221. The Th2 subset, developmentally dependent 
on transcription factor GATA binding protein 3 (GATA3) and induced by cytokine IL-4, 
mediates protection against helminth infection21, but also coordinates the characteristic 
eosinophilic, basophilic and mast cell response in diseases such as allergic asthma22.
This Th1/Th2 model was challenged when in the early 2000’s the Th17 cell was 
discovered23. The Th17 cell is involved in various autoimmune disorders, ranging from 
psoriasis, inflammatory bowel disease (IBD), rheumatoid arthritis (RA), multiple sclerosis 
(MS) to systemic lupus erythematosus (SLE)24, 25. In order of importance, the cytokines 
IL-6, IL-1β and TGF-β are relevant for differentiation of naïve T cells into Th17 cells26, 
and rely on transcription factor RAR-related orphan receptor gamma (RORγt) for their 
development27. Expansion and survival of Th17 cells are maintained by IL-2328.
Suppression of excessive immune responses and autoimmune reactions are performed 
by Tregs, that can be induced from naïve T cells by TGF-β and rely on transcription factor 
Forkhead box P3 (FoxP3) for their development29. Initially, it was thought that only the 
Th2 subset was important for humoral immunity, until the follicular T helper (Tfh) cell 
was discovered. It is primarily the Tfh cell that support germinal center B cell responses 
and plasma cell differentiation30. During certain conditions, such as helminth infections, 
Tfh cells can derive from Th2 cells31, or the other way around, as has been reported in 
HDM-driven allergic airway inflammation32. This might also be cellular plasticity, which 
is known to occur for multiple Th-cell subsets33, 34. Plasma cells can produce autoreactive 
antibodies that play a key role in humoral autoimmune diseases such as SLE35.
Table 1. Overview of cell surface markers to identify DC subsets in mice.
markers *)
















*) Based on markers listed by Gardner et al18
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control of the immune system
Homeostasis of the immune system is of crucial importance. During times of foreign 
pathogens, rapid activation of the immune system is necessary for the extermination of 
antigens. However, immune cell activation is strictly kept in check, as exaggerated in-
nate and adaptive immune responses can tip the immune system towards autoimmune 
diseases. The nuclear factor-κB (NF-κB) signaling pathway is a well-studied molecular 
pathway that promotes cellular activation. The end products of the NF-κB pathway 
result in a pro-inflammatory milieu, differentiation and cell survival37. It also results 
in transcription of a key regulatory zinc finger (de)ubiquitinating enzyme A20/tumor 
necrosis factor α-induced protein 3 (TNFAIP3), that is known to contribute largely to the 
inhibition of NF-κB signaling38, thereby bringing a balanced halt to inflammation.
A20/TNFAIP3: ubiquitin-modifying enzyme
A20/Tnfaip3 is a ring finger ubiquitin-modifying enzyme, with a dual function being 
ubiquitination and de-ubiquitination38. In the TNFα signaling pathway both functions 
are utilized to inhibit NF-kB signaling. Briefly, A20/TNFAIP3 removes an activating type 
of polyubiquitin, (K63–polyubiquitin) from accessory proteins such as RIP1 and NEMO, 
thereby inhibiting signals to downstream proteins38. Furthermore, A20/TNFAIP3 adds an 
inhibitory type of polyubiquitin (K48-polyubiquitin), to these accessory proteins includ-
ing RIP1, thereby targeting them for degradation by proteasomes38.
A20/TNFAIP3 in humans
TNFAIP3 is one of the few genes that has been linked by genome-wide association stud-
ies (GWAS) to multiple immune diseases39, 40. Single nucleotide polymorphisms (SNPs) in 
the vicinity of the TNFAIP3 gene are associated to characteristic autoimmune diseases 
such as SLE, RA and psoriasis40. Over the years, the list of TNFAIP3 gene SNP-associated 
clinical diseases keeps expanding, with recent additions of autoimmune hepatitis (AIH), 
Primary Biliary Cirrhosis (PBC) and colitis ulcerosa (CU)41-43.
A20/Tnfaip3 in mouse models
The identification of various associations of the A20/Tnfaip3 gene with diseases has 
spiked interest of immunologists to study the importance of this gene in cell lines 
and mouse models. A20/Tnfaip3 -/- mice develop severe multiorgan inflammation and 
cachexia, resulting in early death44. Cre-LoxP recombination bioengineering made it 
possible to study cell-specific effects of A20/Tnfaip3 gene deletion45. As an example, 
A20/Tnfaip3 deletion in myeloid cells, using LysM-cre, resulted in a spontaneous auto-
inflammatory disease, characterized by paw inflammation46. Furthermore, A20/Tnfaip3 
deletion in B cells using a CD19-cre resulted in a model that resembles SLE47.
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Another key publication in the field was by Kool et al, who utilized a DC-specific cre 
(CD11c-cre) to ablate A20/Tnfaip348. Aged Tnfaip3CD11c-KO mice had activated DCs and de-
veloped systemic T and B cell activation. In addition, germinal center B cells, plasma cells 
and autoantibodies were produced, resulting in an autoimmune phenotype resembling 
human SLE. Another laboratory used a similar DC-specific A20/Tnfaip3 deletion strategy, 
but this resulted in an IBD resembling phenotype49, indicating that most likely the local 
microbiome may influence the phenotype.
AImS AND oUTlINe oF THIS THeSIS
The paper by Kool et al.48 has been the starting point for several chapters in this thesis, 
which we will touch upon later in our aims. In chapter 2 we summarize the latest knowl-
edge on A20 as a protein, its molecular function, SNPs associated to human disease, as 
well as all immune cell-specific conditional deletions of A20/Tnfaip3 known to date.
Deletion of the A20/Tnfaip3 gene in all DCs resulted in an SLE48 or IBD phenotype49, but 
it remained unknown which of the DC subsets is mainly responsible for the autoimmune 
phenotype. To address this issue, we investigated the phenotypic outcome of targeted 
deletion of A20/Tnfaip3 in more specific DC subsets. Study of DC ontogeny has revealed 
several specific markers, such as DNGR1/Clec9a, which are primarily present on cDC1s50. 
In chapter 3, we studied the effect of loss of A20/Tnfaip3 on the activation status of cDCs 
and moDCs in a Tnfaip3DNGR1-KO mouse model, in which the Tnfaip3 was mainly deleted in 
cDC1s. We further analyzed the systemic effects on T cells and B cells that were associ-
ated with the activation of these cDCs/moDCs, and explored their immunohistopathol-
ogy at the age of 31 weeks. Interestingly, while cDC1s were primarily targeted by A20/
Tnfaip3 deletion, cytotoxic CD8+ T cell activation was hardly altered and, unexpectedly, 
mostly CD4+ T cells and B cells were activated.
The myeloid cell-specific, LysM-cre-driven model of A20/Tnfaip3 deletion is known to 
result in an autoinflammatory phenotype with paw inflammation in aged mice46, 51. In 
chapter 4 we took a step outside of the field of autoimmunity and studied a house-
dust mite (HDM)-driven airway inflammation model in Tnfaip3LysM-KO mice. These mice 
are known to develop a Th17-associated neutrophilic airway inflammation, rather than 
a Th2-associated eosinophilic airway inflammation52. Since neutrophilic recruitment is 
largely induced by IL-1753, we wondered whether IL-17RA-signaling was essential for 
neutrophilic airway inflammation. To determine this, we crossed Tnfaip3LysM-KO mice onto 
an IL-17RA-signaling knockout background and stimulated the airways with HDM and 
assessed the responses.
It occurred to us during the study of aged Tnfaip3CD11c-KO mice, that develop an SLE 
phenotype, that the numbers of B cells were vastly reduced in spleens, pointing to 
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the possibility that a B cell lineage defect occurred in the bone marrow, resulting in 
disrupted generation of immature and mature B cell populations. In chapter 5, we 
therefore examined B cell development in the bone marrow of both young 6-week-old 
mice and 24-week-old Tnfaip3CD11c-KO mice. We further aimed to investigate whether 
in Tnfaip3CD11c-KO mice mature B cells that were released into the periphery were more 
responsive and thus more prone to B cell activation or immunoglobulin production than 
those in wild-type control mice.
B cell activation that is associated with germinal center reactions and plasma cell 
formation is dependent on help from T cells. In the case of autoimmunity, activated DCs 
might overly activate T cells, which can positively select autoreactive B cells in patho-
genic germinal center reactions54. Activated T cells express CD40L which binds CD40 
on B cells and thereby provides proliferation and survival signals besides those initiated 
by B cell receptor (BCR) engagement55. Apart from this T cell-dependent response, a T 
cell-independent activation of B cells by APCs is also known56, 57. A20/Tnfaip3-deficient 
DCs were known to activate B cells independently of T cell help in vitro48. In chapter 6 
we addressed the question whether A20/Tnfaip3-deficient DCs also had the capacity to 
directly activate B cells in vivo and thereby engaged these cells in autoimmune pathol-
ogy. To this end, we crossed Tnfaip3CD11c-KO mice onto a CD40lg deficient background, 
thereby abrogating T-B cell communication. We also examined whether autoreactive 
immunoglobulins and kidney remodeling were altered.
It has been demonstrated that stimulated A20/Tnfaip3-deficient DCs in vitro have the 
capacity of highly inducing IL-17 in T cell co-cultures, likely due to elevated production 
of IL-6 and IL-2348, both of which are beneficial for their survival. Given the importance 
of Th17 cells in autoimmune diseases including SLE58, in chapter 7 we examined 
whether IL-23 was dispensable for Th17 homeostasis in vivo and cytokine production 
in the Tnfaip3CD11c-KO SLE mouse model. To achieve this, we crossed Tnfaip3CD11c-KO mice 
to mice lacking IL-23. Since Th17 cells can stimulate B cells towards class-switched 
immunoglobulin-producing plasma cells59, we further examined autoantibody produc-
tion and kidney remodeling at the age of 24-weeks.
Finally, implications of our work and potential future directions in the field of A20/
Tnfaip3 and (auto)immunity are described in chapter 8.
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ABSTrAcT
Immune cell activation is a stringently regulated process, as exaggerated innate and 
adaptive immune responses can lead to autoinflammatory and autoimmune diseases. 
Perhaps the best-characterized molecular pathway promoting cell activation is the 
nuclear factor-κB (NF-κB) signalling pathway. Stimulation of this pathway leads to tran-
scription of numerous pro-inflammatory and cell-survival genes. Several mechanisms 
tightly control NF-κB activity, including the key regulatory zinc-finger (de)ubiquitinating 
enzyme A20/TNFAIP3. Single nucleotide polymorphisms (SNPs) in the vicinity of the 
TNFAIP3 gene are associated with a spectrum of chronic systemic inflammatory diseases, 
indicative of its clinical relevance. Mice harboring targeted cell-specific deletions of the 
Tnfaip3 gene in innate immune cells such as macrophages spontaneously develop auto-
inflammatory disease. When immune cells involved in the adaptive immune response, 
such as dendritic cells or B-cells, are targeted for A20/TNFAIP3 deletion, mice develop 
spontaneous inflammation that resembles human autoimmune disease. Therefore, 
more knowledge on A20/TNFAIP3 function in cells of the immune system is beneficial in 
our understanding of autoinflammation and autoimmunity. Using the aforementioned 
mouse models, novel A20/TNFAIP3 functions have recently been described including 
control of necroptosis and inflammasome activity. In this review, we discuss the function 
of the A20/TNFAIP3 enzyme, and its critical role in various innate and adaptive immune 
cells. Lastly, we discuss the latest findings on TNFAIP3 SNPs in human autoinflammatory 




Autoinflammatory and autoimmune diseases share a spectrum of chronic immune sys-
tem disorders[1]. Autoinflammatory diseases are rare and occur due to innate immune 
cell dysfunction with increased cytokines such as IL-1β and TNFα[2,3]. In contrast, auto-
immune diseases are caused by adaptive immune system dysfunction and affect millions 
of people worldwide[4]. Self-reactive T-cells and/or auto-reactive antibodies facilitate 
responses against harmless tissue[5]. Essential for development of these diseases, is the 
activation status of immune cells, wherein nuclear factor kappa-light-chain-enhancer of 
activated B-cells (NF-κB) plays a key role. NF-κB activation is tightly controlled by several 
mechanisms, including the key regulatory (de)ubiquitinating enzyme A20 or tumor ne-
crosis factor α-induced protein 3 (TNFAIP3)[6]. Genetic studies have demonstrated the 
association of TNFAIP3 single nucleotide polymorphisms (SNPs) with multiple human 
diseases[7], such as systemic lupus erythematosus (SLE)[8-10], rheumatoid arthritis (RA)
[9], and Crohn’s disease (CD)[11,12]. A20/TNFAIP3 regulates crucial stages in immune cell 
homeostasis, such as NF-κB activation and apoptosis. Recently new functions have be-
come apparent, including the control of necroptosis and inflammasome activity[13-15]. 
Here we review the latest understanding of A20/TNFAIP3 as a key regulator of immune 
signalling and its cell-specific role in the pathogenesis of autoinflammation and autoim-
munity as demonstrated in murine models.
1. NF-κB PATHwAy
1.1 NF-κB activation
An important and well-characterized signaling pathway of immune cell activation is the 
NF-κB pathway[7], which is activated through canonical or non-canonical cascades[16]. 
The canonical pathway is triggered by several pattern recognition receptors (PRRs), 
such as Toll-like receptors (TLRs) and nucleotide oligomerization domain (NOD)-like re-
ceptors  (NLRs) and cytokine receptors, like tumor necrosis factor receptor (TNFR) and 
interleukin-1 receptor (IL-1R)[16]. PRRs are essential within the innate immune response 
in defence against invading pathogens. In addition, T-cell receptor (TCR) or B-cell re-
ceptor (BCR) triggering, crucial in the adaptive immune response, also leads to NF-κB 
activation[17]. In total five NF-κB family members have been identified thusfar, termed 
p65 (RelA), RelB, c-Rel, NF-κB1, and NF-κB2[18]. These five members can form homo- or 
heterodimers and distinctive NF-κB dimers bind different DNA-binding sites, resulting 
in cytokine release, enhanced cell survival, proliferation, differentiation, and changes in 
metabolism[18,19].
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1.2 regulation of NF-κB activity
Several regulatory mechanisms control NF-κB signaling to maintain tissue homeostasis. 
One of the proteins that terminate NF-κB signaling is A20/TNFAIP3[6]. A20/TNFAIP3 
regulates protein ubiquitination, an important post-translational modification[6]. Ubiq-
uitination is reversible and tightly controlled by opposing actions of ubiquitin ligases 
and deubiquitinases (DUBs)[20]. Several ubiquitin chains are known, each having spe-
cific functions. Lysine (K)48-linked polyubiquitin chains target a protein for proteasomal 
degradation, whereas K63-linked or linear polyubiquitin chains stabilize protein-protein 
interactions important for downstream signaling molecules[16]. Interestingly, A20/
TNFAIP3 has both DUB and ligase activity to perform both K48-ubiquitination and K63-
deubiquitination[6].
2. A20/TNFAIP3
2.1 A20/TNFAIP3 protein structure
In 1990, A20/TNFAIP3 was identified as a primary response gene after TNFα exposure in 
endothelial cells[21,22]. The structure of A20/TNFAIP3 reveals its dual function (Figure 
1A). First, the N-terminal OTU domain houses the C103 catalytic cysteine site, respon-
sible for K63-deubiquitination[6,23]. Second, the C-terminal domain ZnF4 domain 
adds K48-ubiquitin to target proteins for degradation[6]. Both domains cooperate to 
inhibit NF-κB signaling[24]. Lastly, A20/TNFAIP3 ZnF7 binds linear polyubiquitin, which 
aids to suppress NF-κB activation[25,26]. To achieve adequate function, A20/TNFAIP3 
must bind either target or accessory proteins. The OTU domain binds the target protein 
TNFR-associated factors (TRAF), while the C-terminus binds accessory molecules like 
A20-binding protein (ABIN1 and ABIN2), Tax1 Binding Protein 1 (TAX1BP1) and NF-κB es-
sential modulator (NEMO)[27]. These accessory molecules function as adaptor proteins 
and localize A20/TNFAIP3 near polyubiquitin chains[28-31] (reviewed in [27,32]).
2.2 Function of A20/TNFAIP3 in the TNFr signaling pathway
The multiple functions of A20/TNFAIP3 on NF-κB regulation are most apparent in the 
TNFR signaling pathway (Figure 1B). Briefly, TNFα binding to TNFR recruits receptor-
interacting serine/threonine-protein kinase 1 (RIP1) and TRAF2/TRAF5 to shape the 
TNFR complex[33,34]. RIP1 is K63-polyubiquitinated by ubiquitin-conjugating enzyme 
(Ubc)13 and cellular inhibitor of apoptosis protein (cIAP)1/2. RIP1-polyubiquitin is a 
scaffold to recruit NEMO and transforming growth factor beta-activated kinase 1 (TAK1)-
TAB2/3 complex[27]. The linear ubiquitin chain assembly complex (LUBAC) produces lin-
ear polyubiquitin on NEMO, recruiting and stabilizing another IKK-NEMO complex[35,36] 
(Figure 1B). TAK1 phosphorylates and activates IκB kinase (IKK), containing IKK2, that 
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finally phosphorylates IκB[37,38]. Phosphorylated IκB will be K48-polyubiquitined and 
degradated[19], thereby releasing NF-κB[16] leading to its nuclear translocation.
To terminate NF-κB activation, A20/TNFAIP3 removes K63-polyubiquitin chains 
from RIP1 and NEMO (Figure 1B), thereby disrupting interactions with downstream 
proteins[6,30]. Furthermore, A20/TNFAIP3 adds K48-polyubiquitin chains to RIP1 and 
Ubc13, leading to their degradation[6,39]. A20/TNFAIP3 also destabilizes Ubc13 inter-
action with cIAP1/2 to prevent new K63-ubiquitinating activity[40]. Lastly, the ZnF7 
domain of A20/TNFAIP3 binds linear ubiquitin, resulting in dissociation of LUBAC and 
IKK/NEMO[25,35] and thus inhibits IKK phosphorylation[41].
2.3 regulation of A20/TNFAIP3 expression and function
A20/TNFAIP3’s expression and function is controlled at several levels, e.g. transcriptional, 
post-transcriptional, and post-translational. During steady state, A20/TNFAIP3 is minimally 
present in several cell types[27] due to repression by downstream regulatory element an-
tagonist modulator (DREAM)[42]. Transcriptional activation of the TNFAIP3 gene is facilitated 
by two NF-κB binding sites in the TNFAIP3 promoter[43]. TNFAIP3 promotor activity is also 
controlled by regulators of cell-instrinsic energy homeostasis such as estrogen-related re-
ceptor α (ERRα)[44], linking energy homeostasis to cell activation. The stability of the TNFAIP3 
transcript is regulated by mRNA-binding proteins (e.g. ROQUIN (Rc3h1)[45]) and micro-(mi)
RNAs, such as miR-125b, miR-19b, miR-29c[46-48]. Interestingly, one of the downstream 
targets of NF-κB is miR125b, which thereby prolongs NF-κB activity[47]. ROQUIN destabilizes 
TNFAIP3 mRNA, leading to lower A20/TNFAIP3 protein expression[45] and mutated ROQUIN 
is known to induce autoimmunity in mice[49]. Posttranslationally, A20/TNFAIP3 protein 
function is improved by IKK2-dependent phosphorylation[50] (Figure 1A) which enhances 
K63-deubiquitination and K48-ubiquitination[51]. Also, cell-extrinsic factors control A20/
TNFAIP3 protein stability, e.g. high glucose levels target A20/TNFAIP3 for proteasomal deg-
radation and/or reactive oxygen species (ROS) inactivate its deubiquitinating activity[52-54]. 
Especially the latter is important in RA, in which elevated ROS plays a pathogenic role[55,56], 
possibly by inhibiting A20/TNFAIP3 function. Lastly, unlike most cell types, resting T-cells 
constitutively express high levels of A20/TNFAIP3 protein[57], which is degradated after 
activation by paracaspase MALT1 to facilitate NF-κB translocation[58] (Figure 1A).
3. ImmUNe cell-SPecIFIc DeleTIoN oF A20/Tnfaip3 IN mIce
A20/TNFAIP3 is critical in inflammation regulation, as mice with germ-line A20/Tnfaip3-
deletion developed severe multi-organ inflammation and cachexia, resulting in early 
death[59]. Conditional A20/Tnfaip3 floxed alleles enabled lineage-specific Tnfaip3-dele-
tion and study of cell-specific contributions to autoinflammation and autoimmunity[60].
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Figure 1: A20/TNFAIP3 protein structure and function in TNFr induced NK-κB inhibition.
(A) The protein structure of A20/TNFAIP3. The N-terminus contains the ovarian tumor (OTU) domain, with 
the C103 cysteine site of K63 deubiquitination. The seven Zinc-Fingers (ZnF) are illustrated, where ZnF4 
has K48 ubiquitinating activity and ZnF7 can bind linear polyubiquitin. The asterix (*) indicates the site 
of IKK2-dependent phosphorylation. An arrow indicates where MALT1 cleaves human A20/TNFAIP3 (after 
Arginine 439), while for murine A20/TNFAIP3 it is only known that MALT1 cleaves A20/TNFAIP3 between 
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3.1 A20/TNFAIP3 function in myeloid cells
To evaluate the role of A20/TNFAIP3 in myeloid cells, Tnfaip3fl/fl mice were crossed with 
lysozyme M (LysM)-cre Tg mice[61], generating Tnfaip3LysM mice[13,60,62,63]. The LysM-
cre promoter is expressed in ~95-99% of macrophages and neutrophils and ~15% of 
splenic DCs[61]. Tnfaip3LysM-KO mice developed enthesitis[62] and paw inflammation[63]. 
While hallmarks of RA comprising increased Th17-cells and serum anti-collagen type II 
antibodies (anti-CII) were present in Tnfaip3LysM-KO mice, T and B cells were dispensable 
for paw inflammation[63]. Rather, paw inflammation in Tnfaip3LysM-KO mice depended on 
IL-1β[13], suggestive of an autoinflammatory disease like Still’s disease or juvenile idio-
pathic arthritis (JIA). In vitro cultured Tnfaip3-deficient macrophages produced increased 
amounts of IL-1β, IL-6, IL-18, and TNFα compared to control macrophages[13,63]. IL-1β 
and IL-18 release is regulated by the NLRP3 inflammasome[64], which is pathogenic in 
autoinflammatory diseases such as Cryopyrin-associated autoinflammatory syndrome 
(CAPS)[3,65]. A20/TNFAIP3 directly controls the activity of the NLRP3 inflammasome in 
macrophages[13,66].
Next, IFNγ or IL-6-induced JAK-STAT signaling is implicated in autoinflammatory 
diseases[3], which is also regulated by A20/TNFAIP3[62]. Tnfaip3-deficient macrophages 
had elevated STAT1-dependent gene transcription, leading to enhanced chemokine 
(C-X-C motif ) ligand (CXCL)9 and CXCL10 production[62]. Pharmacologic JAK-STAT 
inhibition by tofacitinib in Tnfaip3LysM-KO mice resulted in reduced enthesitis[62], which is 
a treatment option for several autoinflammatory diseases[3].
In short, in macrophages A20/TNFAIP3 regulates IL-1β/IL-18 release by controlling NLRP3 
inflammasome activity and CXCL9/CXCL10 production through STAT1-signaling. Both 
pathways are essential in controlling the autoinflammatory arthritis phenotype. However, 
a role for neutrophils and/or DCs in the pathogenesis of arthritis can not be excluded.
ZnF3 and ZnF4. (B) TNFR activation of the NF-κB pathway. Ligand TNFα binds the TNFR receptor and allows 
binding of TNFR1-associated death domain protein (TRADD) to the TNFR. This recruits Receptor-interacting 
serine/threonine-protein kinase 1 (RIP1) and TRAF2 or TRAF5 to form the TNFR complex. RIP1 is K63-poly-
ubiquitinated by E2-E3 ubiquitin-conjugating enzyme (Ubc)13 and cellular inhibitor of apoptosis protein 
(cIAP)1/2. The polyubiquitin acts as a scaffold for TAB2/TAB3 and NF-kappa-B essential modulator (NEMO) to 
recruit the Transforming growth factor beta-activated kinase 1 (TAK1)-TAB2/3 complex. TAK1 phosphory-
lates and activates the IκB Kinase (IKK), composed of IKK1(α), IKK2(β) and NEMO. The linear ubiquitin chain 
assembly complex (LUBAC), was shown to generate linear polyubiquitin on NEMO (and also RIP1), recruit-
ing and stabilizing another IKK-NEMO complex. IKK2, phosphorylates IκB, allowing IκB K48-polyubiquitina-
tion and consequently degrading by proteasomes, thereby releasing NF-κB to translocate to the nucleus. 
A20/TNFAIP3 acts in different levels of the pathway. A20/TNFAIP3 removes K63-linked polyubiquitin chains 
from RIP1 and NEMO, thereby disrupting downstream signals. In addition, A20/TNFAIP3 adds K-48-linked 
polyubiquitin chains to RIP1 and Ubc13, thus targeting them for proteasomal destruction. Beyond (de)
ubiquitinating mechanisms, A20/TNFAIP3 also destabilizes Ubc13 interaction with cIAP1/2, thereby pre-
venting new K63-ubiquitinating activity. The ZF7 of A20/TNFAIP3 binds linear ubiquitin, thereby accelerat-
ing the dissociation of LUBAC and IKK/NEMO, resulting in NF-κB termination.
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3.2 Function of A20/TNFAIP3 in Dcs
DCs play a crucial role in immune homeostasis and arise in two main subsets, compris-
ing conventional DCs type 1 or 2 (cDC1s, cDC2s) and plasmacytoid DCs (pDCs)[67]. 
When activated, cDCs induce antigen-specific adaptive immune responses and pDCs 
control anti-viral responses[67]. During inflammation, monocyte-derived DCs (moDCs) 
are recruited to inflammatory sites[68]. To characterize A20/TNFAIP3 function in DCs in 
vivo, CD11c-cre-mediated[69] targeting was used in mice[70-72]. Tnfaip3CD11c-KO mice had 
perturbed splenic DC homeostasis as cDC1s, cDC2s, and pDCs were drastically reduced, 
while moDCs were increased[71]. In vivo loss of cDCs and pDCs in Tnfaip3CD11c-KO mice 
suggested that A20/TNFAIP3 supports their survival. However, in vitro generated GM-CSF 
bone marrow-derived Tnfaip3-deficient DCs were more resistant to apoptosis due to up-
regulated anti-apoptotic molecules[71]. This discrepancy might be caused by contami-
nating macrophages in GM-CSF-cultures[73]. GM-CSF-cultured DCs from Tnfaip3CD11c-KO 
mice exhibited an activated phenotype, shown by increased co-stimulatory molecules 
(e.g. CD80/CD86) and cytokine expression of IL-6, TNFα[70,71], IL-1β and IL-10[71]. In 
the pathogenesis of SLE, pDCs are pathogenic by secreting type I interferons[74], but 
increased type I interferon by activated pDCs was observed only in vitro[70].
To maintain peripheral tolerance, antigens derived from apoptotic cells are normally 
not presented in an immunogenic manner to T-cells[75]. Strikingly, in vitro Tnfaip3-
deficient DCs present these antigens to T-cells and induce T-cell activation[71] leading 
to a break of tolerance. In vitro apoptotic cell-pulsed DCs produce T-cell differentiating 
cytokines IL-12 and IL-23, leading to increased Th1-cell and Th17-cell differentiation 
respectively in Tnfaip3CD11c-KO mice[70,71,76]. Surprisingly, three independent studies 
with Tnfaip3CD11c-KO mice generated different spontaneous phenotypes, i.e. infammatory 
bowel disease (IBD)[70], systemic autoimmunity resembling SLE[71] and multiorgan 
inflammation[72]. Serum IL-6 was elevated in mice developing SLE or IBD[70,71], while 
both TNFα and IFNγ were significantly increased in mice with multiorgan inflamma-
tion[72]. As IL-6 depletion ameliorated murine colitis and SLE development[77-80], IL-6 
might directly have contributed to IBD and SLE development in Tnfaip3CD11c-KO mice. While 
CD is recently considered an autoinflammatory disease[81], T-cells were essential for 
colitis development in Tnfaip3CD11c-KO mice[70]. SLE patients have increased anti-dsDNA 
autoantibodies[82], which were also observed in Tnfaip3CD11c-KO mice[71]. The diversity of 
phenotypes observed in Tnfaip3CD11c-KO mice might be due to environmental differences, 
such as microbiota[70,83], as antibiotics reduced IBD in Tnfaip3CD11c-KO mice[76].
Summarizing, the expression of co-stimulatory molecules, proinflammatory cytokines 
such as IL-6, and anti-apoptotic proteins in DCs is controlled by A20/TNFAIP3. A20/
TNFAIP3 in DCs functions to maintain in vivo T-cell and B-cell homeostasis, thereby 
preventing spontaneous autoinflammation.
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3.3 A20/TNFAIP3 functions in T-cells
A20/TNFAIP3 is known to regulate TCR/CD28-mediated NF-κB activation and TCR-me-
diated survival [84-86], and is highly expressed in naïve T-cells[57]. A20/TNFAIP3’s influ-
ence on T-cell homeostasis has been examined using maT(mature T cell)-cre and Cd4-cre 
mice, targeting both CD8+ T-cells and CD4+ T-cells[14,15,87]. Tnfaip3-deletion efficiency 
differs between Tnfaip3maT and Tnfaip3CD4 mice. In Tnfaip3maT-KO mice ~80% of CD8+ T-cells 
and ~30% of CD4+ T-cells are affected[88], whereas in Tnfaip3CD4-KO mice ~100% of both 
CD8+ and CD4+ T-cells are targeted[89]. Targeted T-cells from both mouse strains showed 
an activated phenotype[14,87], but only Tnfaip3maT-KO mice developed inflammatory lung 
and liver infiltrates with increased proportions of CD8+ T-cells[87]. TCR-stimulated CD8+ 
T-cells from Tnfaip3maT-KO mice had enhanced IL-2 and IFNγ production in vitro which cor-
related with in vivo increased serum IFNγ[87]. Serum TNFα and IL-17 were also elevated 
in Tnfaip3maT-KO mice[87]. Since both IFNγ and TNFα are hepatotoxic factors[90-92], these 
cytokines likely mediated liver inflammation.
Differences in T-cell specific Tnfaip3-deletion between the two mouse strains could 
indicate that either CD8+ T-cells drive inflammation in Tnfaip3maT-KO mice or CD4+ T-cells 
have increased regulatory function in Tnfaip3CD4-KO mice. Indeed, regulatory T cell (Treg) 
proportions were increased in Tnfaip3CD4-KO mice, because of a reduced IL-2 dependence 
for their development[93]. In vitro activated CD4+ T-cells from Tnfaip3CD4-KO mice died 
quicker than wild-type T-cells[14,15], due to A20/TNFAIP3’s control on necroptosis[14] 
and autophagy[15]. Necroptosis is RIPK3-dependent programmed cell death[94]. 
Increased necroptosis in A20/Tnfaip3-deficient CD4+ T-cells impaired Th1 and Th17-cell 
differentiation in vitro[14]. Interestingly, perinatal death of Tnfaip3KO mice was greatly 
delayed by RIPK3-deficiency, implying that A20/TNFAIP3 may control necroptosis in 
other cell types[14], such as CD8+ T-cells[95]. Preventing necroptosis did not fully restore 
survival of A20/Tnfaip3-deficient CD4+ T-cells[14], which could be attributed to autoph-
agy, a lysosomal degradation pathway necessary for survival after TCR-stimulation[96]. 
Autophagy is regulated by mechanistic target of rapamycin (mTOR), which is increased 
in Tnfaip3-deficient CD4+ T-cells after TCR-stimulation[15]. Consequently, treatment with 
an mTOR inhibitor improves survival by enhancing autophagy[15]. mTOR inhibitors are 
effective in murine SLE and RA[97], but should not be used in patients with A20/TNFAIP3 
alterations, as it may improve pathogenic T-cell survival.
In conclusion, in CD4+ T-cells A20/TNFAIP3 regulates necroptosis and autophagy. In 
contrast to conventional Th-cells, Treg development is restricted by A20/TNFAIP3. In 
CD8+ T-cells, A20/TNFAIP3 regulates necroptosis, IL-2 and IFNγ release, of which IFNγ 
might have contributed to a further undefined lung and liver inflammatory phenotype 
in Tnfaip3maT-KO mice.
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3.4 A20/TNFAIP3 function in B-cells
B-cell homeostasis demands proper integration of TLR, BCR, and CD40-derived signals, 
all leading to NF-κB activation and controlled by A20/TNFAIP3[98,99]. Using CD19-cre 
driven Tnfaip3-ablation in mice[100-102], B-cell-specific function of A20/TNFAIP3 was 
examined. In vitro activated Tnfaip3-deficient B-cells exhibited exaggerated activation 
as assessed by CD80 and CD95 expression[101,102] and IL-6 production[100,102]. B-cell 
numbers in Tnfaip3CD19-KO mice are increased in secondary lymphoid organs[100-102], 
most likely due to increased anti-apoptotic protein B-cell lymphoma-extra large (Bcl-
x) expression[102]. Already in 6-week-old Tnfaip3CD19-KO mice, elevated numbers of 
germinal center B-cells and plasma cells in spleen and peripheral lymph nodes were 
observed[100-102]. Tnfaip3CD19-KO mice developed autoreactive immunoglobulins, 
including anti-dsDNA antibodies[100-102] and glomerular immunoglobulin depos-
its[102], features also observed in SLE patients. Surprisingly, no malignancies developed 
in Tnfaip3CD19-KO mice[100,102], which might have been expected as A20/TNFAIP3 also 
functions as a tumor suppressor gene in B-cell lymphomas[103-105].
Summarizing, A20/TNFAIP3 in B-cells controls co-stimulatory molecule expression, 
IL-6 production, and Bcl-x survival protein expression, thereby preventing autoreactive 
B-cells formation resulting in an autoimmune SLE phenotype.
4. A20/TNFAIP3 IN AUToINFlAmmATory AND AUToImmUNe PATIeNTS
TNFAIP3 is one of the few genes that has been linked by genome-wide association 
studies (GWAS) to multiple immune diseases[106,107]. The list of common coding and 
non-coding variants (SNPs) in the vicinity of the TNFAIP3 gene region associated with 
autoimmune conditions keeps expanding, with recently reported associations with 
autoimmune hepatitis (AIH)[108,109], primary biliary cirrhosis (PBC)[110] and colitis 
ulcerosa (CU)[111]. Since a comprehensive overview of SNPs within and around the TN-
FAIP3 gene has been provided elsewhere[7], we focus on a selection of SNPs with known 
different functional, clinical, and therapeutical consequences (Figure 2). We also discuss 
a recently described monogenic disease ‘Haplo-insufficiency of A20 (HA20)’[112], which 
clearly illustrates the importance of functional A20/TNFAIP3 protein expression levels 
(Figure 2).
4.1. Tnfaip3 SNPs and novel mutations affecting A20/TNFAIP3 expression and 
function
Reduced TNFAIP3 mRNA expression was observed in peripheral blood mononuclear cells 
(PBMCs) in SLE and RA patients[113-115] and in disease affected organs, e.g. in colon 
or skin biopsies from CD and psoriasis patients compared to healthy tissues[116-118]. 
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In RA synovium, reduced A20/TNFAIP3 protein expression was detected compared to 
non-autoimmune osteoarthritic synovium[119]. SNPs near the TNFAIP3 gene can result 
in reduced A20/TNFAIP3 mRNA expression and consequently protein concentrations. 
For instance, specific SNPs associated with SLE (“TT>A”, Figure 2H) are situated in an 
enhancer region of the TNFAIP3 gene and hamper DNA-looping, resulting in reduced TN-
FAIP3 mRNA expression[120] and reduced A20/TNFAIP3 protein expression in B-cells[8].
Recently, novel rare familial TNFAIP3 mutations (Figure 2B,G) causing HA20 have 
been described[112]. These mutations lead to severely reduced functional A20/TN-
FAIP3 protein expression[112,121]. HA20 is a dominantly inherited disease caused by 
high-penetrance heterozygous germline (mostly nonsense or frameshift) mutations in 
TNFAIP3[112]. Previously, A20/TNFAIP3 loss-of-function mutations were only identified 
as somatic variants in lymphomas[105] (reviewed in [122]). HA20-associated mutations 
were first reported in 7 unrelated families with an early-onset inflammatory disease 
resembling the common polygenic Behçet disease[112]. Some patients diagnosed with 
Behçet-like disease were found to have similar HA20 mutations[123,124]. Recently, in a 
Japanese cohort the majority (59%) of HA20 patients did not fulfill criteria of Behçet dis-
ease[125], thus carefull evaluation of clinical characteristics of HA20 and Behçet disease 
will aid disease diagnosis[126]. Also HA20 patients with autoimmune disease were rec-
ognized[121] with excess Th17-cell differentiation[126], including autoimmune lympho-
proliferative syndrome (ALPS)[127]. All HA20 patients identified thusfar have a strong 
inflammatory signature as demonstrated by elevated levels of many pro-inflammatory 
cytokines (e.g. IL-1β, IL-6, TNFα, IL-17, IFNγ) and most patients respond to treatment 
with cytokine inhibitors (anti-TNF, anti-IL-1)[112,125,126]. Interestingly, Tnfaip3+/- mice 
do not have an overt inflammatory phenotype despite elevated inflammatory cytokines 
(e.g. IL-1β and IL-6) in serum[128] and brain[129]. Nevertheless, Tnfaip3+/- mice are more 
susceptible to experimental psoriasis[118] and atherosclerosis[128], but these specific 
symptoms are not commonly reported for HA20. Increased NLRP3 activity was detected 
in PBMCs of HA20 patients after LPS stimulation, leading to elevated IL-1β[112]. Trans-
fection of mutant truncated A20/TNFAIP3 prolonged NF-κB activation due to reduced 
deubituinating function[112] (Figure 2B). PBMCs of a patient with HA20 also demon-
strated prolonged NF-κB activation[112,121]. Mutant truncated A20/TNFAIP3 proteins 
do not exert a dominant-negative effect on protein function and this indicates that 
sustained NF-κB activation in HA20 is due to haploinsufficiency rather than an aberrant 
protein function[112]. It remains unclear whether missense high penetrance mutations 
may have a different impact on A20/TNFAIP3 function.
Two SNPs, rs5029941 (A125V) and rs2230926 (F127C), are located in close proximity 
of each other near the C103 catalytic site in the OTU domain and result in nonsynony-
mous coding changes in the A20/TNFAIP3 protein (Figure 2D,e). The rs2230926 (F127C) 
SNP, associated with multiple autoimmune diseases (Figure 2e) hampers A20/TNFAIP3 








Impaired enhancer disabling 














































Increased liver enzymes 
and cirrhosis in AIH Increased Fibrosing




Increased swollen joint count and







Prolonged NF-κB signal 





























































Mutation Location Mutation Location
Figure 2: overview of Single Nucleotide Polymorphisms (SNPs) and novel HA20 mutations in the 
proximity of Tnfaip3 which are highlighted in this review
TNFAIP3 gene SNPs, adapted from Ma et al. Nat Rev Immunol; 2012. Exons contributing to the OTU do-
main are depicted green and exons forming the zinc-fi nger (ZnF) domains are blue. Non-coding exons 
are grey. The catalytic C103 site, ZnF4 and ZnF7 are highlighted. Black triangles indicate all known SNPs 
in the TNFAIP3-gene with associations to autoimmune diseases. Among the various documented SNPs/
novel mutations, several lead to (1) reduced A20/TNFAIP3 protein level, (2) reduced A20/TNFAIP3 effi  ciency, 
(3) altered disease prognosis or (4) therapeutic implications and are thus highlighted in this fi gure (A-G). 
Known associations to (autoimmune) diseases for SNPs are indicated in the top grey bar. Multiple novel mu-
tations causing “HA20” and two SNPs termed “TT>A” (associated to SLE) are listed in the box in the lower left 
corner. The reported p.Gln415fs mutation[127], should be reported as p.Lys417Serfs*4 to stay consistent 
with Human Genome Variation Society nomenclature[142]. Abbreviations: OTU; Ovarian Tumor, ZnF; Zinc 
Finger, TF; transcription factors, TNFAIP3; HA20; Haploinsuffi  ciency of A20, AIH; autoimmune hepatitis, SLE; 
systemic lupus erythematosus, SSc; Systemic Sclerosis, RA; Rheumatoid arthritis, T1D; Type 1 Diabetes, JIA; 
Juvenile Idiopathic Arthritis, CD; Crohn’s disease, Pso; Psoriasis, SS; Sjögren syndrome.
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function after TNFα-stimulation[10]. The SNP location within the OTU domain (Figure 
2e) suggests that the K63-deubiquitinating efficacy is decreased, although this was 
not evaluated. The A125V mutation (Figure 2D) results in reduced DUB activity and 
was shown to impair A20-mediated degradation and deubiquitination of TRAF2[130]. 
Although the A125V mutation was associated with protection from SLE, surprisingly the 
same allele was associated with increased risk of IBD[130].
In conclusion, specific SNPs functionally alter A20/TNFAIP3 expression or function and 
HA20 is a disease with generalized inflammation due to severely reduced functional 
A20/TNFAIP3 protein expression.
4.2 Tnfaip3 SNPs affecting disease progression and treatment in patients
Common, presumably hypomorphic, variants in TNFAIP3 can have clinical consequences. 
For instance, lower TNFAIP3 mRNA expression in PBMCs correlates with SLE disease 
activity as susceptibility to lupus nephritis is increased[113]. SLE or SSc patients with an 
intron SNP (Figure 2c) predisposes for increased risk for either renal involvement[131] 
or aggravated disease with fibrosing alveolitis and pulmonary hypertension[132]. 
Similarly, RA patients with a previously described functional SNP (Figure 2e) had more 
swollen joints and increased disease activity scores (DAS28) compared to RA patients 
without this SNP, indicating worse clinical prognosis[9,115]. Lastly, AIH patients with an 
upstream SNP (Figure 2A) harboured increased liver enzymes and more cirrhosis at dis-
ease presentation compared to patients without this SNP[109]. These findings illustrate 
that within autoimmune patients certain SNPs around the TNFAIP3 gene predispose a 
worse clinical prognosis.
Analysis of TNFAIP3 SNPs might guide treatment choices, e.g. with TNF-blocking 
therapy. For RA and CD patients, reduced TNFAIP3 mRNA in PBMCs or colonic biopsies 
respectively is correlated with effective TNF-blocking therapy[116,133]. Psoriasis pa-
tients harbouring specific TNFAIP3 SNPs (Figure 2e,F) respond more effectively to TNF-
blockade[134]. This indicates that TNFAIP3 SNP analysis before TNF-blocking therapy 
initiation is worthwhile to perform in several autoimmune diseases and may be more 
practical than evaluating TNFAIP3 mRNA expression.
4.3 Treatment of autoinflammation and autoimmunity.
Knowledge from cell-specific targeting studies in mice illustrate that loss of A20/TNFAIP3 
results in either autoinflammation or autoimmunity. The pathophysiologic distinction 
between these conditions has therapeutic implications. Autoinflammatory diseases 
such as Still’s disease, Behçet’s disease, and most cases of HA20 are well treated with IL-1 
blockade, which has only marginal effect in autoimmune diseases including RA[135]. 
Autoinflammation may also underlie other chronic disorders such as atherosclerosis, 
as these patients benefit from anti-IL-1 therapy[136,137]. In contrast, autoimmune 
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disorders (e.g. SLE) have a strong contribution of IL-6 highlighted by successful anti-IL-6 
treatment[138]. This is in line with mouse studies in which innate cell activation (e.g. 
Tnfaip3LysM-KO mice) leads to increased IL-1β[13] and adaptive immune cell activation 
(e.g. Tnfaip3CD19-KO mice) lead to enhanced IL-6[70,71,100,102]. In line with the adap-
tive nature of the disease, several autoimmune diseases also improve after treatments 
targeting adaptive immune cells (e.g. T-cell suppression using cyclosporine[139,140] or 
B-cell depletion using Rituximab)[141].
coNclUSIoN
Control of immune system activation is crucial to prevent both autoinflammation 
and autoimmunity. A20/TNFAIP3 hereby plays an important role in several innate and 
adaptive immune cells. Through analysis of cell-specific deletion of A20/Tnfaip3 in 
mice, it became apparent that innate myeloid cells require A20/TNFAIP3 to suppress 
autoinflammation, while the development of autoimmunity is primarily controlled by 
A20/TNFAIP3 in DCs and B-cells. In addition, novel functions of A20/TNFAIP3 on inflam-
masome activity and necroptosis are uncovered. It would be of great value to examine in 
patient material cell-specific profiles of A20/TNFAIP3 and its effector function. The direct 
consequence of many SNPs on A20/TNFAIP3 is yet unknown. However, it is becoming 
increasingly clear that specific TNFAIP3 SNPs can alter A20/TNFAIP3 function, can affect 
its expression level, or are associated to poor clinical outcomes. Lastly, future studies on 
TNFAIP3 SNPs to predict therapeutic effectivity would greatly benefit patient healthcare 
to obtain personalized therapy.
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ABSTrAcT
Dendritic cells (DCs) are central regulators of tolerance versus immunity. The outcome 
depends amongst others on DC subset and activation status. Whereas CD11b+ type 2 
conventional DCs (cDC2s) initiate proinflammatory helper T (Th)-cell responses, CD103+ 
cDC1s are crucial for regulatory T-cell (Treg) induction and CD8+ T-cell activation. DC 
activation is controlled by the transcription factor NF-κB. Ablation of A20/Tnfaip3, 
a critical regulator of NF-κB activation, in DCs leads to constitutive DC activation and 
development of systemic autoimmunity. We hypothesized that the activation status of 
cDCs controls the development of autoimmunity.
To target cDCs, DNGR1(Clec9a)-mediated excision of A20/Tnfaip3 was used through 
generation of Tnfaip3fl/flxClec9a+/cre (Tnfaip3DNGR1-KO) mice. Immune cell activation was 
evaluated at 31-weeks of age.
We found that DNGR1-mediated deletion of A20/Tnfaip3 resulted in liver pathology 
characterized by inflammatory infiltrates adjacent to the portal triads. Both cDC subsets 
as well as monocyte-derived DCs (moDCs) in Tnfaip3DNGR1-KO livers harbored an activated 
phenotype. Specifically, the costimulatory molecule CD40 in liver cDCs and moDCs was 
regulated by A20/Tnfaip3 expression. Livers from Tnfaip3DNGR1-KO mice had augmented 
proportions of Th1, Th17, Treg, and follicular Th (Tfh)-cells compared to control mice, ac-
companied by an increase in IgA-producing plasma cells. Serum IgA from Tnfaip3DNGR1-KO 
mice recognized self-proteins, specifically cytoplasmic proteins in liver periportal 
regions.
These data show that enhanced activation of cDCs and moDCs, due to A20/Tnfaip3 
ablation, promotes the development of organ-specific autoimmunity but not systemic 
autoimmunity. This model could be useful to examine the pathobiological processes 
contributing to autoimmune liver diseases.
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1. INTroDUcTIoN
The adaptive immune response is critically altered in autoimmune diseases, where 
activation of T-cells is induced by dendritic cells (DCs). DCs are also known as central 
regulators in the delicate balance between tolerance and immunity1. During steady 
state, immature DCs present self-antigens to T-cells, thereby inducing regulatory CD4+ 
T-cell (Tregs), T-cell anergy or autoreactive T-cell deletion2-4. These mechanisms prevent 
T-cell mediated autoimmunity5. The balance between tolerance and immunity depends 
on the maturation status of DCs, a process that is strictly regulated6, 7. During infec-
tions and inflammation, DCs are activated through ligand-receptor interaction on DCs, 
which initiates the NF-κB pathway is initiated and provokes proinflammatory cytokine 
production8. NF-κB activation is tightly controlled by several mechanisms. One major 
inhibitor of NF-κB signalling is the ubiquitin-editing enzyme TNFα-induced protein 3 
(TNFAIP3) or A209. DC-specific deletion of Tnfaip3/A20 using the Cd11c promotor in 
mice (Tnfaip3CD11c-KO mice) resulted in spontaneous activation of DCs and induction of 
autoreactive CD4+ T helper (Th)1-cells and Th17-cells differentiation, causing a severe 
and complex autoimmune inflammatory phenotype10, 11. Tnfaip3CD11c-KO mice developed 
features of inflammatory bowel disease10 (IBD) and systemic lupus erythematosus 
(SLE)11. Importantly, genetic polymorphisms in the TNFAIP3 gene are associated with 
several human autoimmune disorders12, 13.
DCs comprise different subsets with specialized functions5. Both conventional 
DCs (cDCs) and plasmacytoid DCs (pDCs) are present during steady state. CD103+/
CD8+ type 1 cDCs (cDC1s) are important for peripheral tolerance as they can present 
tissue-associated self-antigens5. During steady state, cDC1s can induce Tregs14-16, Th-cell 
deletion17, CD8+ T-cell tolerance17, 18, and once activated, cDC1s also provoke cytotoxic 
T-cell responses19. Strikingly, ablation of cDC1s does not cause spontaneous autoimmu-
nity19, 20, it only alters intestinal T-cell homeostasis21. Under steady state, CD11b+/CD4+ 
type 2 cDCs (cDC2s) also induce T-cell tolerance22, and provoke Treg proliferation and 
differentiation16, 23. Activated cDC2s strongly promote Th-cell activation and induce Th-
cell differentiation into Th224 or Th17-cells25. During inflammation, monocyte-derived 
DCs (moDCs) arise and produce chemokines to attract immune cells to the inflammatory 
lesion26.
It is unclear what the contribution of different DC subsets is to the autoimmune pheno-
type in Tnfaip3CD11c-KO mice. As cDCs are important instructors of T-cell tolerance, we hy-
pothesized that cDCs crucially contribute to the autoimmune phenotype. To determine 
cDC function, we used DNGR1-driven27 deletion of Tnfaip3/A20 (Tnfaip3DNGR1-KO mice) as 
DNGR1-driven cre-expression can induce efficient deletion of target genes in ~95% of 
organ cDC1s, 25-40% of cDC2s, and ~5-25% of moDCs in wildtype mice 27.
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2. mATerIAl & meTHoDS
2.1. mice
Male and female mice harbouring a conditional Tnfaip3 allele flanked by LoxP sites28 were 
crossed to mice expressing the Cre recombinase under the Clec9a promotor (DNGR1)27, 
generating Tnfaip3fl/flxClec9a+/cre mice (Tnfaip3DNGR1-KO mice). Mice were >10 times back-
crossed to obtain a C57Bl/6 background. Tnfaip3fl/flxClec9a+/+ littermates (Tnfaip3DNGR1-WT 
mice) served as controls. All mice were sacrificed between 11-31 weeks of age.
To trace Tnfaip3-deletion and function in cDCs, we crossed Tnfaip3+/+xClec9a+/cre mice 
to Rosa26-Stopfl/fl-YFP mice29 (Tnfaip3DNGR1-ROSA-WT mice) and Tnfaip3fl/flxClec9a+/cre mice 
to Rosa26-Stopfl/fl-YFP mice (Tnfaip3DNGR1-ROSA-KO mice). Mice were housed under specific 
pathogen-free conditions and had ad libitum access to food and water. All experiments 
were approved by the animal ethical committee of the Erasmus MC, Rotterdam, The 
Netherlands and comply to the EU Directive 2010/63/EU for animal experiments.
2.2. cell suspension preparation
Spleen and liver were isolated and used for flow cytometry. Spleens were homogenized 
through a 100-μm cell strainer. Erythroid cells present in the spleen cell suspensions were 
lysed using osmotic lysis buffer (8.3% NH4CL, 1% KHCO3, and 0.04% NA2EDTA in Milli-Q). 
Liver single-cell suspensions were obtained, as previously described30, by digesting with 
Liberase TM (Roche, Basel, Switzerland) for 30 minutes at 37°C. After digestion, the livers 
were homogenized using a 100-μm cell strainer (Fischer Scientific). Hepatocytes were 
discarded using two low speed centrifuge steps. Lastly, erythroid cells were lysed using 
osmotic lysis buffer.
2.3. Flow cytometry procedures
Flow cytometry surface and intracellular staining procedures have been described pre-
viously31. Monoclonal antibodies used for flow cytometric analyses are listed in Supple-
mentary table 1. For all experiments, dead cells were excluded using fixable Amcyan 
viability dye (eBioscience, San Diego, CA, USA). To measure cytokine production, cells 
were stimulated with 10 ng/mL PMA (Sigma-Aldrich, St. Louis, MI, USA) and 250 ng/mL 
ionomycin (Sigma-Aldrich) in the presence of GolgiStop (BD Biosciences, San Jose, CA, 
USA) for 4 h at 37°C. Flow cytometry absolute counting beads (Polysciences, Warrington, 
PA, USA) were added to liver flow cytometry samples. Data were acquired using an LSR 
II flow cytometer (BD Biosciences) with FACS DivaTM software and analyzed by FlowJo 
version 9 (Tree Star Inc software, Ashland, OR, USA).
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2.4. liver histology
The right lobe of the liver was fixated with 4% PFA (Carl Roth, Karlsruhe, Germany) for 
24 hr before paraffin embedding. Six-μm-thick paraffin embedded liver sections were 
stained with hematoxylin and eosin, and using Sirius Red (Sigma-Aldrich) and Fast Green 
(Sigma-Aldrich) to stain for collagen fibers, as previously described32. Liver pathology 
was scored using the histopathologic scoring system according to Ishak et al.33 For 
immunohistochemical stainings, antigen retrieval on paraffin-sections was established 
using citrate buffer (Sigma-Aldrich).
Paraffin sections were stained for Cytokeratin 7, CD3 and B220. The primary antibod-
ies used for immunohistochemistry are listed in Supplementary table 2. Sections were 
incubated for 1 hr with the primary antibodies. After washing, slides were incubated 
for 30 minutes with secondary antibodies (Supplementary table 2). On paraffin sec-
tions which were stained for Cytokeratin 7 and CD3, the anti-Rabbit ABC Peroxidase Kit 
was utilized (Vector Labs, Burlingame, CA, USA). Diaminobenzene (DAB) and Fast Blue 
Alkaline phosphatase substrates were used to retrieve specific staining.
2.5. Serum measurements
To determine liver function, aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) enzymes were measured in serum.
For total immunoglobulin concentrations, Nunc Microwell plates (Life technologies, 
Carlsbad, CA, USA) were coated with 1 μg/ml goat-anti-mouse IgM, IgA, IgG1, IgG2a, 
IgG2b, or IgG3 (Southern Biotech, Birmingham, AL, USA) overnight at 4Co. Wells were 
blocked with 10% FCS (Capricorn Scientific, Ebsdorfergrund, Germany) in PBS (Thermo 
Scientific, Waltham, MA, USA) for 1 hr. Standards and serum were diluted in PBS and 
incubated for 3 hrs at room temperature. Depending on the isotype of interest, anti-
mouse biotin-labeled IgM, IgA, IgG1, IgG2a, IgG2b, or IgG3 (Southern Biotech) was in-
cubated for 1 hr. Streptavidin-HRP (eBioscience) and TMB substrate (eBioscience) was 
used to develop the ELISA and then optical density (OD) was measured at 450 nm on a 
Microplate Reader (Bio-Rad, Hercules, CA, USA).
For detection of anti-cardiolipin antibodies, Nunc Microwell plates were coated with 
10 μg/ml cardiolipin from bovine heart (Sigma) in ethanol and left to dry overnight. For 
detection of dsDNA, 20μg/ml dsDNA from calf thymus (Sigma) was coated overnight on 
pre-coated poly-l-lysine microwells. Wells were blocked with 2% BSA/PBS for 2 hrs, after 
which serum was incubated for 2 hrs. Anti-mouse IgG1 biotin/streptavidin-HRP (eBiosci-
ence) was used to develop the ELISA with TMB substrate (eBioscience). Detection of 
immunoglobulin IgG/IgA versus PDC-E2, sp100 and gp210 was performed as previously 
described34.
For detection of autoreactive IgA binding to tissues, we used 5μm cryo-sectioned 
liver and pancreas from Rag1KO mouse35, as these mice lack mature B-cells and conse-
chapter 3  | Tnfaip3 deficiency in DCs in context of autoimmune liver pathology
54
quently endogenous immunoglobulins are absent. After 10 minutes acetone fixation 
(Sigma) and 10 minutes block with 10% normal goat serum (NGS), sera from Tnfaip-
3DNGR1-WT mice (dilution 1/33) and Tnfaip3DNGR1-KO mice (dilution 1/100) were incubated for 
1 hr. Different dilutions were used to correct for total IgA concentrations in serum from 
Tnfaip3DNGR1-WT and Tnfaip3DNGR1-KO mice. Incubation with anti-mouse IgA biotin/streptavi-
din (BD) and subsequently goat anti-Rat-AP (Sigma), followed by New Fuchsine (Sigma) 
staining were used to visualize liver-specific IgA. Slides were counterstained with Gills 
hematoxylin (Sigma).
2.6. Statistics
Statistical significance of data was calculated using the non-parametric Mann Whitney 
U test. P-values <0.05 were considered significant. All analyses were performed using 
Prism (GraphPad Software version 9, La Jolla, CA, USA). All data are presented as the 
mean with the standard error of the mean (SEM).
3. reSUlTS
3.1. Tnfaip3DNGr1-Ko mice have spontaneous periportal liver infiltrates and signs 
of chronic inflammation.
To investigate whether immune homeostasis is altered when cDCs harbor a DNGR1-
mediated deletion of the A20/Tnfaip3 gene, we evaluated 31-week-old Tnfaip3DNGR1 mice. 
Tnfaip3DNGR1-KO mice had splenomegaly and hyper cellularity in contrast to Tnfaip3DNGR1-WT 
littermate controls (Supplementary Figure 1A). Splenic DC and T-cell numbers did not 
differ between Tnfaip3DNGR1-KO mice and Tnfaip3DNGR1-WT mice (Supplementary Figure 
1B-c). Mainly marginal zone B-cells contributed to the increase of total splenic B-cells 
numbers in Tnfaip3DNGR1-KO mice compared to Tnfaip3DNGR1-WT mice (Supplementary Fig-
ure 1D).
We next evaluated kidneys, pancreas, intestines, and livers in 31-week-old Tnfaip-
3DNGR1-KO mice for signs of inflammation. Spleens of Tnfaip3DNGR1-KO mice showed mild 
architectural changes of the white pulp lymphoid follicles in comparison to WT mice 
(Supplementary Figure 2A). Pancreas, terminal ileum, colon, and kidneys of Tnfaip-
3DNGR1-KO mice did not show any sign of inflammation or remodelling (Supplementary 
Figure 2B-e). In contrast, livers of all Tnfaip3DNGR1-KO mice showed periportal inflammatory 
infiltrates at 31-weeks of age compared to WT mice (Figure 1A/B). Mild interface hepa-
titis (also known as piecemeal necrosis) and focal necrosis with inflammation, that are 
often seen in autoimmune hepatitis (AIH)36, could also be observed Tnfaip3DNGR1-KO mice, 
but not in WT mice (Figure 1c/D). Mild liver fibrosis also occurred around portal triads 
of Tnfaip3DNGR1-KO mice compared to controls (Figure 1e/F). These features resulted in 
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a significantly higher liver histopathologic score for Tnfaip3DNGR1-KO mice compared to 
WT mice (Figure 1G). Also increased cytokeratin 7 expression, a protein expressed in 
bile ducts and indicative for ductular reaction, could be observed in Tnfaip3DNGR1-KO mice 

























































































Figure 1: Tnfaip3DNGr1-Ko mice have spontaneous periportal liver infiltrates and signs of chronic in-
flammation.
Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice were analyzed at 31-weeks of age. (A) Hematoxylin and eosin 
(H&E) stained liver histology with periportal infiltrates (black dashed line) and lobular infiltrates (red dashed 
line). (B) Quantification of the portal inflammation score (max. 4). (C) Larger magnification H&E stained 
liver histology indicating areas of interface hepatitis (white arrow) and focal necrosis with inflammation 
(black arrows). (D) Quantified interface hepatitis and focal necrosis with inflammation score (max. 4). (E-F) 
Sirius Red staining to stain collagen fibers (E) and enumeration of the resulting fibrosis score (max. 6) (F). 
(G) Quantification of the total histopathology score (max. 18). (H) Immunohistochemistry of livers for Cyto-
keratin 7 (brown). (I) Quantification of serum liver enzymes AST and ALT in 31-week-old Tnfaip3DNGR1-WT mice 
and Tnfaip3DNGR1-KO mice. Scale bars represent 200 μm. Results of pooled data from 3 experiments and are 
presented as mean ± SEM of n = 15 mice per group. *P < 0.05, ***P < 0.001.





















































































































































































































































































































































Figure 2: DNGr1-mediated deletion of A20/Tnfaip3 targets both cDcs and mo-Dcs
57
crease in serum aspartate aminotransferase (AST) was observed in Tnfaip3DNGR1-KO mice 
compared to WT controls (Figure 1I). No differences were observed between male or 
female Tnfaip3DNGR1-KO mice (data not shown).
Summarizing, these data illustrate that aged Tnfaip3DNGR1-KO mice develop a spontane-
ous liver pathology characterized by the presence of periportal inflammatory infiltrates 
and signs of chronic inflammation.
3.2. DNGr1-mediated deletion of A20/Tnfaip3 targets both cDcs and mo-Dcs.
In line with histological findings, the total number of liver CD45+ hematopoietic cells 
was increased in Tnfaip3DNGR1-ROSA-KO mice compared to Tnfaip3DNGR1-ROSA-WT mice (Figure 
2A). Within liver CD45+ cells, we determined the different DC subsets (Figure 2B). The 
proportion of DCs from total CD45+ cells was lower in Tnfaip3DNGR1-ROSA-KO mice compared 
to Tnfaip3DNGR1-ROSA-WT mice, but total liver DC numbers were not significantly different 
(Figure 2c). Conventional DC1s and cDC2s were neither significantly altered as propor-
tions of DCs nor in cell numbers between the two genotypes (Figure 2D/e). To investi-
gate DNGR1-cre mediated deletion efficiency and the effect of A20/Tnfaip3 ablation on 
liver cDC homeostasis, we examined Tnfaip3DNGR1-ROSA-WT mice and Tnfaip3DNGR1-ROSA-KO mice, 
in which YFP expression can be used as a lineage tracer of DNGR1 expression. DNGR1-
lineage tracing studies revealed that DNGR1-mediated cre-recombinase activity 
targeted almost all mature cDC1s and ~30% of cDC2s. As mature cDC2s do not express 
DNGR127, this ~30% deletion is caused by DNGR1-cre efficacy in cDC progenitors, which 
do express DNGR1 although to a lower extent27. Similar to other organs27, in livers of 
Tnfaip3DNGR1-ROSA-WT mice ~95% of cDC1s showed YFP expression, which was reduced to 
~55% in Tnfaip3DNGR1-ROSA-KO mice (Figure 2F). YFP expression in liver cDC2s did not differ 
between Tnfaip3DNGR1-ROSA-WT mice and Tnfaip3DNGR1-ROSA-KO mice and remained ~35% (Fig-
ure 2F). The absolute number of YFP+ cDC1s was similar between Tnfaip3DNGR1-ROSA-WT mice 
and Tnfaip3DNGR1-ROSA-KO mice (Figure 2G). Plasmacytoid DCs in liver were unaffected by 
DNGR1-mediated deletion (~2% YFP+; data not shown). We next determined Kupffer 
cells and monocyte-derived DCs (moDCs) (Figure 2H). The total number of both Kupffer 
Tnfaip3DNGR1-ROSA-WT mice and Tnfaip3DNGR1-ROSA-KO mice were analyzed at 31-weeks of age. (A) Enumera-
tion of liver CD45+ cells. (B) Flow cytometric gating strategy of liver cDC1s (CD103+ CD11b-CD11chiMHC-
IIhiFcεRIα-CD64-) and cDC2s (CD11b+CD103-CD11chiMHC-IIhiFcεRIα-CD64-). Representative flow cytometry 
examples are shown from Tnfaip3DNGR1-ROSA-WT mice and Tnfaip3DNGR1-ROSA-KO mice. (C) Total DC number and pro-
portion of CD45+ cells. (D-G) Quantification of cDC1s and cDC2s as a proportion of liver DCs (D), cell num-
bers (E), proportion of YFP+ expressing cells (F) and the YFP+ cell numbers (G). (H) Flow cytometric gating 
strategy of liver Kupffer cells (F4/80+CD11bintMHC-IIhiCD64+CD11clo/int) and moDCs (F4/80+CD11bintMHC-
IIhiCD64+CD11chi) in Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice. (I-K) Quantification of Kupffer cell and 
moDC numbers (I), proportion of CD45+ hematopoietic cells (J), and proportion of YFP+ expressing cells (K) 
using flow cytometry. Representative data is shown from one experiment of 2 independent experiments. 
Results are presented as mean ± SEM of n = 4-7 mice per group. *P<0.05, **P<0.01.
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cells and moDCs was increased in Tnfaip3DNGR1-KO mice compared to Tnfaip3DNGR1-WT mice 
(Figure 2I). While Kupffer cell proportions of CD45+ cells were similar, moDCs sig-
nificantly expanded as a proportion of CD45+ cells in Tnfaip3DNGR1-KO mice compared 
to littermate controls (Figure 2J). YFP expression was almost absent in Kupffer cells 
(<1%) in both genotypes (Figure 2K). Liver moDCs, albeit present in low numbers in 
Tnfaip3DNGR1-ROSA-WT mice, harbored a slightly higher YFP expression WT mice (~45%) 
compared to and in Tnfaip3DNGR1-ROSA-WT and Tnfaip3DNGR1-ROSA-KO mice (~30%) (Figure 2K).
Concluding, DNGR1-lineage tracing indicated that in livers of control mice respectively 
95% and 35% of cDC1s and cDC2s, as well as 45% of moDCs express or once expressed 
DNGR1. Furthermore, due to deletion of A20/Tnfaip3 55% and 35% of liver cDC1s and 
cDC2s, along with 30% of liver moDCs were affected by DNGR1-targeting.
3.3. Surface cD40 expression is increased through both cell-intrinsic and cell-
extrinsic effects of Tnfaip3-deficiency in cDc1s, cDc2s, and moDcs.
In livers of Tnfaip3DNGR1-KO mice, both cDC1s and cDC2s showed significantly enhanced 
surface expression of the costimulatory molecule CD40 compared to Tnfaip3DNGR1-WT mice 
(Figure 3A/B). In Tnfaip3DNGR1-WT mice, expression of the co-inhibitory molecule PD-L1 was 
higher in cDC2s than in cDC1s (Figure 3B). Both cDC1s and cDC2s in Tnfaip3DNGR1-KO mice 
significantly increased PD-L1 expression in comparison to Tnfaip3DNGR1-WT mice (Figure 
3A/B). No differences were observed for MHC-I or MHC-II expression in cDCs (data not 
shown).
We next analyzed whether the altered co-stimulatory molecule expression was 
a direct consequence of A20/Tnfaip3-deletion, and compared YFP+ and YFP- cDCs, 
indicative of A20/Tnfaip3-deficient or A20/Tnfaip3-sufficient cDCs respectively in Tnfaip-
3DNGR1-ROSA-KO mice. YFP+ cDC1s and YFP+ cDC2s from Tnfaip3DNGR1-ROSA-KO mice harboured 
significantly higher CD40 expression in comparison to YFP- cDCs within the same livers 
(Figure 3c), whereas PD-L1 expression was similar in YFP+ and YFP- cDC1s/cDC2s from 
Tnfaip3DNGR1-ROSA-KO mice (Figure 3D). CD40 and PD-L1 expression was already enhanced 
on YFP-negative Tnfaip3-sufficient cDC1s/cDC2s from Tnfaip3DNGR1-ROSA-KO mice compared 
to Tnfaip3-sufficient cDC1s/cDC2s in Tnfaip3DNGR1-ROSA-WT mice (Figure 3c/D). CD40 
expression on liver moDCs did not differ between Tnfaip3DNGR1-KO mice and WT controls 
(Figure 3e/F). In contrast, YFP+ moDCs of Tnfaip3DNGR1-ROSA-KO mice showed a higher CD40 
expression than YFP- moDCs (Figure 3G/H). Liver moDCs also harboured higher PD-L1 
expression in Tnfaip3DNGR1-KO mice compared to Tnfaip3DNGR1-WT controls (Figure 3e/F), but 
this did not differ between YFP+ or YFP- moDCs in Tnfaip3DNGR1-ROSA-KO mice (Figure 3G/H).
In summary, both liver cDC1s and cDC2s of Tnfaip3DNGR1-KO mice show an activated 
phenotype, e.g. increased CD40 and PD-L1 expression, irrespective of Tnfaip3 dele-
tion. Only CD40 expression is specifically enhanced due to cell-intrinsic loss of Tnfaip3. 
Liver moDCs of Tnfaip3DNGR1-KO mice show elevated PD-L1 expression compared to 
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Tnfaip3DNGR1-WT mice. Strikingly, enhanced CD40 expression is specifically observed in 
Tnfaip3-deficient moDCs.
3.4. livers of Tnfaip3DNGr1-Ko mice have increased proportions of Th1-cells, Th17-
cells and Tregs.
The proportion of CD8+ T-cells and natural killer (NK)-cells within CD45+ cells were 
elevated in the livers of Tnfaip3DNGR1-KO mice compared to control mice (Figure 4A). 
The percentage of CD4+ Th-cells and neutrophils were reduced in Tnfaip3DNGR1-KO mice 
compared to Tnfaip3DNGR1-WT controls (Figure 4A). Liver F4/80+ macrophages and Kupffer 
cells, monocytes, and B-cell percentages were not significantly different (Figure 4A). 
Due to an increase in absolute numbers of CD45+ hematopoietic cells (Figure 2A), the 
total number of CD8+ T-cells, CD4+ Th-cells, and B-cells were significantly increased in 
Tnfaip3DNGR1-KO mice compared to controls (Figure 4B). Clusters of T-cells and B-cells 
were observed in the periportal infiltrates of Tnfaip3DNGR1-KO mice, while only occasion-
ally among hepatocytes in Tnfaip3DNGR1-WT mice (Figure 4c). In Tnfaip3DNGR1-KO mice, the 
majority of inflammatory lesions in the portal triads consisted of T-cells only (Figure 
4c). In addition, clusters of DCs and CD8+ T-cells were localised in periportal infiltrates in 
Tnfaip3DNGR1-KO mice, compared to sparsely located DCs and CD8+ T-cells in control mice 
(Supplementary Figure 3A). DNGR1+ cells, most likely cDC1s, were also localised within 
these periportal infiltrates of Tnfaip3DNGR1-KO mice (Supplementary Figure 3B).
The percentage of effector CD44+ CD8+ T-cells was increased in Tnfaip3DNGR1-KO mice 
compared to WT controls, however the percentage of granzyme B or interferon gamma 
(IFNγ)-positive CD8+ T-cells was unaltered (Supplementary Figure 4). No differences 
were observed in the proportions of CD44+ effector liver Th-cells (Figure 4D), but the 
proportions of liver Foxp3+CD25+ Tregs were augmented in Tnfaip3DNGR1-KO mice in 
comparison to WT mice (Figure 4e). Increased percentages of IFNγ single-positive, 
IFNγ/IL-10 double-producing, and IL-17A single-positive Th-cells were found in livers 
of Tnfaip3DNGR1-KO mice compared to WT mice (Figure 4F/G/H). No differences were 
observed in IL-10 single-positive Th-cells (Figure 4G). Interleukin-12-positive cells could 
also be observed within the periportal infiltrates in Tnfaip3DNGR1-KO mice (Supplementary 
Figure 3c).
In summary, liver CD8+ T-cells, Th-cells, and B-cells in Tnfaip3DNGR1-KO mice increase in 
number due to a total increase in hematopoietic cells and they accumulate in the peri-
portal regions. Th-cells within livers from Tnfaip3DNGR1-KO mice showed augmented pro-
portions of IFNγ and IL-17A single-producing Th-cells and IFNγ/IL-10 double-producing 
Th-cells.


















































































































































































































Figure 3: cD40 expression is increased through both cell-intrinsic and cell-extrinsic effects of Tn-
faip3-deficiency in cDc1s, cDc2s, and moDcs.
Tnfaip3DNGR1-ROSA-WT mice and Tnfaip3DNGR1-ROSA-KO mice were sacrificed at 31-weeks of age. (A) Histograms 
showing expression of CD40 and PD-L1 on liver cDC1s and cDC2s. (B) Quantification of CD40 and PD-L1 by 
median fluorescence intensity (MFI) on liver cDC1s and cDC2s. (C-D) Quantification of CD40 MFI (C) and 
PD-L1 MFI (D) in YFP-positive and YFP-negative liver cDC1s and cDC2s. (E) Histograms showing expres-
sion of CD40 and PD-L1 on liver moDCs. (F) Quantification of CD40 and PD-L1 by MFI on liver moDCs. (G) 
Histograms illustrating expression of CD40 and PD-L1 on liver YFP+ and YFP- moDCs in Tnfaip3DNGR1-ROSA-KO 
mice. (H) Quantification of CD40 and PD-L1 by MFI in YFP-positive and YFP-negative liver moDCs in Tn-
faip3DNGR1-ROSA-KO mice. Representative data is shown from one experiment of 2 independent experiments. 
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Results are presented as mean ± SEM of n = 4-7 mice per group. Significance in (C,H) is only shown for YFP+ 
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Figure 4: livers of Tnfaip3DNGr1-Ko mice have increased proportions of Th1-cells, Th17-cells and Tregs.
Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice were sacrificed at 31-weeks of age. (A) Representation of liv-
er immune cell proportions, being F4/80+ cells (CD45+F4/80+CD11bint), CD8+ T-cells (CD3+CD8+), Th-cells 
(CD3+CD4+), B-cells (CD19+), monocytes (CD11b+CD11c-GR1-NK1.1-), neutrophils (CD11b+GR1+NK1.1-), total 
DCs, and NK-cells (NK1.1+, GR1-). (B) Quantification of CD8+ T-cells, Th-cells and B-cells (CD19+B220+) in liver. 
(C) Immunohistochemistry of livers for CD3+ (brown, T-cells) and B220+ (purple, B-cells) cells in 31-week-old 
Tnfaip3DNGR1-KO mice and Tnfaip3DNGR1-WT mice also indicated by arrowheads. (D-E) Quantification of the pro-
portion activated (CD44+) Th-cells (D) and Tregs (E) using flow cytometry. (F) A representative example of 
flow cytometry data of liver CD4+ Th-cells with IFNγ, IL-10 and IL-17A production is shown for Tnfaip3DNGR1-WT 
mice and Tnfaip3DNGR1-KO mice. (G-H) Percentages of cytokine-producing Th-cells is shown, being IFNγ sin-
gle-positive, IFNγ/IL-10 double-positive, IL-10 single-positive (G) and IL-17A single-positive (H) using flow 
cytometry. Representative data from one experiment is shown out of 4 experiments for (B, D), 2 experi-
ments (G-H) or 1 experiment (A,C). Results are presented as mean ± SEM of n =4 mice per group. *P < 0.05.
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Figure 5: livers of Tnfaip3DNGr1-Ko mice contain increased Tfh-cells and plasma cells, likely producing 
liver-specific IgA antibodies.
Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice were sacrificed at 31-weeks of age. (A) Flow cytometry data 
of liver Tfh-cells (CD3+CD4+CXCR5+PD1+) from Tnfaip3DNGR1-KO mice and control mice. (B) Quantification of 
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3.5. livers of Tnfaip3DNGr1-Ko mice contain increased Tfh-cells and plasma cells, 
likely producing liver-specific IgA antibodies.
The presence of liver inflammatory lesion with both T-cells and B-cells could indicate di-
rect communication of follicular T-helper (Tfh)-cells with germinal center (GC) B-cells. In 
Tnfaip3DNGR1-KO mice, the proportions and absolute numbers of Tfh-cells (Figure 5A/B) as 
well as the number GC B-cells and plasma cells (Figure 5c) were significantly increased in 
the livers compared to littermate controls. Moreover, total IgG1 and IgA concentrations 
were significantly elevated in the serum of 31-week-old Tnfaip3DNGR1-KO mice compared to 
WT controls (Figure 5D). This increase coincided with significantly increased numbers of 
IgG1+ and IgA+ plasma cells in spleens and bone marrow (BM) (Figure 5e/F). In liver, only 
IgA+ plasma cells were significantly increased in Tnfaip3DNGR1-KO mice compared to control 
mice (Figure 5G). Remarkably, we detected increased serum IgG1 and IgA already in 
11-week-old mice (Supplementary Figure 5A).
We next investigated whether IgG1 and IgA from Tnfaip3DNGR1-KO mice recognised self-
antigens, but could not detect significant differences for antibodies against pyruvate 
dehydrogenase complex subunit E2 (PDC-E2), sp100, glycoprotein 210 (gp210), dsDNA 
or cardiolipin (Figure 5H/I/J). While IgG1 anti-dsDNA and anti-cardiolipin was enhanced 
in Tnfaip3DNGR1-KO mice compared to WT mice, these concentrations were very low in com-
parison to the reference serum of lupus-prone lpr mice (Figure 5J) and most likely not 
physiological relevant as no IgG deposition nor pathology was observed in the kidneys 
of Tnfaip3DNGR1-KO mice (Supplementary Figure 2D/e).
We next examined whether serum IgG1 or IgA of Tnfaip3DNGR1-KO mice recognized liver-
specific proteins. Serum IgG1 from Tnfaip3DNGR1-KO mice did not bind proteins present in 
liver or pancreas (data not shown). In contrast, serum IgA from 6 out of 10 mice from 
a panel of 31-week-old Tnfaip3DNGR1-KO mice recognized antigens in the liver periportal 
regions, while this was only detected by serum IgA from 1 out of 9 WT mice (Figure 
5K/l). Primarily liver cytoplasmic proteins were recognized by serum IgA from Tnfaip-
3DNGR1-KO mice (Figure 5m). Importantly, serum IgA from 11-week-old Tnfaip3DNGR1-KO mice 
did not recognize liver-specific proteins, whereas total IgA was elevated at that age 
the proportion Tfh-cells and cell numbers. (C) Enumeration of liver GC B-cells (CD19+B220+CD95+IgD-) and 
plasma cells (B220-CD138+). (D) Quantification of all serum immunoglobulin isotypes in 31-week-old mice. 
(E-G) Enumeration of IgG1+ plasma cells (B220-CD138+IgG1+) and IgA+ plasma cells (B220-CD138+IgGA+) in 
spleen (E), bone marrow (F), and liver (G). (H-J) Assessment of autoreactive IgG and IgA immunoglobulins 
towards PDC-E2 (H), IgG towards sp100 and gp210 (I) and IgG1 towards dsDNA and cardiolipin (J) in serum 
from 31-week-old mice using ELISA. 100 arbitrary units represent the average level of lupus-prone lpr mice 
in (J). (K) Livers from Rag1KO mice were incubated with serum from 31-week-old Tnfaip3DNGR1-WT and Tnfaip-
3DNGR1-KO mice and assessed for IgA binding. (L) Negative and positive autoreactive IgA staining numbers on 
Rag1KO livers using serum from Tnfaip3DNGR1-KO mice or Tnfaip3DNGR1-KO mice, depicted in pie-chart format, and 
in (M) higher magnification of bound IgA on Rag1KO livers. Results are presented as mean ± SEM of n = 4-19 
mice per group. *P < 0.05, **P < 0.01, ****P < 0.0001. Scale bars represent 200μm.
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(Supplementary Figure 5A/B), indicating that the auto-reactivity of IgA developed 
after the age of 11 weeks. Serum IgA from ~30% of Tnfaip3DNGR1-KO mice recognized 
pancreas-specific proteins, albeit with reduced staining intensity compared to liver tis-
sue (Supplementary figure 5c/D).
In summary, livers of Tnfaip3DNGR1-KO mice contain increased number of Tfh-cells, GC 
B-cells, and IgA+ plasma cells, accompanied by elevated serum IgG1 and IgA concentra-
tions. Importantly, IgA from Tnfaip3DNGR1-KO mice recognized self-proteins, specifically 
cytoplasmic proteins of cells within the hepatic periportal regions, which could be in-
volved in the pathogenesis of liver inflammation.
4. DIScUSSIoN
DCs play a crucial role in the maintenance of tolerance during steady state. The activa-
tion status of DCs can act like a switch in the development of tolerance or immunity6. 
Previously we and others have shown that DC-specific ablation of A20/Tnfaip3 led to 
spontaneous DC activation and subsequently T and B-cell activation, resulting in an 
inflammatory phenotype resembling SLE11 or IBD10. DCs comprise different subsets and 
cDCs are primarily known to maintain tolerance17, 22. To investigate whether A20/Tnfaip3 
deletion in cDCs induces autoimmunity, we crossed Tnfaip3-floxed mice to Clec9a/
DNGR1-cre recombinase mice, as previously this promotor was shown to mainly target 
cDCs in wild-type mice27.
In contrast to A20/Tnfaip3 ablation in all DC subsets, which induced systemic 
autoimmune disease resembling SLE11 or IBD10 in mice, Tnfaip3DNGR1-KO mice develop 
organ-specific autoimmune disease. Aged Tnfaip3DNGR1-KO mice acquired aggravated 
liver inflammatory infiltrates, consisting mainly of T-cells and some B-cells, adjacent to 
the portal triads and in lobules. This was accompanied by increased autoreactive IgA 
in serum, recognizing liver cytoplasmic proteins. DNGR1-driven targeting of DCs in the 
liver of control mice was similar to other organs27, being ~95% in cDC1s, ~35% in cDC2s 
and ~45% in moDCs. However, in Tnfaip3DNGR1-KO mice we found a striking decrease in 
the proportions of targeted cDC1s (~55%). It is not very likely that the DNGR1-driven 
excision in cDC1s was reduced in Tnfaip3DNGR1-KO mice. Rather, this finding indicates that 
due to A20/Tnfaip3-ablation, DC homeostasis was disturbed. Furthermore, liver cDC1s, 
cDC2s and moDCs show an enhanced activation status (e.g., increased CD40 expression) 
upon A20/Tnfaip3-ablation.
First signs of chronic liver inflammation, shown by increased cytokeratin 7 expression37 
and liver fibrosis, were found in 24-week-old Tnfaip3DNGR1-KO mice (data not shown) and 
further increased at 31-weeks of age. Kidneys and intestines, did not show inflammatory 
lesions, and only very mild inflammation was observed in pancreas. Inflammation plays 
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an important role in several liver pathologies, and genome-wide association studies 
(GWAS) have revealed TNFAIP3 single nucleotide polymorphisms (SNPs) associated to 
primary biliary cirrhosis (PBC)38, 39 and autoimmune hepatitis (AIH)40, 41. Our data show 
that A20/Tnfaip3-deletion in cDCs and moDCs leads to spontaneous (auto) immune 
responses in the liver.
Strikingly, DNGR1-cre mediated deletion of A20/Tnfaip3 in cDC1s reduces the 
proportion of cells targeted by DNGR1 from ~95% in Tnfaip3DNGR1-WT mice to ~55% 
in Tnfaip3DNGR1-KO mice. This could be induced by an enhanced sensitivity of cDC1s to 
undergo apoptosis, which is also regulated by A20/Tnfaip342. As the total number of 
DNGR1-targeted cDC1s was similar between Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO 
mice, this suggests that Tnfaip3-deficient cDC1s do not undergo apoptosis. The reduced 
proportion of Tnfaip3-deleted cDC1s in Tnfaip3DNGR1-KO mice could be a consequence of a 
robust selective advantage for the residual Tnfaip3-sufficient cDC1s in the Tnfaip3DNGR1-KO 
mice, as total CD45+ hematopoietic cells and thus total DCs increase in the liver. Alter-
natively, monocytes can adopt to a cDC1-phenotype in the presence of inflammatory 
signals43 and start expressing cDC1-typical molecules, like CD103, XCR1, and IRF8. Ad-
ditional studies are needed to identify the cause for the increase in Tnfaip3-sufficient 
cDC1s in Tnfaip3DNGR1-KO mice.
Next to DCs, the liver contains other myeloid antigen presenting cells (APCs) such as 
Kupffer cells and moDCs. Kupffer cell proportions in Tnfaip3DNGR1-KO mice remained con-
stant, while moDCs slightly increased in Tnfaip3DNGR1-KO mice livers, most likely recruited 
due to liver inflammation44, 45. Approximately 30% of moDCs in Tnfaip3DNGR1-KO mice were 
targeted by DNGR1-driven Cre expression and consequently deleted Tnfaip3. While 
kidneys are also known to have a similar proportion of DNGR1-Cre-mediated deletion27, 
we saw no inflammation in kidneys in Tnfaip3DNGR1-KO mice. Nevertheless, the liver phe-
notype observed in Tnfaip3DNGR1-KO mice will most likely not be solely induced by Tnfaip3 
ablation in cDCs, because affected moDCs may also contribute. Liver cDC1s, cDC2s, and 
moDCs are activated upon A20/Tnfaip3-ablation, indicated by enhanced co-stimulatory 
CD40 expression. Subtle differences in CD40 expression on cDCs can lead to substantial 
differences in T-cell activation, possibly due to a threshold effect. For instance, a 2-fold 
higher CD40 increase on cDC1s in non-obese diabetic (NOD) mice turns the balance from 
tolerant Tregs to effector Th1-cell responses46. In contrast, absence of CD40 on APCs/DCs 
during inflammatory conditions expands the number of Tregs47, 48. Thus, enhanced CD40 
expression on cDCs and a proportion of moDCs in Tnfaip3DNGR1-KO could well explain the 
increased induction of Th1-cells in the liver. Remarkably, transgenic mice with constitu-
tive CD11c-specific CD40-signalling have a break in tolerance, which coincided with 
increased Th1 and Th17-cell responses and strikingly also elevated serum IgA49. These 
features are also observed in Tnfaip3DNGR1-KO mice. Evaluating CD40 expression on A20/
Tnfaip3-deficient and A20/Tnfaip3-sufficient cDCs within the same Tnfaip3DNGR1-KO mouse 
chapter 3  | Tnfaip3 deficiency in DCs in context of autoimmune liver pathology
66
demonstrated that CD40 expression is largely, but not completely regulated by A20/
Tnfaip3 in a cell-autonomous way. Suppression of CD40 expression by A20/Tnfaip3 
has also been demonstrated in in vitro mesothelial cells50. However, elevated CD40 
expression was also observed on A20/Tnfaip3-sufficient cDCs from Tnfaip3DNGR1-KO mice 
compared to control mice, suggesting CD40 expression is additionally influenced by 
cell-extrinsic factors. In Tnfaip3DNGR1-KO mice both cDCs and moDCs expressed higher 
surface levels of the co-inhibitory molecule PD-L1 which was most likely regulated cell-
extrinsically as both A20/Tnfaip3-deficient and A20/Tnfaip3-sufficient cDCs within the 
same Tnfaip3DNGR1-KO mouse harbored similar elevated expression compared to control 
mice. Increased PD-L1 expression is probably driven by enhanced IFNγ51, produced by 
liver Th1-cells and CD8+ T-cells (data not shown) in Tnfaip3DNGR1-KO mice.
The inflammatory infiltrates in Tnfaip3DNGR1-KO mouse livers contained CD8+ T-cells, 
Th-cells, and B-cells. These lymphocytes were detected next to DCs in the periportal 
inflammatory infiltrates, which could imply local T- and B-cell activation. A number of 
genes involved in T-cell activation, such as IL12A, IL12RB2 and STAT4, all involved in IL-12R 
signaling, are strongly associated to liver autoimmune biliary diseases52, and involved in 
Th1 and Th17-cell polarization. Tnfaip3DNGR1-KO mice showed increased liver Th1-cells and 
Th17-cells, together with augmented IL-12+ cells, which are present around periportal 
infiltrates.
Although the percentage of IFNγ-producing CD8+ T-cells did not increase in livers of 
Tnfaip3DNGR1-KO mice, their total cell number did (data not shown). While the Th1 cytokine 
IFNγ is hepatotoxic53 and plays pathological roles in mouse models of autoimmune liver 
disease54, 55, controversy exists regarding the function of the Th17 cytokine IL-17A, being 
either protective56 or pathogenic54, 57. In our study, Th17-cells appeared dispensable for 
liver inflammation in Tnfaip3DNGR1-KO mice, as the liver pathology was unaltered in the 
absence of liver IL-17A+ Th-cells (data not shown). Since Th-cell transfer from IFNγ-
overexpressing mice induced similar liver pathology58 as observed in Tnfaip3DNGR1-KO mice, 
this could be indicative that Th1-cells are pathogenic in Tnfaip3DNGR1-KO mice. Strikingly, the 
majority of IFNγ-producing Th-cells co-expressed IL-10 in livers from Tnfaip3DNGR1-KO mice, 
which has broad anti-inflammatory properties. Expression of IL-10 by Th1-cells could 
be a self-regulatory mechanism to prevent excessive local inflammation59, as IL-10 can 
reduce IL-12 secretion from DCs60.
Aggregation of DCs, T-cells, and B-cells in the livers of Tnfaip3DNGR1-KO mice could pro-
mote active TLO formation, in which a GC reaction with help of Tfh-cells would support 
B-cell activation, class switching, and antibody production. Indeed, liver Tfh-cells, GC B-
cells, and plasma cells are increased in Tnfaip3DNGR1-KO mice. In autoimmune liver disease 
patients, liver Tfh-cells are expanded compared to healthy controls61 and Tfh-cells even 
correlate with serum anti-nuclear antibody (ANA) titers62. Elevated IgG63 or IgM64 are 
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often seen in autoimmune liver diseases, which are known to correlate with circulating 
Tfh-cells65. The increased liver Tfh-cells in Tnfaip3DNGR1-KO mice may have contributed to 
establishing elevated serum total IgG and IgA from a young age. In autoimmune liver 
disease, increased autoreactive IgA is observed66, which we also find in Tnfaip3DNGR1-KO 
mice. Serum of Tnfaip3DNGR1-KO mice contained autoreactive IgA specifically recognizing 
cytoplasmic proteins within the periportal regions. The explicit increase in liver IgA+ 
plasma cells, and not liver IgG1+ plasma cells, might explain why only liver-specific 
autoreactive IgA is observed. As liver periportal inflammation was already present on 
11-weeks of age, but autoreactive IgA was not yet detected in Tnfaip3DNGR1-KO mice at that 
time, this could indicate that auto-antibodies do not initiate liver pathology but rather 
exacerbate the phenotype.
In summary, DNGR1-cre-mediated deletion of A20/Tnfaip3 in cDCs and moDCs pro-
vokes chronic liver inflammatory infiltrates surrounding the portal triads. A20/Tnfaip3 
directly controls CD40 expression in liver cDC1s, cDC2s and moDCs in vivo, with increased 
proportions of Th1-cells, Th17-cells, and Tfh-cells and autoreactive B-cell activation. Our 
data illustrate that activation of conventional DCs and moDCs is sufficient to shift the 
balance between tolerance and immunity and induces organ-specific autoimmunity, 
especially in the liver.
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Supplementary Figure 1: Tnfaip3DNGr1-Ko mice have splenomegaly with increased marginal zone B-
cells.
Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice were analyzed at 31-weeks of age. (A) Quantification of 
both spleen weight and total cell count. (B-c) Enumeration of dendritic cells (CD11chiMHC-IIhi) (B) T-
cells (CD3+) (c), B-cells (CD19+B220+), Follicular B-cells (CD19+B220+CD23+) and marginal zone B-cells 
(CD19+B220+CD21/35+) (D) in spleen cell suspensions by flow cytometry. Results are presented as mean 
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Supplementary Figure 2: most tissues have absence of inflammation in Tnfaip3DNGr1-Ko mice.
(A-c) H&E staining of spleens (A), pancreas (B) and terminal ileum and colon (c) from 31-week-old Tn-
faip3DNGR1-KO mice. Arrowheads indicate mild inflammatory infiltrate. (D) Periodic acid-Schiff (PAS)+ staining 
of kidneys from 31-week-old Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice. (e) Immunohistochemistry for 
glomerular IgG+ (brown) depositions in kidneys of 31-week-old mice. Dashed line highlights glomeruli. A 
lupus mouse positive control (Cd11c-cre mediated Tnfaip3-deleted mice) is also illustrated for comparison. 
Scale bars represent 200μm.











Supplementary Figure 3: Inflammatory infiltrates in Tnfaip3DNGr1-Ko mice contain Dcs, cD8+ T-cells 
and DNGr1+ cells.
(A-c) Immunohistochemistry for CD8+ (purple, arrowhead) and CD11c+ cells (orange, arrowhead) (A) 
DNGR1+ cells (pink, arrowhead, positive in n=5/5 mice) (B) and IL-12 (brown, arrowhead, positive in n=4/6 












































Supplementary Figure 4 A         
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Supplementary Figure 4: Tnfaip3DNGr1-Ko mice have increased liver cD8+ T-cell activation.
Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice were sacrificed at 31-weeks of age under naïve conditions and 
the livers were examined. (A-c) Quantification of the proportion activated (CD44+) (A), Granzyme B+ (B) and 
IFNγ+ (c) CD8+ T-cells using flow cytometry. Pooled data from 4 experiments is shown for (A), 3 experiments 
for (B) and representative data from one out of 2 experiment is shown for (c). Results are presented as mean 
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Supplementary Figure 5: IgA from Tnfaip3DNGr1-Ko mice are primarily directed to liver antigens.
Serum of Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice was obtained. (A) Quantification of IgG1 and IgA 
immunoglobulin levels over time between 11 and 31-week-old mice. (B) Representative illustration of IgA 
autoreactivity towards liver proteins on liver of Rag1KO mice in serum of 11, 15 and 31-week-old Tnfaip-
3DNGR1-KO mice. (c-D) Representative negative and positive IgA staining on pancreas of Rag1KO mice (c) and 
illustrated in pie chart format from both Tnfaip3DNGR1-WT mice and Tnfaip3DNGR1-KO mice (D). Results are from 2 
experiments presented as mean ± SEM of n = 6-10 per group. *P<0.05, **P < 0.01, ***P < 0.001. Scale bars 
represent 200μm.
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SUPPlemeNTAry mATerIAl meTHoDS:
liver and Kidney (immuno)histochemistry
Liver cryosections were stained for DNGR1 (Clec9a, included in Supplementary table 
2) and CD11c with CD8 (also included in Supplementary table 2). Cryo-sections were 
initially fixed in acetone. Sections were then incubated for 1hr with the primary antibod-
ies. After washing, slides were incubated for 30 min with secondary antibodies (Supple-
mentary table 2). Diaminobenzene (DAB) (for CD11c), Fast blue alkaline phosphatase 
(for CD8) and new fuchsin alkaline phosphatase (for DNGR1) substrates were used to 
retrieve specific staining. Counterstaining was performed with Gills hematoxylin (Sigma) 
(only for DNGR1-staining).
Six-μm-thick paraffin embedded kidney sections were stained with Periodic Acid 
Schiff (PAS; Sigma). For immunohistochemical stainings, antigen retrieval on paraffin-
sections were established using citrate buffer (Sigma Aldrich). Paraffin kidney sections 
were stained for IgG with the primary antibody (Supplementary table 2) and paraffin 
liver sections were stained for IL-12 (Supplementary table 2). After washing, slides 
were incubated for 30 min with secondary antibodies (Supplementary table 2). The 
anti-Rabbit ABC Peroxidase Kit was utilized (Vector Labs, Burlingame, CA, USA). Diami-
nobenzene (DAB) was used to retrieve specific staining.
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Supplementary Table 1: Antibodies used for flow cytometry.
Antibody conjugate clone company
B220 Alexa Fluor 700 RA3-6B2 eBioscience
B220 Pe-Cy7 RA3-6B2 eBioscience
CD103 ef450 2E7 eBioscience
CD11b Biotin M1/70 BD
CD11c PE-Texas Red N418 Invitrogen
CD138 Brilliant Violet 605 281-2 BD
CD19 APC-Cy7 1D3 BD
CD25 Biotin PC61.5 eBioscience
CD3 PE-CF594 145-2C11 BD
CD4 Brilliant Violet 605 RM4-5 BD
CD4 Brilliant Violet 711 RM4-5 BD
CD44 FITC IM7 eBioscience
CD44 APC-Cy7 IM7 BD
CD45 Brilliant Violet 711 30-F11 BD
CD45 PerCP-ef710 30-F11 eBioscience
CD62L APC-ef780 MEL-14 eBioscience
CD64 Alexa Fluor 647 X54-5/7.1 BD
CD8 PE-Cy7 53-6.7 eBioscience
CD95 PE-Texas Red Jo2 BD
CXCR5 Biotin J43 eBioscience
F4/80 APC-ef780 BM8 eBioscience
FCƐRIα Biotin MAR-1 eBioscience
Foxp3 Alexa Fluor 700 FJK-16s eBioscience
Granzyme B PE MHGB04 Caltag
IFN-γ ef450 XMG1.2 eBioscience
IgA FITC C10-3 BD
IgD APC 11-26c eBiosicence
IgG1 PE A85-1 BD
IgM PE-Cy7 II/41 eBioscience
IL-10 Alexa Fluor 488 JES5-16E3 eBioscience
IL-17A Alexa Fluor 700 TC11-18H10.1 BD
Ly6G/GR1 FITC RB6.8C5 eBioscience
MHC-II Alexa Fluor 700 M5/114.15.3 eBioscience
NK1.1 PE PK136 eBioscience
PD1 Brilliant Violet 421 J43 BD
RORγt PerCP-Cy5.5 Q31-378 BD
Streptavidin Brilliant Violet 786 BD
Streptavidin Brilliant Violet 711 BD
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Supplementary Table 2: Primary and secondary antibodies for Immunohistochemistry
Primary 
Antibody
clone company   Secondary Antibody Product 
code
company
rat anti-cD8-Pe 53-6.7 eBioscience, 











San Diego, CA, 
USA









  Goat anti-rabbit Po PK-4001 Vector Laboratories, 
Burlingame, CA, 
USA
rat anti-clec9a MAB67761 R&D, 
Minneapolis, 
MN, USA




rabbit anti-cD3 Polyclonal DAKO, 
Glostrup, 
Denmark
  Goat anti-rabbit Po PK-4001 Vector Laboratories
rat anti-B220 RA3-6B2 Bioceros, 
Utrecht, The 
Netherlands
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deficient myeloid cells is IL‐17‐independent
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ABSTrAcT
Background: Asthma is a heterogeneous disease of the airways that involves several 
types of granulocytic inflammation. Recently, we have shown that the activation status 
of myeloid cells regulated by TNFAIP3/A20 is a crucial determinant of eosinophilic or 
neutrophilic airway inflammation. However, whether neutrophilic inflammation ob-
served in this model is dependent on IL-17 remains unknown.
objective: In this study, we investigated whether IL-17RA-signalling is essential for 
eosinophilic or neutrophilic inflammation in house dust mite (HDM)-driven airway 
inflammation.
methods: Tnfaip3fl/flxLyz2+/cre (Tnfaip3LysM-KO) mice were crossed to Il17raKO mice, generat-
ing Tnfaip3LysMIl17raKO mice and subjected to an HDM-driven airway inflammation model.
results: Both eosinophilic and neutrophilic inflammation observed in HDM-exposed WT 
and Tnfaip3LysM-KO mice respectively, was unaltered in the absence of IL-17RA. Production 
of IL-5, IL-13 and IFNg by CD4+ T cells was similar between WT, Tnfaip3LysM-KO, and Il17raKO 
mice, whereas mucus-producing cells in Tnfaip3LysM-KOIl17raKO mice were reduced com-
pared to controls. Strikingly, spontaneous accumulation of pulmonary Th1, Th17 and 
gd-17 T-cells was observed in Tnfaip3LysM-KOIl17raKO mice, but not in the other genotypes. 
Th17 cell-associated cytokines such as GM-CSF and IL-22 were increased in the lungs 
of HDM-exposed Tnfaip3LysM-KOIl17raKO mice, compared to IL-17RA-sufficient controls. 
Moreover, neutrophilic chemo-attractants CXCL1, CXCL2, CXCL12, and Th17-promoting 
cytokines IL-1b and IL-6 were unaltered between Tnfaip3LysM-KO and Tnfaip3LysM-KOIl17raKO 
mice.
conclusion and clinical relevance: These findings show that neutrophilic airway 
inflammation induced by activated TNFAIP3/A20-deficient myeloid cells can develop 
in the absence of IL-17RA-signalling. Neutrophilic inflammation is likely maintained by 
similar quantities of pro-inflammatory cytokines IL-1b and IL-6, that can independently 
of IL-17 signalling, induce the expression of neutrophil chemo-attractants.
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INTroDUcTIoN
Asthma is characterized by reversible airway obstruction, airway remodelling and mu-
cus production, together with increased pulmonary inflammation1. Granulocytic cells 
observed in pulmonary inflammation of asthmatic patients can comprise eosinophils, 
neutrophils, or a mixture of both cell types2. Eosinophilic inflammation is induced by 
interleukin (IL)-5, a type 2 cytokine produced by both Th2 cells and innate lymphoid 
cells type 2 (ILC2s)3. Neutrophilic inflammation is triggered by IL-8 produced by airway 
epithelial cells after activation by IL-174. IL-17 furthermore contributes to asthma symp-
toms, because (1) it induces airway remodelling by promoting fibroblast proliferation, 
(2) reduces apoptosis of smooth muscle cells, and (3) increases the expression of mucin 
genes in airway epithelial cells5-7. Th17 cells primarily produce IL-17 and Th17-associated 
neutrophilic inflammation is particularly found in late-onset asthma patients with a 
severe phenotype8, 9. Unfortunately, severe asthma patients are often unresponsive to 
corticosteroid treatment, leading to frequent asthma exacerbations and higher morbid-
ity10. Neutrophils and Th17 cells are likely contributing to this phenotype, as both cell 
types are corticosteroid insensitive11-13. Therefore, it is imperative to investigate the 
contribution of IL-17-signalling to the development of neutrophilic asthma.
Dendritic cell (DC) activation is essential for Th cell differentiation as antigen load, 
expression of costimulatory molecules, and DC-derived cytokines determine whether 
Th2 or Th17 cell differentiation is induced14. DC activation is controlled by TNFAIP3 
(TNFα-induced protein 3, also known as A20), an ubiquitin modifying enzyme that deu-
biquitinates several key intermediate NF-κB signalling molecules, and thereby controls 
NF-κB-mediated cell activation15. TNFAIP3 is also implicated in Th2-associated disorders, 
as genetic polymorphisms in TNFAIP3 and TNFAIP3 interacting protein (TNIP) have been 
associated with risk of developing allergies and asthma16, 17. Recently, we found that 
increasing the activation status of DCs by ablation of the Tnfaip3 gene in myeloid cells 
induced a neutrophilic inflammation in house dust mite (HDM)-mediated asthma proto-
cols, which was accompanied with enhanced number of IL-17-producing CD4+ T cells18.
To investigate whether the HDM-driven neutrophilic airway inflammation is depen-
dent on IL-17, we crossed myeloid-specific Tnfaip3 knockout mice (Tnfaip3LysM-KO mice)19 
to Il17raKO mice, generating Tnfaip3LysMIl17raKO mice, in which IL-17A, IL-17E and IL-17F-
signalling is disabled20. Absence of IL-17RA-signalling in Tnfaip3LysM-KO mice does not 
significantly affect neutrophilic inflammation, most likely due to enhanced amounts 
of IL-1β and IL-6 that can also promote the production of several neutrophil chemo-
attractants.
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mATerIAlS AND meTHoDS
mice
Male and female C57BL/6 mice harbouring a conditional  Tnfaip3  allele  between 
LoxP-flanked sites21 were crossed to transgenic mice expressing the Cre recombinase 
under the LysM  promotor22, generating Tnfaip3fl/flxLyz2+/cre mice, in which Tnfaip3 will 
be deleted in cells that express or have expressed LysM19 (Tnfaip3LysM-KO mice). Tn-
faip3fl/flLyz2+/+ littermates (wild type (WT) mice) were used as controls. Tnfaip3LysM mice 
were crossed with conventional Il17raKO mice23, creating Tnfaip3fl/flxLyz2+/crexIl17ra-/- mice 
(Tnfaip3LysM-KOIl17raKO mice) and Tnfaip3fl/flxLyz2+/+xIl17ra-/- mice (Il17raKO mice). Mice were 
housed under specific pathogen-free conditions and were analysed at ~8 weeks (naïve 
and House Dust Mite (HDM) experiments) or at ~18 weeks (arthritis experiments). All 
experiments were approved by the animal ethical committee of the Erasmus MC, Rot-
terdam, The Netherlands (EMC3328 and EMC3333).
HDm-induced allergic airway inflammation
During intranasal (i.n.) exposures, mice were anesthetized using isofluorane. On day 0, 
mice were sensitized with 1 μg/40 μL HDM (Greer Laboratories Inc, Lenoir, NC, USA) i.n. or 
with 40 μL PBS (GIBCO Life Technologies, Carlsbad, CA, USA) as a control and challenged 
with 10 μg/40 μl HDM on days 7-11. Four days after the last challenge, bronchoalveolar 
lavage (BAL), lung, and mediastinal lymph node (MLN) were collected.
cell suspension preparation
BAL was obtained by flushing the lungs three times with 1 mL PBS containing 0.5 
mm EDTA (Sigma-Aldrich, St. Louis, MO, USA). The right lung was inflated with either 1:1 
PBS/Tissue-TEK O.C.T. (VWR International, Darmstadt, Germany) solution, or snap-frozen 
in liquid nitrogen, and kept at −80°C until further processing for histology. The left lung 
was used for flow cytometry. Single-cell suspensions of the left lung were obtained by 
digesting using DNase (Sigma-Aldrich) and Liberase (Roche, Basel, Switzerland) for 30 
min at 37°C. After digestion, the lungs were homogenized using a 100-μm cell strainer 
(Fischer Scientific, Waltham, MA, USA) and red blood cells were lysed using osmotic lysis 
buffer (8.3% NH4CL, 1% KHCO3, and 0.04% NA2EDTA in Milli-Q). MLN and spleen were 
isolated for flow cytometry, for which they were homogenized through a 100-μm cell 
strainer.
Flow cytometry procedures
Flow cytometry surface and intracellular staining procedures have been described pre-
viously24. Monoclonal antibodies used for flow cytometric analyses are listed in Supple-
mentary table 1. For all experiments, dead cells were excluded using fixable viability 
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dye (eBioscience, San diego, CA, USA). For measuring cytokine production, cells were 
stimulated with 10 ng/mL PMA (Sigma-Aldrich), 250 ng/mL ionomycin (Sigma-Aldrich), 
and GolgiStop (BD Biosciences, San Jose, CA, USA) for 4 h at 37°C. Data were acquired 
using a LSR II flow cytometer (BD Biosciences) with FACS DivaTM software and analysed 
with FlowJo version 9 (Tree Star Inc software, Ashland, OR, USA).
lung histology
Six-μm-thick paraffin embedded lung sections were stained with periodic acid-Schiff 
(PAS) to visualize goblet cell hyperplasia.
cytokine mrNA assessment by Quantitative real-Time Pcr
Homogenized left lower lung lobe was used to isolate and purify total RNA using the 
GeneElute mammalian total RNA miniprep system (Sigma-Aldrich) and RNA quantity 
was determined using a NanoDrop 1000 (VWR International). Up to 0.5 μg of total RNA 
was reverse-transcribed with SuperScript II reverse transcriptase (Invitrogen). Gene ex-
pression was analysed for Gapdh, Cxcl1, Cxcl2, Cxcl12, Il1b, Il6, Il22, Il23, Csf2, and Muc5a in 
SYBR Green Master Mixes (Qiagen, Hilden, Germany) using an ABI Prism 7300 Sequence 
Detector and ABI Prism Sequence Detection Software version 1.4 (Applied Biosystems, 
Foster City, CA, USA). Forward and reverse primers for each gene are listed in Supple-
mentary table 2. Samples were analysed simultaneously for Gapdh mRNA as internal 
control. Each sample was assayed in duplicate and relative expression was calculated 
as 2^(-DCt), where DCt is the difference between Ct of the gene of interest and GAPDH.
Statistical analysis
All data was presented as means ± SEM. Mann–Whitney U-tests were used for compari-
son between two groups, and a P-value of <0.05 was considered statistically significant. 
All analyses were performed using Prism (Version 5, GraphPad Software, La Jolla, CA, 
USA).
reSUlTS
loss of Il-17rA-signalling combined with myeloid TNFAIP3 deficiency increases 
splenic monocytes, neutrophils and γδ T cells with progressing age.
To investigate the role of IL-17RA-signalling in HDM-driven neutrophilic airway inflam-
mation responses, we crossed Tnfaip3LysM mice18, 19 with conventional Il17raKO mice23. It 
has been demonstrated that aged Tnfaip3LysM-KO mice develop arthritis19 and that Il17raKO 
mice have altered monocyte25 and neutrophil26, 27 homeostasis. We therefore first exam-
ined whether abrogation of IL-17RA-signalling in Tnfaip3LysM-KO mice induces additional 
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alterations in the immune system. We assessed spleens of 8 and 18-week-old mice, as a 
representation of the systemic immune state. Both 8 and 18-week-old Tnfaip3LysM-KO and 
Tnfaip3LysM-KOIl17raKO mice showed splenomegaly in comparison to WT and Il17raKO control 
mice (Figure 1A), whereas total splenic cell counts were only increased in 8 and 18-week 
old Tnfaip3LysM-KOIl17raKO mice (Figure 1B). Monocytes and neutrophils (gated as shown in 
Supplementary Figure 1) were significantly increased in 8-week-old Tnfaip3LysM-KO mice 
in comparison to WT mice (Figure 1c-D), however only neutrophils were significantly 
increased in 18-week-old Tnfaip3LysM-KO mice compared to WT mice (Figure 1D), confirming 
previous findings19. Interestingly, both neutrophils and monocytes were significantly in-
creased in 18-week-old Tnfaip3LysM-KOIl17raKO mice compared to Tnfaip3LysM-KO mice (Figure 
1c-D). Despite elevated monocyte and neutrophil numbers in Tnfaip3LysM-KOIl17raKO mice, 
the macroscopic and microscopic arthritis phenotype was similar between Tnfaip3LysM-KO 
mice and Tnfaip3LysM-KOIl17raKO mice (Supplementary Figure 2).
As IL-17 controls its own expression in CD4+ T cells26, we assessed conventional TCRαβ 
T cells and γδ T cells in the spleen (gating shown in Figure 1e). Total CD4+ T helper (Th) 
cell numbers were not different between the genotypes in 8-week old mice, but were 
significantly increased in 18-week-old Il17raKO mice compared to WT mice (Figure 1F). 
Splenic RORγt+ Th17 cells were elevated in 8-week-old Tnfaip3LysM-KOIl17raKO mice com-
pared to Tnfaip3LysM-KO mice, but this was no longer seen in 18-week-old mice (Figure 
1G). Only 18-week-old Il17raKO mice and Tnfaip3LysM-KOIl17raKO mice had increased splenic 
γδ T cell numbers compared to respective Il17raWT controls (Figure 1H). Splenic CD8+ 
T cells were reduced in Tnfaip3LysM-KO mice and Tnfaip3LysM-KOIl17raKO mice compared 
to respective Tnfaip3LysM-WT littermate controls at both ages (Figure 1I). Splenic B cell 
numbers did not differ between genotypes in both 8-week-old and 18-week-old mice 
(Figure 1J).
Taken together, these data show that myeloid TNFAIP3 deficiency with additional 
loss of IL-17RA-signalling induces minimal systemic immune changes at a young age, 
as only splenic Th17 cells are increased and CD8+ T cells are decreased. In contrast, with 
progressing age myeloid TNFAIP3 deficient mice with abrogated IL-17RA-signalling ac-
cumulate splenic monocytes, neutrophils and γδ T cells.
House dust mite-induced eosinophilic and neutrophilic airway inflammation is 
unaltered in the absence of Il-17rA-signalling.
To investigate the requirement of IL-17RA-signalling on neutrophilic airway inflamma-
tion, we exposed young Tnfaip3LysMIl17ra mice to an HDM-driven airway inflammation 
model (Figure 2A). As previously shown18, HDM-sensitization and challenge induced 
a predominant eosinophilic inflammation in WT mice compared to PBS-sensitization, 
whereas Tnfaip3LysM-KO mice developed a primarily neutrophilic inflammation in the bron-
choalveolar lavage (BAL) (Figure 2B). Absence of IL-17RA-signalling did not significantly 
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alter eosinophilic or neutrophilic inflammation in HDM-sensitized Tnfaip3LysM-KOIl17raKO 
mice compared to HDM-sensitized Tnfaip3LysM-KO mice (Figure 2B). BAL DCs were in-
creased in both HDM-sensitized WT mice and Il17raKO mice compared to their respective 
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Figure 1: loss of Il-17rA-signalling combined with myeloid TNFAIP3 deficiency increases splenic 
monocytes, neutrophils and γδ T cells with progressing age.
Tnfaip3LysMIl17ra mice were analysed at 8 weeks and 18 weeks of age. (A-B) Quantification of spleen weight 
(A) and total cell numbers (B). (c-D) Enumeration of monocytes (c) and neutrophils (c) analysed in spleen 
cell suspensions by flow cytometry. (e) Flow cytometric gating strategy of T cells and γδ T cells. Example is 
shown from a spleen obtained from a WT mouse. (F-H) Cell numbers are depicted of Th cells (F), Th17 cells 
(G), γδ T cells (H), CD8+ T cells (I) and B cells (J) in spleen cell suspensions by flow cytometry. Results are 
presented as mean ± SEM of n = 4-10 per group and are pooled from several experiments. *P < 0.05, **P < 
0.01, ***P < 0.001.
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DC numbers were reduced compared to HDM-sensitized WT mice and were increased 
in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice compared to HDM-sensitized Tnfaip3LysM-KO 
mice (Figure 2B). The absence of IL-17RA did not significantly alter the number of BAL 
macrophages in comparison to IL-17RA sufficient controls (Figure 2B).
HDM-sensitized WT and Il17raKO mice exhibited enhanced small airway mucus-
producing goblet cells and inflammatory cells compared to their PBS-sensitized controls 
(Figure 2c). HDM-sensitized Tnfaip3LysM-KO mice had similar numbers of mucus-positive 
cells in both small and large airways compared to HDM-sensitized WT mice (Figure 2c). 
Remarkably, with additional loss of IL-17RA-signalling, the amount of goblet cells in 
small and large airways and lung Muc5a mRNA levels were severely reduced in HDM-
sensitized Tnfaip3LysM-KOIl17raKO mice compared to HDM-sensitized Il17raKO mice (Figure 
2c-D).
In HDM-sensitized WT mice, the numbers of total T cells and CD4+ T cells in BAL fluid 
increased compared to PBS-sensitized WT mice (Figure 2e). Total BAL T cells, Th cells and 
γδ T cells were prominently elevated in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice com-
pared to HDM-sensitized Tnfaip3LysM-KO mice (Figure 2e). HDM-sensitized Il17raKO mice 
had a slight increase in γδ T cells compared to HDM-sensitized WT mice (Figure 2e). 
Differences in total T cells and γδ T cells were not observed in the MLN (Supplementary 
Figure 3).
In conclusion, absence of IL-17RA-signalling did not significantly alter eosino-
philic or neutrophilic airway inflammation in respectively HDM-treated Il17raKO and 
Tnfaip3LysM-KOIl17raKO mice. In contrast, abrogated IL-17RA-signalling in combination with 
Tnfaip3-deficient myeloid cells hampered goblet cell hyperplasia. While Th cells and 
γδ T cells increase equally in Tnfaip3LysM-KO and WT mice upon HDM sensitisation, these 
populations remarkably increase with loss of IL-17RA-signalling.
loss of Il-17rA-signalling does not reduce lung Th2 cytokines in an HDm-
sensitized model, but increases Il-17 production.
The effects of IL-17 on Th2 differentiation in allergic asthma models depend on the 
allergen used and the timing of IL-17 exposure28-30. As eosinophilia and neutrophilia 
were only moderately affected by the loss of IL-17RA in HDM-sensitized Tnfaip3LysM-WT 
and Tnfaip3LysM-KO mice, we determined the effects of IL-17RA-signalling on cytokine 
secretion by T cells upon HDM-provoked airway inflammation. As expected, IL-13 and 
IL-5-expressing Th cells were increased within the BAL of HDM-sensitized WT mice com-
pared to PBS-sensitized WT mice (Figure 3A-B). IL-13+ and IL-5+ Th cells were unaltered 
in HDM-sensitized Il17raKO and Tnfaip3LysM-KOIl17raKO mice compared to their respective 
controls with functional IL-17RA-signalling (Figure 3B). HDM-sensitized Tnfaip3LysM-KOIl-
17raKO mice had reduced IL-13+ and IL-5+ Th cells compared to HDM-sensitized Il17raKO 
mice (Figure 3B). As previously shown18, BAL IL-17+ Th cells increased in HDM-sensitized 
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Tnfaip3LysM-KO mice compared to HDM-sensitized WT controls. Already in PBS-sensitized 
Il17raKO mice, an increase of BAL IL-17+ Th cells was observed compared to PBS-sensi-
tized WT mice, which was even more enhanced in HDM-sensitized Tnfaip3LysM-KOIl17raKO 
mice (Figure 3B). BAL IFNγ-producing Th cells were only increased in HDM-sensitized 
0 7 8 9 10 11 15








































































 T cells 
BAL 









































WT    PBS
WT     HDM
Tnfaip3LysM-KO  HDM
Il17raKO   
Il17raKO    

































































WT  HDM WT  HDM
Figure 2: House dust mite induced eosinophilic and neutrophilic airway inflammation is unaltered in 
the absence of Il-17rA-signalling.
(A) Mice were sensitized with PBS or HDM (1 μg) on day 0 and challenged with 10 μg HDM from day 7-11. 
Analysis was performed at day 15. (B) Quantification of bronchoalveolar lavage (BAL) fluid eosinophils, 
neutrophils, dendritic cells and macrophages by flow cytometry. (c) Periodic Acid Schiff (PAS) stained lung 
small airway and large airway histology of Tnfaip3LysMIl17ra mice after HDM exposure. Scale bar indicates 
200μM. (D) Muc5a mRNA levels within lung homogenates of PBS and HDM challenged Tnfaip3LysMIl17ra 
mice. (e) Enumeration of total CD3+ T cells, CD4+ Th cells, CD8+ T cells and γδ T cells in BAL by flow cytom-
etry. Results are presented as mean ± SEM of n = 6 per group and are representative of two independent 
experiments. *P < 0.05, **P < 0.01.
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Tnfaip3LysM-KOIl17raKO mice compared to either HDM-sensitized Il17raKO or Tnfaip3LysM-KO 
mice (Figure 3B).
In conclusion, lack of IL-17RA-signalling did not alter Th2 cytokines in HDM-sensitized 
mice, which correlated with the previously seen eosinophilic infiltrate. In contrast, IL-17-
production and IFNγ-production by Th cells significantly increased in HDM-sensitized 
mice lacking myeloid TNFAIP3 with absent IL-17RA-signalling.
myeloid TNFAIP3-deficient mice have Il-17rA-independent increases of 
neutrophil chemokines upon HDm-sensitization.
IL-17 may contribute to neutrophil chemokine (C-X-C motif ) ligand (CXCL)131, 32, 
CXCL223, 33, and CXCL12 release34. Since neutrophilic inflammation persisted in lungs of 
HDM-sensitized Tnfaip3LysM-KOIl17raKO mice, we assessed mRNA expression levels of these 
chemokines. HDM-sensitized lungs of Tnfaip3LysM-KO mice expressed increased amounts 
of Cxcl1, Cxcl2 and Cxcl12 mRNA compared to HDM-sensitized WT mice (Figure 4A). 
Surprisingly, Cxcl1 and Cxcl12 mRNA expression did not differ between HDM-sensitized 
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Figure 3: loss of Il-17rA-signalling does not affect lung Th2 cytokines in a HDm-sensitized model, 
but increase Il-17 production.
Tnfaip3LysMIl17ra mice were analysed after completion of the HDM exposure protocol. (A) Flow cytometry 
data is shown of intracellular cytokine expression within Th cells of broncho-alveolar lavage (BAL) of repre-
sentative HDM exposed mice. (B) Quantification of BAL Th cell cytokines IL-13, IL-5, IL-17 and IFNγ as deter-
mined by flow cytometry. Results are presented as mean ± SEM of n = 6 per group and are representative 
of two independent experiments. *P < 0.05, **P < 0.01.
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Cxcl2 mRNA expression was partially reduced in HDM-sensitized Tnfaip3LysM-KOIl17raKO 
mice as compared to HDM-sensitized Tnfaip3LysM-KO mice (Figure 4A). As absence of IL-
17RA-signalling only moderately influenced chemokine expression, we evaluated other 
pro-inflammatory cytokines that can promote their expression, such as IL-1β31, 35, IL-636 
and IL-2337. HDM-treated Tnfaip3LysM-KO mice demonstrated elevated Il1b and Il6 expres-
sion as compared to HDM-treated WT controls (Figure 4B). Abrogated IL-17RA-signal-
ling in HDM-exposed Tnfaip3LysM-KOIl17raKO mice resulted in similar Il1b and Il6 cytokine 
expression as Tnfaip3LysM-KO mice (Figure 4B). In contrast, Il23 expression was markedly 
increased in HDM-exposed Tnfaip3LysM-KOIl17raKO mice compared to Tnfaip3LysM-KO controls 
(Figure 4B).
Next to IL-17A, Th17 cells can produce other cytokines, such as granulocyte-macro-
phage colony-stimulating factor (GM-CSF)38 and IL-2239, 40, which are known to regulate 
neutrophil chemokines CXCL1/CXCL2 and directly attract neutrophils respectively. 
mRNA expression of Csf2 and Il22 were augmented in HDM-sensitized Il17raKO mice 
compared to PBS-sensitized Il17raKO mice (Figure 4c). Only Il22 gene expression was 
further increased in HDM-sensitized Tnfaip3LysM-KOIl17raKO mice lungs compared to 
HDM-sensitized Il17raKO mice (Figure 4c). Both lung Csf2 and Il22 mRNA expression 
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Figure 4: myeloid TNFAIP3-deficient mice have Il-17rA-independent increases of neutrophil chemo-
kines upon HDm-sensitization.
Total lung homogenates of HDM-challenged Tnfaip3LysMIl17ra were analysed by RT-PCR. (A-c) Quantifica-
tion of neutrophil chemokines Cxcl1, Cxcl2, Cxcl12 gene expression (A), pro-inflammatory cytokines Il1b, 
Il6 and Il23 gene expression (B) and Th17-associated cytokines Csf2 and Il22 gene expression (c) in lung 
homogenates of PBS and HDM challenged Tnfaip3LysMIl17ra mice. Results are presented as mean ± SEM 
of n = 6 per group. *P < 0.05, **P < 0.01.
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Tnfaip3LysM-KO mice (Figure 4c), which corresponded to the number of Th17 cells (Figure 
3B).
In summary, myeloid TNFAIP3-deficient HDM-sensitized mice had elevated lung mRNA 
expression of the neutrophil chemokines Cxcl1, Cxcl2 and Cxcl12, despite abrogated IL-
17RA-signalling. IL-17RA-signalling partially contributes to Cxcl2 expression in response 
to HDM-sensitization in myeloid TNFAIP3-deficient mice. Neutrophil chemo-attractants 
are probably maintained in the absence of IL-17RA-signalling by equal quantities of IL-
1β and IL-6, that are most likely derived from activated myeloid cells.
DIScUSSIoN
IL-17 is implicated in severe and uncontrolled asthma, as patients who suffer from severe 
asthma display increased levels of IL-17 in lung tissue41. Recently we have shown that 
the presence of intrinsically activated myeloid cells, obtained through TNFAIP3/A20 
ablation, induces development of neutrophilic inflammation accompanied by increased 
Th17 cells in contrast to Th2 cell-driven eosinophilic inflammation induced in control 
mice18. To investigate whether neutrophilic inflammation development as observed in 
HDM-treated Tnfaip3LysM mice is dependent on IL-17-signalling, Tnfaip3LysM mice were 
crossed to IL-17RA-deficient mice.
Surprisingly, absence of IL-17RA-signalling had only limited effects on neutrophilic 
inflammation, and neutrophil chemo-attractants in our HDM-driven airway inflamma-
tion mouse model. Ablation of IL-17RA-signalling increased the number of Th1 and Th17 
cells, whereas Th2 cell differentiation and eosinophilic inflammation was not hampered. 
Strikingly, the presence of mucus-producing cells was severely reduced in mice with 
deficient IL-17RA-signalling and TNFAIP3-deficient myeloid cells.
The IL-17RA subunit forms a heterodimer with either the IL-17RC or IL-17RB subunit. 
IL-17RA/C heterodimer is used by IL-17A, IL-17F, and IL-17A/F and the IL-17RA/B het-
erodimer is activated by IL-17E (also known as IL-25)20. Ablation of the IL-17RA subunit 
will therefore affect the signalling of IL-17A, IL-17F, IL-17A/F, and IL-25. We observed that 
neutrophilic inflammation and neutrophil chemo-attractants persisted in the absence 
of IL-17RA-signalling, indicating that neutrophilia can develop without the presence of 
the described IL-17R family members IL-17A, IL-17F, and IL-25. This is in contrast to other 
reports that showed dependency of neutrophil influx on IL-17RA-signalling not only in 
asthma and COPD, but also in pulmonary bacterial and viral infections9, 11, 23, 42-44. Neu-
trophil chemo-attractants CXCL1, CXCL2 and CXCL12 were not altered upon ablation of 
IL-17RA-signalling indicating that these chemo-attractants can be induced by factors 
independent of IL-17RA-signalling. Similar quantities of Th17-promoting cytokines IL-1β 
and IL-6 were found in the lungs of HDM-exposed Tnfaip3LysM-KO and Tnfaip3LysM-KOIl17raKO 
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mice, whereas IL-23 expression was increased in HDM-exposed Tnfaip3LysM-KOIl17raKO as 
compared to Tnfaip3LysM-KO mice. IL-1β has been shown to induce CXCL1 as efficiently as 
IL-17 by mouse embryonic fibroblasts31. Furthermore, IL-1β-deficient mice have defec-
tive neutrophil mobilization upon group B streptococcus infection, most likely caused 
by strongly reduced CXCL1 and CXCL2 production35. Likewise, IL-6 can induce CXCL1 
transcription in endothelial cells36. This could indicate that pulmonary IL-1β and IL-6 
expression in Tnfaip3LysM-KOIl17raKO mice can induce CXCL1 expression by lung epithelial 
cells, independent of IL-17RA-signalling.
Ablation of IL-17RA-signalling alone only slightly increases the presence of IL-17-
expressing T cells, however combined with Tnfaip3-deficient myeloid cells, pulmonary 
Th17 cells were massively enhanced in allergen-exposed Tnfaip3LysM-KOIl17raKO mice. 
Increased pulmonary IL-23-expression, high levels of IL-1b and IL-6, and defective 
negative feedback normally provided by IL-17 in Tnfaip3LysM-KOIl17raKO mice, could be 
responsible for this massive increase. It is known that IL-23 expression by myeloid cells, 
such as DCs and macrophages drives clonal expansion of Th17 cells45, whereas IL-17 acts 
as a negative feedback to control its own expression26. Strikingly, only IL-23, and not 
IL-1b and IL-6, was specifically increased in Tnfaip3LysM-KOIl17raKO mice when compared 
to Tnfaip3LysM-KO mice, suggesting that IL-17RA-signalling also controls IL-23 production.
We found limited effects of defective IL-17RA-signalling on all features observed in 
HDM-mediated allergic airway inflammation including Th2 differentiation and eosino-
philic inflammation. This implicates that IL-17A, IL-17A/F, IL-17F and IL-25 are dispensable 
for Th2-mediated eosinophilic inflammation upon HDM treatment. Blockade of IL-17A 
also did not influence eosinophilic inflammation and Th2 cytokine secretion upon expo-
sure to the HDM Der f allergen42. This is in contrast to ovalbumin (OVA)-mediated allergic 
airway models, where reduced eosinophilic inflammation, Th2 cytokines, and airway 
hyper responsiveness (AHR) were observed in either IL-17RA-deficient or IL-17-deficient 
mice28, 29. This suggests that the importance of IL-17 depends on the allergen/model 
used. While IL-17-depletion during HDM challenges has no effect on eosinophilia and 
Th2 cytokines42, blockade of IL-17 during challenge in OVA-mediated models promotes 
Th2-mediated eosinophilic inflammation28. Treatment with recombinant IL-17 promotes 
inflammatory resolution upon OVA-mediated airway inflammation30, indicating that IL-
17 during the resolution phase can be beneficial.
Next to airway type-2 inflammation, goblet cell hyperplasia was also almost com-
pletely absent in Tnfaip3LysM-KOIl17raKO mice. This suggests that the presence of Th2 
cytokines in WT mice, or Th17 cytokines in Tnfaip3LysM-KO are essential for goblet cell 
hyperplasia. Indeed, mucus production by goblet cells is induced by Th2 cytokines IL-4, 
IL-1346-49, and Th17 cytokines IL-17A7 and IL-17F50. Furthermore, IL-25 (e.g. IL-17E) is also 
implicated in goblet cell hyperplasia51, 52. The combination of OVA-specific Th2 and Th17 
cells was shown to induce more mucus-producing goblet cells than OVA-specific Th2 
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cells alone53. This indicates that both Th2 and Th17 cytokines can induce hyperplasia of 
mucus-producing cells separately and can even take over each other function, as com-
bined absence of Th2 cytokines and abrogated IL-17RA-signalling in Tnfaip3LysM-KOIl17raKO 
mice completely hampers the induction of goblet cell hyperplasia. Furthermore, mucus 
production by goblet cells in Il17raKO mice develops independent of IL-25.
In conclusion, our results show that neutrophilic airway inflammation induced by 
activated TNFAIP3/A20-deficient myeloid cells can develop in the absence of IL-17RA-
signalling. Increased pulmonary pro-inflammatory cytokines IL-1b and IL-6 quantities 
are not influenced by IL-17RA-deficiency in mice with activated myeloid cells after HDM 
exposure. Both IL-1b and IL-6 can induce the expression of neutrophil chemo-attractants, 
contributing to neutrophilic airway inflammation independently of IL-17 signalling.
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Supplementary Table 1: Antibodies used for flow cytometry.
Antibody conjugate clone company
CD3 APC-eF780 17A2 ebioscience
CD4 PE-CF594 RM4-5 BD
CD4 BV711 RM4-5 BD
CD8 PE-Cy7 53-6.7 ebioscience
CD11b PerCP-cy5.5 M1/70 BD Bioscience
CD11c PE Texas Red N418 ebioscience
CD25 Pe-Cy7 PC61.5 ebioscience
CD27 Biotin LG.7F9 ebioscience
CD44 FITC IM7 ebioscience
CD44 APC-cy7 IM7 BD
CD45 PE Texas Red I3/2.3 Abcam
CD64 APC X54-5/7.1 BD
CD64 PE X54-5/7.1 BD
CD86 PE Cy7 GL1 BD
CD103 APC 2E7 ebioscience
FcƐRI Biotin MAR-1 ebioscience
GR1 Pe-cy7 1A8 BD
IFNγ eF450 XMG1.2 ebioscience
IL-5 PE TRFK-5 BD
IL-5 APC TRFK-5 BD
IL-13 AF647 eBio13A ebioscience
IL-17A AF700 TC11-18H10.1 BD
MHC-II Alexa Fluor 700 M5/114.15.3 ebioscience
RORγt PE Q31-378 BD
Streptavidin PerCP-Cy5.5 BD
Streptavidin APC-eF 780 ebioscience
Streptavidin Brilliant Violet 786 BD
TCRγδ Biotin UC7-13D5 ebioscience
Ter119 APC TER-119 ebioscience
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Supplementary Table 2: The RT-PCR primers have been listed with the gene name, corresponding en-





Forward sequence reverse sequence
Csf2 GM-CSF AAAGGGACCAAGAGATGTGGC GTTTGTCTTCCGCTGTCCAAG
Cxcl1 CXCL1 CTGGGATTCACCTCAAGAACATC CAGGGTCAAGGCAAGCCTC
Cxcl12 CXCL12 GTCAGCCTGAGCTACCGATG TTCTTCAGCCGTGCAACAATC
Cxcl2 CXCL2 CGCTGTCAATGCCTGAAG GGCGTCACACTCAAGCTCT
Gapdh GAPDH TTCACCACCATGGAGAAGGC GGCATGGACTGTGGTCATGA
Il1b IL-1β AGTTGACGGACCCCAAAAG TTTGAAGCTGGATGCTCTCAT
Il22 IL-22 GTGACGACCAGAACATCCAG TCCACTCTCTCCAAGCTTTTTC
Il23 IL-23 CCAGCGGGACATATGAATCT TGGATACGGGGCACATTATT
Il6 IL-6 ACACATGTTCTCTGGGAAATCGT AAGTGCATCATCGTTGTTCATACA
Muc5a Mucin 5AC ACCACTTTCTCCTTCTCCACAC CCCCTGAGGACCCTACACTC































Supplementary Figure 1: Flow cytometric gating strategy of myeloid cells. An example is shown of a 
spleen derived from a WT mouse. 
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Supplementary Figure 2: Aged myeloid Tnfaip3-deficient mice develop arthritis, regardless of Il-
17rA-signalling. 
Mice were analysed at 18 weeks of age when arthritis had spontaneously developed. (A-B) Paws were 
scored biweekly for severity (A) and the derived prevalence graph (B) of spontaneous arthritis is shown. (c) 
Hematoxylin and eosin (H&E) stained paraffin embedded, EDTA decalcified, talo-tibial joints at a magnifica-
tion of 50x is shown. (D) Tolluidine blue stain of the talo-tibial cartilage region is depicted at a magnification 
of 200x. Arrows represent areas of cartilage loss. Scale bars (200μm) are at the lower right corner of the mi-
croscopic images. (e) Histopathologic score of talo-tibial joints as assessed by combining H&E and toluidine 
blue stain scores. Results are presented as mean ± SEM of n = 4-10 per group and are pooled from several 
experiments. **P < 0.01, **P < 0.001, ****P < 0.0001. 
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Supplementary Figure 3: HDm exposure does not lead to increased T cells or γδ T cells in the mlN of 
myeloid Tnfaip3-deficient and Il-17rA-signalling deficient mice. 
Quantification of total CD3+ T cells, Th cells, CD8+ T cells and γδ T cells in cell suspensions of the mediastinal 




Assessment of joint swelling
To assess the degree of joint swelling, we evaluated hind and front paws swelling of 
mice from 6 weeks of age giving a maximum score of 2 per paw (Corneth et al, Arthritis 
Rheum, 2014), rising to a theoretical total of 8 per mouse. Mice were removed from the 
experiment with scores of 6 to alleviate suffering. Disease severity and incidence were 
monitored.
Histology
Ankle joints were fixed in formalin, decalcified in EDTA and embedded in paraffin. 
The tissues were stained with Hematoxylin and Eosin (H&E) to visualize the structure 
of bone. Toluidine blue staining was done to assess the cartilage integrity (Schmitz et 
al, Osteoarthritis Cartilage, 2010). Each histology slide was arbitrarily scored for tissue 
inflammation and cartilage integrity by two independent blinded researchers.
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ABSTrAcT
Background: Dendritic cells (DCs) are central regulators of tolerance versus im-
munity. Mice with a DC-specific deficiency of deubiquitinating enzyme A20/Tnfaip3 
(Tnfaip3CD11c-cre), a major negative regulator of NF-κB signaling, exhibit increased DC acti-
vation. Aged Tnfaip3CD11c-cre mice show activation of mature B cells and develop humoral 
autoimmunity resembling systemic lupus erythematosus (SLE). In addition, mature B 
cells are severely decreased in numbers.
objective: To identify the arrest in B cell development in Tnfaip3CD11c-cre mice and to 
investigate whether mature peripheral B cells have functional defects.
methods: B cell development was studied in bone marrow and spleen of 6-week-old 
and 24-week-old Tnfaip3CD11c-cre mice. Splenic naïve B cells were stimulated in vitro to 
measure cellular activation and immunoglobulin production capacity. In vivo B cell 
responses were determined.
results: B cell development in the bone marrow was hampered at the immature B 
cell stage in 6-week-old Tnfaip3CD11c-KO mice and at the pre-B cell stage in 24-week-old 
Tnfaip3CD11c-KO mice. The observed age-dependent developmental arrest of B-lineage 
cells most likely reflected changes in the bone marrow micro-environment. Although 
development of B-1 cells in Tnfaip3CD11c-KO appeared impaired, the IgM and IgG3 B cell 
responses to T cell independent antigen DNP-Ficoll were unaffected. While serum 
immunoglobulin levels were increased, Tnfaip3CD11c-KO mice displayed a defective T 
cell-dependent B cell response in vivo. In addition, mature naïve peripheral B cells from 
Tnfaip3CD11c-KO mice showed increased activation upon in vitro stimulation compared 
with control mice.
conclusion: DC-specific deficiency of A20/Tnfaip3 is associated with defective B cell 
development, reflecting a dysfunctional bone marrow micro-environment. The ob-




Systemic lupus erythematosus (SLE) is a multifactorial disease1. Often malfunction of 
multiple innate and adaptive immune cell types, such as dendritic cells (DCs), T cells 
and B cells lies at the base of the autoimmune phenotype1. B cells can contribute to 
pathology by autoantigen presentation, secretion of pro-inflammatory cytokines, ecto-
pic germinal center generation and autoantibody secretion2. DCs have a crucial role in 
the maintenance of tolerance3. Control of immune cell activation is essential to prevent 
autoimmunity. For example, transgenic removal of regulatory proteins such as the 
tyrosine kinase Lyn or Src homology region 2 domain–containing phosphatase-1 (SHP1) 
in B cells4, 5 or DCs6, 7 in mice results in the spontaneous development of SLE symptoms.
Proper signals within the NF-κB pathway are also essential to maintain tolerance8. Tu-
mor necrosis factor alpha-induced protein 3 (TNFAIP3), also known as A20, is one of the 
major negative regulators of the NF-κB pathway9. Targeted deletion of the Tnfaip3 gene 
in B cells or DCs in mice resulted in spontaneous autoimmunity resembling SLE and was 
characterized by increased germinal center (GC) responses, autoantibody production 
and glomerulonephritis10, 11. Interestingly, in mature 24-week-old mice in which the 
Tnfaip3 gene was conditionally deleted in DCs, the numbers of B cells in the periphery 
were reduced, indicating that B cell development may be disturbed.
Development of autoreactive B cells in the bone marrow is prevented by various 
central tolerance mechanisms, including receptor editing12, 13 and clonal deletion14. 
Tolerance mechanisms that function at later stages, such as B cell anergy15, are referred 
to as peripheral tolerance. Because defects due to central tolerance can be observed 
in autoimmune patients with rheumatoid arthritis (RA)16, 17, type 1 diabetes (T1D)16 and 
SLE18-20, as well as in corresponding mouse models21, 22, we investigated B cell develop-
ment in the bone marrow and peripheral B cell function in A20/Tnfaip3CD11c-KO mice.
In this study, we demonstrate that B cell development is hampered in the bone mar-
row of Tnfaip3CD11c-KO mice in an age-dependent fashion. Mature B cells that reach the 
periphery exhibit various abnormalities. They display a more activated phenotype upon 
activation in vitro, but fail to efficiently respond to a T cell-dependent antigen in vivo. 
Thus, hyperactivation of DCs, due to loss of A20/Tnfaip3, did not only deregulate mature 
T and B cells, but also disturbed B cell development in the bone marrow.
mATerIAl & meTHoDS
mice
Male and female C57BL/6 mice harbouring a conditional Tnfaip3 allele flanked by LoxP 
sites23, were crossed onto a transgenic line expressing the Cre recombinase under the 
chapter 5  | Developmental B-cell defects within a model of Tnfaip3-deficient dendritic cells.
108
control of the CD11c promotor24, generating CD11c-Cre transgenic Tnfaip3fl/fl mice 
(Tnfaip3CD11c-KO mice). CD11c-Cre non-transgenic Tnfaip3fl/fl littermates (Tnfaip3CD11c-WT 
mice) served as controls and heterozygous CD11c-Cre transgenic Tnfaip3fl/+ mice 
(Tnfaip3CD11c-HZ) mice were also analyzed. Mice were sacrificed at ~6-8 weeks or ~24-26 
weeks of age. Mice were housed under specific pathogen-free conditions and attained 
food and water ad libitum. All experiments were approved by the animal ethical com-
mittee of the Erasmus MC, Rotterdam, The Netherlands.
cell suspension preparation
Spleen, bone marrow (BM) and mesenteric lymph node (MesLN) were obtained using 
standard procedures. The hind legs were crushed initially, and spleen and MesLN were 
homogenized through a 100-μm cell strainer to obtain single-cell suspensions. To 
remove erythrocytes, spleens and BM were lysed using an osmotic lysis buffer (8.3% 
NH4CL, 1% KHCO3, and 0.04% NA2EDTA in Milli-Q).
Flow cytometry procedures
Flow cytometry surface and intracellular staining procedures have been described 
previously25.  Monoclonal antibodies used for flow cytometric analyses are listed in 
Supplementary Table 1. For all experiments, dead cells were excluded using fixable 
AmCyan viability dye (eBioscience, San diego, CA, USA). To measure cytokine production 
(in the case of B cells), cells were stimulated with 10 ng/mL Phorbol 12-myristate 13-ac-
etate PMA (Sigma-Aldrich, St. Louis, MI, USA) and 250 ng/mL ionomycin (Sigma-Aldrich) 
in the presence of GolgiStop (BD Biosciences, San Jose, CA, USA) for 4 hrs at 37°C. To 
measure cytokine production in DCs, cells were kept in the presence of GolgiPlug (BD 
Biosciences) for 4 hrs at 37 oC. Data were acquired using an LSR II flow cytometer (BD 
Biosciences) with FACS Diva™ software and analysed by FlowJo version 9 (Tree Star Inc 
software, Ashland, OR, USA).
in vitro B cell stimulation
Via MACS separation (Miltenyi Biotec, Bergisch Gladbach, Germany) naïve B cells were 
isolated from spleen single-cell suspensions via negative selection. Cells were labeled 
with the biotin-conjugated markers NK1.1, CD4, CD8, Ter119, CD11c, GR-1, FcRI, CD5, 
CD43, CD138, CD11b, CD95 and Streptavidin Microbreads (Miltenyi Biotec).
For investigating B cell activation markers, naïve B cells were stimulated with 10 μg/
ml anti-IgM F’ab fragments (Jackson Immunoresearch, West Grove, PA, USA), 5 ng/ml 
LPS (Enzo Life Sciences, Farmingdale, NY, USA), 1 μM CpG (Invitrogen, Carlsbad, CA, USA) 
or 20 μg/ml anti-CD40 (BD Biosciences, San Jose, CA, USA) overnight in RPMI medium 
(Thermo Fisher, Waltham, Massachusetts) supplemented with gentamycin (Thermo 
Fisher), β-mercapto-ethanol (Sigma) and 5% Fetal Bovine Serum (Capricorn Scientific, 
109
Ebsdorfergrund, Germany). To investigate immunoglobulin production, naïve B cell frac-
tions were stimulated for 4 days in context of LPS (Enzo Life Sciences) with/without IL-4 
(Peprotech, Rocky Hill, NJ, USA).
Il-7 culture of small pre-B cells and immature B cells
Hind legs of Tnfaip3CD11c-KO and Tnfaip3CD11c-WT mice were crushed and erythrocytes were 
lysed. After labeling with anti-CD19 beads, B cells were positively separated from the 
CD19neg fraction that also contains stromal cells, using a MACS column. In a 24-wells 
plate, 2 x 106 stroma cells and 300.000 B cells, from either Tnfaip3CD11c-KO or Tnfaip3CD11c-WT 
mice, were cultured in 1 ml IMDM medium supplemented with gentamycin (Thermo 
Fisher), β-mercaptoethanol (Sigma), 5% Fetal Bovine Serum (Capricorn Scientific, Ebs-
dorfergrund, Germany), Glutamine (Gibco) and 100U/ml recombinant IL-7 (Peprotech) 
per well. B cell and stromal cell suspensions were sex-matched. On day 4, cells were 
harvested, washed and cultured with or without the presence of IL-7 for 2 days. At day 7, 
cells were prepared for FACS analysis.
DNP-Ficoll and oVA-Alum immunization
For T cell–independent immunization, 50 mg of DNP(49)-Ficoll (Biosearch Technologies, 
Petaluma, CA, USA) in PBS was injected i.p. Serum was collected at baseline and 7 days 
after immunization.
For T cell-dependent immunization, mice received 10 μg OVA (Worthington Biochemi-
cal Corp, Lakewood, NJ, USA) i.p. in a saline solution containing 1:20 Imject-alum adjuvant 
(Thermo Scientific). The mixture was left stirring for 1hr, and then 500μl of OVA-Alum 
solution was injected per mouse. A booster was given after 1 week. Serum was collected 
at a pre-immune timepoint, at 8 days and 15 days after booster immunization.
Immunoglobulin levels
For quantification of total immunoglobulin (Ig) levels, Nunc Microwell plates (Life tech-
nologies, Carlsbad, CA, USA) were coated overnight at 4Co with 1 μg/ml goat-anti-mouse 
Igx (being the immunoglobulin isotype, Southern Biotech, Birmingham, AL, USA). Wells 
were blocked with 10% FCS/PBS for 1 hr. Subsequently, standards and serum (diluted 
in multiple series) were incubated for 3 hrs. Depending on the isotype, anti-mouse Igx 
biotin/streptavidin-HRP were used to develop the ELISA.
For DNP-specific sandwich ELISA assays, Nunc Microwell plates were coated with 
DNP-Ficoll in 0.1M carbonate buffer (pH 9.5); the standard curve wells were plated with 
purified unlabeled goat anti-IgM or IgG3 (Southern Biotech) in PBS overnight at 4Co. 
Wells were blocked with 1% BSA for 1 hr, followed by 3 hrs of incubation with serum 
samples (diluted in multiple series) and standard IgM or IgG3. Anti-mouse Igx biotin/
streptavidin-HRP was used to develop the ELISA.
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Figure 1: Age-dependent arrest in B cell development in the bone marrows of Tnfaip3cD11c-Ko mice.
(A) Enumeration of total bone marrow cells in Tnfaip3CD11c-WT, Tnfaip3CD11c-HZ and Tnfaip3CD11c-KO mice at 
the indicated age, using flow cytometry. (B) Flow cytometric analysis of bone marrow Pro-/Pre-B cells 
(CD19+B220loIgM-), immature B cells (CD19+B220loIgM+) and mature B cells (CD19+B220hiIgM+). Representa-
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Statistics
Statistical significance of data was calculated using the non-parametric Mann Whitney 
U test. P-values <0.05 were considered significant. All data were plotted as mean values 
with the standard error of the mean (SEM).
reSUlTS
Age-dependent arrest in B cell development in the bone marrows of 
Tnfaip3cD11c-Ko mice.
To investigate how DC-specific A20/Tnfaip3 deficiency affects B cell development, we 
analyzed bone marrows of ~6-week-old and ~24-week-old Tnfaip3CD11c-KO mice, as well 
as Tnfaip3CD11c-HZ and Tnfaip3CD11c-WT controls. Bone marrow total cell counts did not dif-
fer between the three genotypes at either age (Figure 1A). We used flow cytometry to 
quantify the populations of developing B cells in the bone marrow and found that at the 
age of ~6 weeks the Tnfaip3CD11c-KO mice had significantly lower numbers of immature B 
cells compared to Tnfaip3CD11c-WT controls (Figure 1B,1c). These young mice showed a 
near-significant reduction of mature B cells. However, at the age of 24 weeks, the total 
numbers of bone marrow B cells, pro/pre B cells, immature B cells and mature B cells 
were significantly reduced in Tnfaip3CD11c-KO mice compared to WT and Tnfaip3CD11c-HZ 
mice (Figure 1c), indicating a progressive loss of mature B cell development over time.
Because we found evidence for a B cell development disorder already at ~6 weeks 
of age, we investigated mice at this age for the remaining experiments. To identify the 
individual stages of early B cell development, we used the classification according to 
Hardy et al26. The total numbers of pre/pro-B cells within Hardy fractions A, B or C were 
not different between the three genotypes (Figure 1D,1e). Accordingly, as proportions 
of these fractions from live cells, all these fractions showed no differences across the 
genotypes (Supplementary Figure 1). Although a significant decrease of the propor-
tions of small pre-B cells (Hardy fraction D) was noticed in Tnfaip3CD11c-KO mice compared 
to Tnfaip3CD11c-WT mice (Supplementary Figure 1), there was no significant reduction of 
the absolute cell numbers of fraction D small pre-B cells (Figure 1e). As a proportion 
tive examples of gated CD19+ lymphoid cells fractions are shown from Tnfaip3CD11c-WT, Tnfaip3CD11c-HZ and 
Tnfaip3CD11c-KO mice. (c) Quantification of total B cells, Pro-/Pre-B cells, immature B cells and mature B cells in 
bone marrow of mice (legend shown in panel A) at the indicated age. (D) Flow cytometric analysis of bone 
marrow total lymphoid cells, showing B cell stages according to Hardy et al.26 in representative examples 
from three genotypes in 6-week-old mice. (e) Quantification of Hardy fraction A (B220loIgM-CD43+BP1-CD24-), 
Hardy fraction B (B220loIgM-CD43+BP1-CD24+), Hardy fraction C (B220loIgM-CD43+BP1+CD24+), Hardy frac-
tion D (B220loIgM-CD43-), Hardy fraction E (B220loIgM+) and Hardy fraction F (B220hiIgM+), using flow cy-
tometry in 6-week-old mice. Results are representative of 3 independent experiments and are presented 
as mean values ± SEM of n = 4-6 per group. *P<0.05, **P < 0.01 using the Mann-whitney U statistical test.
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Figure 2: cell non-intrinsic defect in B lineage cells and evidence for aberrant Bcr repertoire selec-
tion of Igλ B cells in Tnfaip3cD11c-Ko mice.
Combinations of CD19pos and CD19neg fractions from bone marrows of Tnfaip3CD11c-WT mice (termed 
‘WT’) and Tnfaip3CD11c-KO mice (termed ‘KO’) were cultured in vitro. (A) Flow cytometric analysis of in vi-
tro Mature B cells (B220+CD19+IgDhiIgMhi), immature B cells (B220+CD19+IgDloIgMhi), small pre-B cells 
(B220+CD19+IgDloIgMloCD2+FSClo) and remaining surface Igneg B-lineage cells containing mainly large cy-
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of live cells, immature B cells and mature B cells (Fractions E and F, respectively), were 
decreased in Tnfaip3CD11c-KO mice compared to Tnfaip3CD11c-WT mice (Supplementary 
Figure 1).
In conclusion, ~6-week-old Tnfaip3CD11c-KO mice have a B cell development disorder at 
the transition of small pre-B cells to immature B cells. This progresses over time, resulting 
in a reduction of all B cell stages at 24 weeks of age.
cell non-intrinsic defect in B lineage cells in Tnfaip3cD11c-Ko mice.
Since the Tnfaip3 gene was specifically deleted in DCs, it was highly unlikely that the 
observed B cell arrest in Tnfaip3CD11c-KO mice was due to an intrinsic B cell defect. Rather, 
the defective B cell development in these mice might be explained by changes in the 
cytokine milieu or cell-cell interactions in the bone marrow micro-environment. For 
example, it has been reported that cytokines such as IL-1α27 or IL-1β28, interferon (IFN) 
α or β 29, 30, IFNγ31 or TNFα32 can hamper B cell development in the bone marrow. It is 
therefore conceivable that high systemic levels of pro-inflammatory cytokines – associ-
ated with the autoimmune phenotype – affect B lymphopoiesis.
We utilized an in vitro co-culture system to distinguish whether the small pre-B cell 
to immature B cell transition was hampered due to local cytokines signals or due to 
anomalous cell-cell interactions between developing B cells and stromal components 
or myeloid cells, including DCs, present in the bone marrow. We assumed that in such an 
in vitro co-culture all inhibitory cytokines present that would have been present in the 
bone marrow in vivo were removed by the extensive washing procedures. As IL-7 is cru-
cial for B cell development, we performed in vitro IL-7-driven bone marrow co-cultures 
of magnetically sorted CD19pos B-lineage cell fractions in combination with CD19neg 
fractions containing bone marrow stromal cells as well as myeloid cells. In these experi-
ments, we used various combinations of CD19pos and CD19neg fractions of Tnfaip3CD11c-KO 
or Tnfaip3CD11c-WT bone marrows. Continuous IL-7 supplementation is known to support 
pre-B cell survival and proliferation and to limit the developmental progression of pre-B 
cells into IgM+ immature B cells33. This condition resulted in a major population (~80%) 
of surface Igneg B cells that precede small pre-B cells, such as large pre-B cells (Figure 
2B; for gating strategy see Figure 2A). This condition also results in a low percentage 
of small pre-B cells, immature B cells and mature B cells of about ~10%, ~2% and ~4%, 
respectively, irrespective of the genotypes of the CD19pos and CD19neg cell fractions (Fig-
cling pre-B cells (B220+CD19+IgDnegIgMlo/negCD2-). (B-c) Quantification of previously described (in A) B cell 
proportions in continuous presence of IL-7 (B) and in absence of IL-7 during the last 2 days of culture (c) 
using flow cytometry. (D) Quantification of the proportion of Igκ+ and Igλ+ light chain of immature B cells 
and mature B cells in the bone marrow using flow cytometry. (e) The percentage Igλ+ B cells in spleen and 
Mesenteric Lymph node (MesLN) quantified using flow cytometry. Results are presented as mean values ± 
SEM of n = 4-6 per group. *P<0.05 using the Mann-whitney U statistical test.
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ure 2B). A moderate, yet significant, reduction of the proportions of small pre-B cells was 
observed in the co-cultures of Tnfaip3CD11c-WT CD19pos B cell fractions and Tnfaip3CD11c-KO 
CD19neg supporting cells, in comparison to WT cultures of CD19pos and CD19neg fractions, 
and also in comparison to the condition with both CD19pos and CD19neg fractions from 
Tnfaip3CD11c-KO mice (Figure 2B).
Upon removal of IL-7 after 5 days of culture, pre-B cells stop cycling and a propor-
tion of the pre-B cells generally proceeds to the IgM+ immature B cell stage33. Thus, the 
proportions of small pre-B cells were expected to rise, which however only occurred in 
conditions whereby B-lineage cells were cultured with Tnfaip3CD11c-WT CD19neg support-
ing cells, irrespective of the Tnfaip3CD11c-WT or Tnfaip3CD11c-KO genotype of the B-lineage 
cell fractions (Figure 2c). In contrast, the CD19neg fraction from Tnfaip3CD11c-KO bone mar-
row hampered the efficient generation of small pre-B cells, both from Tnfaip3CD11c-KO and 
Tnfaip3CD11c-WT CD19pos B-lineage cells (Figure 2c). Consistently, the largest population 
cells that contained the pre-B cells, were reduced in the conditions that gave rise to 
high small pre-B cells (Figure 2c). After withdrawal of IL-7, the proportions of immature 
B cells were also higher in the presence of Tnfaip3CD11c-WT than Tnfaip3CD11c-KO CD19neg 
supporting cells, which reached significance for B-lineage cells from Tnfaip3CD11c-WT bone 
marrow (Figure 2c).
Taken together, these in vitro experiments support a cell non-intrinsic defect in B lin-
eage cells in Tnfaip3CD11c-KO mice. Our finding that the function of Tnfaip3CD11c-KO CD19neg 
supporting cells in vitro was impaired, suggest that inhibitory signals from cytokines 
are not directly responsible for the defective B cell development in Tnfaip3CD11c-KO mice.
evidence for aberrant Bcr repertoire selection of Igλ B cells in Tnfaip3cD11c-Ko 
mice.
After successful rearrangement of the Ig heavy chain, immunoglobulin light (IgL) chain 
rearrangement is initiated at the transition from large to small pre-B cells33. The light 
chain can be either Igκ or Igλ34, whereby Igλ+ B cells often contain non-productive Igκ 
rearrangements or productive Igκ rearrangements that are associated with autoreactiv-
ity35. We thus investigated Igκ and Igλ light chain usage in immature B cells and mature 
B cells within the bone marrow samples (For gating strategy according to Dingjan et 
al36, see Supplementary Figure 2A). As expected, the majority of immature B cells was 
Igκ+, irrespective of the genotype (Figure 2D). Importantly, we found that the propor-
tions of Igλ+ immature B cells was significantly reduced in Tnfaip3CD11c-KO mice compared 
to WT controls (Figure 2D). In contrast, mature B cells had significantly reduced Igκ+ 
proportions in Tnfaip3CD11c-KO compared to WT mice, while a non-significant rise of the 
proportions of Igλ+ cells in the population of recirculating mature B cells was observed 
(Figure 2D).
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Mature B cell populations in peripheral organs such as spleen (For gating strategy 
according to Dingjan et al36, see Supplementary Figure 2B) and mesenteric lymph 
node (MesLN) from Tnfaip3CD11c-KO mice and Tnfaip3CD11c-HZ mice displayed significantly 
increased usage of Ig λ chain, compared to B cells from WT littermates (Figure 2e), in line 
with the observed (non-significant) rise of the proportions of Igλ+ recirculating mature 
B cells. Subpopulation analysis or the splenic B cell population indicated that IgDhiIgMhi 
and IgDhiIgMlo B cell splenic fractions were responsible for the elevated Igλ proportions 
(Supplementary Figure 2B). Likewise, we found elevated proportions of Igλ+ B cells in 
the IgDhi B cell fraction in the MesLN of Tnfaip3CD11c-KO mice (data not shown).
Taken together, these data show that immature B cells in Tnfaip3CD11c-KO mice had sig-
nificantly decreased proportions of Igλ+ cells, compared to Tnfaip3CD11c-HZ or Tnfaip3CD11c-KO 
control mice. Remarkably, during B cell maturation in the spleen these Igλ+ B cell propor-
tions increased in Tnfaip3CD11c-KO mice, resulting in elevated Igλ usage in IgDhiIgMlo B cells 
in spleen, MesLN and bone marrow. Although we cannot exclude that Tnfaip3CD11c-KO mice 
have a reduced Igλ locus accessibility affecting Igλ recombination, it is more likely that in 
these mice BCR repertoire selection is abnormal. This would then explain reduced receptor 
editing in the bone marrow and decreased selection against Igλ+ B cells in the periphery37.
Defects in the B-1 cell compartment in Tnfaip3cD11c-Ko mice.
Since in contrast to B-2 cell development, B-1 cell precursors do not abide in the bone 
marrow38 and develop independently of IL-739, we studied B-1 cells in Tnfaip3CD11c-KO mice.
We investigated B-1 and B-2 cells in the peritoneal (Figure 3A) and pleural cavities. 
While total B cell numbers were unchanged, the proportions of B-1 cells (from total B 
cells) were reduced in Tnfaip3CD11c-HZ and Tnfaip3CD11c-KO mice compared with WT controls, 
both in the peritoneal cavity (Figure 3B) and in the pleural cavity (Figure 3c). B-1 cells 
have a restricted B cell receptor (BCR) repertoire and a considerable fraction of these cells 
recognize neutral phospholipids such as phosphatidylcholine PtC40, 41. When we stained 
peritoneal B cells for PtC-specificity, we observed reduced PtC binding in Tnfaip3CD11c-HZ 
mice and Tnfaip3CD11c-KO mice compared with Tnfaip3CD11c-WT controls (Figure 3D,3e). The 
frequency of intracellular IL-10+ B-1 and B-2 cells in the peritoneum of Tnfaip3CD11c-KO mice 
was decreased compared to Tnfaip3CD11c-WT mice and Tnfaip3CD11c-HZ mice (Figure 3F).
Potential mechanisms for the observed abnormalities in peritoneal B-1-cells may 
involve changes in DC activity. We did not detect differences in surface expression of 
co-stimulatory molecules on DCs or in the capacity of T-cells to produce cytokines across 
the three genotypes (data not shown). However, we did find increased proportions of 
IL-6+ and IL-10+ DCs in the peritoneum of Tnfaip3CD11c-HZ mice and Tnfaip3CD11c-KO mice 
compared to controls (Supplementary Figure 3). Conversely, the frequencies of IFNγ+ 
DCs were decreased in the peritoneum of Tnfaip3CD11c-KO mice compared to WT controls 
(Supplementary Figure 3).
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Summarizing, these data show that the absence of Tnfaip3 in the DC-lineage affected 
the numbers of peritoneal B cells. The reduction in PtC-binding and the changes in 
cytokine profile furthermore suggest altered B-1 cell function.
reduction of B cell numbers in the spleen of Tnfaip3cD11c-Ko mice.
Given that B cell development was disturbed in Tnfaip3CD11c-KO mice, we next character-
ized the B cell populations in peripheral lymphoid organs. Total splenic B-2 cell numbers 
were reduced in Tnfaip3CD11c-KO mice compared to WT controls (Figure 4A). Splenic 
transitional B cells did not differ between the three genotypes (Figure 4B). Marginal 
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Figure 3: Defects in the B-1 cell compartment in Tnfaip3cD11c-Ko mice.
(A) Flow cytometric analysis of peritoneal cavity B-1 cells (CD19+B220+CD43+CD5int) and B-2 cells 
(CD19+B220+CD43-CD5-). FACS profiles of gated CD19+ lymphoid cells fractions are shown for the in-
dicated mice. (B-c) Enumeration of total B cells, B-1 cells and B-2 cells in peritoneal (B) and pleural (c) 
cavity, using flow cytometry. (D) Flow cytometry plots of peritoneal PtC+ B-1 cells, identified by CD5/PtC 
profiles of CD19+CD43+ B cells. Representative examples are shown from Tnfaip3CD11c-WT, Tnfaip3CD11c-HZ and 
Tnfaip3CD11c-KO mice. (e) Quantification of PtC+ B-1 cells as a proportion of B-1 cells in the peritoneal cavity, 
using flow cytometry. (F) Quantification intracellular IL-10+ cells in the B-1 and B-2 cell population in peri-
toneal cavity from the three mouse groups, using flow cytometry. Legend for the individual mouse groups 
is shown in panel A. Results of (A-C) are representative of 3 independent experiments, and (D-F) are from 2 
independent experiment and are presented as me an values ± SEM of n = 4-7 per group. *P<0.05, **P < 0.01 
using the Mann-whitney U statistical test.
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Tnfaip3CD11c-WT mice (Figure 4c), but the numbers of total follicular (FO) B cells did not 
differ significantly between the three genotypes (Figure 4D). While the numbers of 
splenic germinal center (GC) B cells were highest in Tnfaip3CD11c-HZ mice, GC B cells and 
plasma cells were not different between Tnfaip3CD11c-WT and Tnfaip3CD11c-KO mice (Figure 
4e, 4F). Parallel to our findings in the peritoneal cavity, also the number of splenic B-1 
cells were reduced in Tnfaip3CD11c-KO mice compared to WT littermate controls (Figure 
4G). The numbers of B cell subpopulations in MesLN were similar between Tnfaip3CD11c-WT 
and Tnfaip3CD11c-KO mice, except for a small but significant increase in the total numbers 
of plasma cells in Tnfaip3CD11c-KO mice (Figure 4H).
Taken together, at ~6 weeks of age defective B cell development in the bone marrow 
of Tnfaip3CD11c-KO mice was associated with a reduction of the numbers of splenic B cells, 
in particular of the mature B-2 cell and MZ B cell fractions.
Tnfaip3CD11c-WT
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Figure 4: reduction of B cell numbers in the spleen of Tnfaip3cD11c-Ko mice.
(A-G) Enumeration of splenic B-2 cells (CD19+B220+CD43-CD5-) (A), Transitional B cells 
(CD19+B220+CD21/35-CD23-) (B), marginal zone B cells (CD19+B220+CD21/35+CD23-) (c), follicular B 
cells (CD19+B220+CD21/35-CD23+) (D), Germinal center B cells (CD19+B220+CD95+IgD-) (e), plasma cells 
(B220-CD138+) (F) and B-1 cells (CD19+B220+CD43+CD5int) (G) using flow cytometry. (H) Quantification of 
all B cell subsets from (A-G) except transitional B-cells, MZ and B-1 B cells within the MesLN, using flow 
cytometry. Mice were 6 weeks of age. Results are from representative of 2 independent experiments and 
are presented as mean values ± SEM of n = 6 per group. *P<0.05, **P < 0.01 using the Mann-whitney U 
statistical test.
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B cells from Tnfaip3cD11c-Ko mice show normal T-cell independent and defective 
T-cell dependent antibody responses.
Since supernatants of WT B cells that were co-cultured with Tnfaip3CD11c-KO DCs contained 
increased amounts of IgA and IgG1, when compared to co-cultures with Tnfaip3CD11c-WT 
DCs10, we determined total Ig levels in serum of ~6-week-old mice. Total IgM was high-
est in Tnfaip3CD11c-HZ mice, compared to Tnfaip3CD11c-WT and Tnfaip3CD11c-KO mice (Figure 
5A). Total IgA and IgG was increased in the serum of Tnfaip3CD11c-HZ and Tnfaip3CD11c-KO 
mice, compared with Tnfaip3CD11c-WT controls (Figure 5A). Specifically, the IgG1, IgG2b 
and IgG2c isotypes were increased in these two genotypes (Figure 5B). In contrast, IgG3 
serum levels were specifically elevated in Tnfaip3CD11c-HZ mice, paralleling our findings for 
serum IgM levels (Figure 5B).
We next examined the specific Ig response against the T-cell dependent antigen 
ovalbumin (OVA). While Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice elicited an anti-OVA IgG1 
response at day 8 and day 15 after booster immunization, this response was severely 
reduced in Tnfaip3CD11c-KO mice (Figure 5c). On the other hand, a T-cell independent anti-
gen such as DNP-Ficoll, elicited anti-DNP-Ficoll IgM and IgG3 responses in Tnfaip3CD11c-KO 
mice that were in the normal range (Figure 5D).
In summary, Tnfaip3CD11c-KO mice had increased serum levels of several Ig subclasses 
including IgG1, but showed a severely reduced T-cell dependent IgG1 response. In these 
mice IgM and IgG3 levels, as well as type II T cell-independent IgM and IgG3 responses, 
were not affected.
Splenic naïve mature B cells in Tnfaip3cD11c-Ko mice show enhanced 
responsiveness to activating stimuli.
Because spontaneous Ig production by B cells from aging Tnfaip3CD11c-KO mice was 
increased10, we wondered whether mature naïve splenic B cells from 6-week-old Tn-
faip3CD11c-KO mice displayed an increased capacity to produce pro-inflammatory cytokines. 
Indeed, splenic B cells in Tnfaip3CD11c-HZ and Tnfaip3CD11c-KO mice showed an increased ca-
pacity to produce IFNγ, compared with Tnfaip3CD11c-WT mice, as measured by intracellular 
cytokine staining upon short in vitro activation with PMA and ionomycin (Figure 6A).
This prompted us to investigate whether naïve mature B cells in the periphery from 
Tnfaip3CD11c-KO mice showed evidence for enhanced activation by stimuli such as lipopoly-
saccharide (LPS) in comparison to B cells from control mice. Indeed, stimulating naïve B 
cells in vitro with LPS or the TLR9 ligand CpG, resulted in higher surface expression levels 
of CD86 and CD80 on B cells from Tnfaip3CD11c-KO mice, compared to Tnfaip3CD11c-WT con-
trols (Figure 6B-6D). The GC marker Fas Ligand or CD95 was more readily induced upon 
anti-IgM, LPS, CpG or anti-CD40 stimulation of naïve splenic B cells from Tnfaip3CD11c-KO 
mice, compared with B cells from WT control mice (Figure 6e). The stimulation-induced 
expression of CD69 did not differ across the genotypes (Figure 6F).
119
We next evaluated in vitro plasma cell differentiation upon LPS stimulation in the pres-
ence or absence of IL-4. Increased proportions of IgG1+CD138+ plasmablasts were found 
upon LPS/IL-4 stimulation of purified B cell fractions from Tnfaip3CD11c-KO mice, compared 
with WT mice (Figure 6G). After LPS stimulation alone, the proportions of IgG3+ B cells 
or plasmablasts were not different between cultures from Tnfaip3CD11c-KO or Tnfaip3CD11c-WT 
mice (Figure 5H).
In conclusion, these data illustrate that following in vitro activation naïve splenic B cells 
from Tnfaip3CD11c-KO mice display a more activated phenotype and an increased differentia-















































































































































Figure 5: B cells from Tnfaip3cD11c-Ko mice show normal T-cell independent and defective T-cell depen-
dent antibody responses.
(A-B) Measurement of total serum levels of IgM, IgA and IgG (A) and subclasses IgG1, IgG2b, IgG2c and IgG3 
(B) using ELISA. (c) T-cell dependent B cell response: pre-immune and post-OVA immunisation assessment 
of OVA-specific IgG1 serum levels using ELISA. (D) T-cell independent type II B cell response: pre-immune 
and post-immunisation assessment of DNP-specific IgM and IgG3 serum levels, using ELISA. Results are 
presented as mean values ± SEM of  n = 3-10 per group. *P<0.05, **P < 0.01 using the Mann-whitney U 
statistical test.
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B B cells after LPS stimulation
Figure 6: Splenic naïve mature B cells in Tnfaip3cD11c-Ko mice show enhanced responsiveness to acti-
vating stimuli.
(A) Quantification of the proportions of IL-6+, IL-10+ and IFNγ+ splenic B cells in the indicated mice. (B-F) 
Purified naïve B cells (CD19+B220+NK1.1-CD4-CD8-Ter119-CD11c-GR1-FCRIα-CD5-CD43-CD138-CD11b-CD95-) 
were in vitro stimulated using LPS (B) and assessed for the indicated activation markers. Data are shown as 
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DIScUSSIoN
B cells are crucial in autoimmune diseases2, 42 and therefore the immune system has 
several checkpoints to remove autoreactive B cells from the repertoire. In a lupus 
mouse model of DC-specific deletion of A20/Tnfaip3 (Tnfaip3CD11c-cre), we previously 
demonstrated that B cells are more activated and engaged in autoreactive Ig produc-
tion associated with glomerulo-nephritis10. Because aged Tnfaip3CD11c-cre mice displayed 
severely reduced numbers of peripheral B cells and B cell tolerance is initiated in the 
bone marrow12-15, we studied bone marrow B cell development in Tnfaip3CD11c-cre mice.
We observed an age-dependent developmental arrest of B-lineage cells: B cell devel-
opment was hampered at the immature B cell stage in 6-week-old Tnfaip3CD11c-KO mice 
and at the pre-B cell stage in 24-week-old Tnfaip3CD11c-KO mice. Various molecular mecha-
nisms may explain these findings. An intrinsic defect in B cell differentiation affecting 
the pre-B cell stage is not very likely, since deletion of the Tnfaip3 gene was specifically 
targeted to the DC-lineage. Secondly, B cell development might be hampered as a result 
of the circulating pro-inflammatory cytokines arising during autoimmune pathology. 
For example, IFN α/β30 and IFNγ31 can directly induce apoptosis of IL-7 dependent B cell 
precursors. In addition, cytokines such as IL-443, IL-1(α/β)27, 28 and transforming growth 
factor (TGF)-β44, 45 can exert inhibitory effects on B cell development. Thirdly, B cells in 
Tnfaip3CD11c-KO mice might be subjected to improper cell-cell interaction signals, because 
of an altered activation status of DCs or because activated DCs affected stromal cells 
or other supportive cells in the bone marrow environment. Finally, a possible scenario 
could be that B-lineage cells have a reduced migration capacity into IL-7Rlo niches in the 
bone marrow, e.g. due to reduced expression of CXCL1232.
To address this issue, we performed IL-7-driven bone marrow cultures in vitro using 
combinations of Tnfaip3CD11c-KO and Tnfaip3CD11c-WT B cells and supporting stromal/myeloid 
cells. We found that Tnfaip3CD11c-KO stromal/myeloid cells were less beneficial for develop-
mental progression of pre-B cells, indicating that cell-cell contact rather than external 
cytokines or chemokine gradients hampered B cell development in Tnfaip3CD11c-KO mice. 
With this in vitro experiment, however, we cannot formally exclude the possibility that 
Tnfaip3CD11c-KO stromal/myeloid cells in our culture system produced soluble factors that 
hamper B cell development.
histogram overlays (B) or quantifications of expression of the activation markers CD86 (c), CD80 (D), CD95 
(e) and CD69 (F), as determined by flow cytometry, on B cells that were cultured in the presence of the 
indicated activating stimuli. (G-H) Naïve B cells were cultured in vitro with LPS in the presence or absence 
of IL-4, as indicated, and assessed for IgG1+ (G) and IgG3+ (H) B cells or plasmablasts (CD19+B220+CD138+), 
using flow cytometry. Results are representative of 2 independent experiments and are presented as mean 
values ± SEM of n = 6 per group. *P<0.05, **P < 0.01 using the Mann-whitney U statistical test.
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Small pre-B cells rearrange their Ig κ or λ light chains, with a 95:5 ratio respectively in 
the peripheral B cell population in mice46. We found that immature B cells in the bone 
marrow of Tnfaip3CD11c-KO mice had significantly decreased proportions of Igλ+ cells, 
whereas Igλ usage was elevated in the most mature IgDhiIgMlo B cells in peripheral im-
mune compartments. It is possible that Tnfaip3CD11c-KO mice have a reduced Igλ locus 
accessibility which would subsequently affect Igλ recombination and receptor editing 
events. However, it appears much more likely that in Tnfaip3CD11c-KO mice the BCR reper-
toire selection is abnormal, leading to reduced receptor editing in the bone marrow and 
decreased selection against Igλ+ B cells in the periphery37. This could e.g. be related to 
reduced survival of B cells in these mice.
Further experiments, e.g. involving crosses with transgenic mice expressing autoreac-
tive and non-autoreactive BCRs are likely to show whether or not deletion of the Tnfaip3 
gene in DCs affects selection of the BCR repertoire in mice.
B-1 cell progenitors develop independently of IL-739 and the bone marrow38. Although 
in Tnfaip3CD11c-KO mice B-1 cells were reduced in numbers and had an altered BCR reper-
toire, as evidenced by reduced PtC-binding, we found that serum IgM and IgG3 levels 
were normal and that B-1 cells were able to mount a normal response to the type II 
T cell-independent antigen DNP-Ficoll. In contrast to this relatively unaffected B-1 cell 
compartment, we detected severe defects in B-2 cells. Serum levels of IgG1, IgG2b and 
IgG2c were increased, but B cells were unable to mount a specific T cell-dependent 
antibody response towards OVA in vivo, suggesting that B cells in Tnfaip3CD11c-KO mice 
received aberrant stimulatory signals from T-cells. This might well be related to the 
disturbed micro-architecture of the spleen observed in Tnfaip3CD11c-KO mice10. Although 
we did not check for autoreactive IgG in 6-week-old mice, it was already demonstrated 
that 12-week-old mice had enhanced anti-dsDNA IgG and one 10-week-old mice had 
positivity for self-antigen RNP-A10.
Naïve splenic B cells from Tnfaip3CD11c-KO mice showed an enhanced response to 
activating stimuli. A minor proportion of B cells might have been targeted by CD11c-
cre-mediated deletion47, because CD11c can be expressed by a small fraction of B cells, 
associated with aging and autoimmunity48. However, such CD11c+ B cells were hardly 
present in the B cell fractions of our in vitro experiments, because we negatively selected 
for CD11c during our magnetic B cell purification procedure. More likely, the enhanced 
responsiveness of B cells was a result of activating signals in vivo, which appear to be 
present in a very early phase of the developing autoimmune pathology. Similar co-
stimulatory molecule enhancements was also seen in autoimmune disease, as CD80 
MFI values were higher in unstimulated naïve peripheral B cells of multiple sclerosis 
patients49 and CD80/CD86 MFI values were elevated in CD40-stimulated naïve B cells 
from SLE patients50, compared to healthy controls. Although increased MZ B cells51 and 
memory B cells52 could explain rapid and enhanced activation or class switched immu-
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noglobulin production, this is not likely to underlie the increased responsiveness of B 
cells in Tnfaip3CD11c-KO mice: these mice have reduced MZ B cell numbers and no presence 
of memory B cells, as suggested by equal memory B cell marker CD8053 levels at baseline 
as WT controls.
To conclude, we demonstrated that loss of A20/Tnfaip3 in DCs mainly affects B cell 
development, BCR repertoire selection and function. Improper signals from the bone 
marrow microenvironment are likely responsible for the age-dependent arrest of B cell 
development. B cells that reach the periphery act differently to stimuli, indicating that 
either (i) B cell selection in bone marrow might alter the activation threshold of B cells, 
or (ii) that the activation status of DCs and T cells in lymphoid organs have a large impact 
on B cell activation and function. These findings in mice indicate that humoral B cell-
driven diseases including SLE, may develop from primary defects in immune cells from 
a different compartment, such as DCs.
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Tnfaip3CD11c-KO                           
Supplementary Figure 1: Pro B cell stages are unaffected in Tnfaip3cD11c-Ko mice.
The indicated developmental B-lineage fractions, according to the Hardy nomenclature26 in the bone mar-
row of the three mouse groups, calculated as a percentage of living cells. Results are representative of 3 
independent experiments and are presented as mean values ± SEM of n = 6 per group. *P<0.05, **P < 0.01 




























































































































Tnfaip3CD11c-KO                           
Supplementary Figure 2
Supplementary Figure 2: Igκ+ and Igλ+ light chains in bone marrow and spleens in Tnfaip3cD11c-Ko mice.
(A) Flow cytometric analysis Igκ+ and Igλ+ light chains in bone marrow immature B cells (B220+CD19+IgDloIgMhi) 
and mature B cells (B220+CD19+IgDhiIgMhi), in the indicated mice. Gating strategy according to Dingjan et al36. 
(B) Flow cytrometric analysis Igκ+ and Igλ+ light chains in splenic immature B cells (B220+CD19+IgDloIgMhi), 
IgDhiIgMhi B cells (B220+CD19+IgDhiIgMhi) and mature B cells (B220+CD19+IgDhiIgMlo), with enumeration of 
the proportion Igλ+ light chain across all indicated genotypes.





































Supplementary Figure 3 
Tnfaip3CD11c-WT
Tnfaip3CD11c-HZ
Tnfaip3CD11c-KO                           
Supplementary Figure 3: Peritoneal cavity Dcs from Tnfaip3cD11c-Ko mice express increased Il-6, Il-10 
and reduced IFN-γ.
6-week-old Tnfaip3CD11c mice were analyzed for peritoneal cavity DCs. Quantification of DC (CD11c+MHC-
II+) that expressed IL-6, IL-10 and IFN-γ, using flow cytometry. Results are from a single experiment and 
are presented as mean values ± SEM of n = 6 per group. *P<0.05 using the Mann-whitney U statistical test.
Supplementary Table 1: Antibodies used for flow cytometry
Antibody conjugate clone company
B220 PE-Cy7 RA3-6B2 eBioscience
B220 Alexa Fluor 700 RA3-6B2 eBioscience
B220 Biotin RA3-6B2 BD
BP-1 (Ly-51) Biotin 6C3/BP BD
CD11c PE-Texas Red N418 Invitrogen
CD138 Brilliant Violet 605 281-2 BD
CD19 PerCP-Cy5.5 eBio1D3 eBioscience
CD2 PE RM2-5 eBioscience
CD24 Briljant Violet 650 M1/69 BD
CD25 Brilliant Violet 605 PC61 BioLegend
CD4 Brilliant Violet 711 RM4-5 BD
CD34 Alexa Fluor 700 RAM34 eBioscience
CD43 Briljant Violet 605 S7 BD
CD5 PE 53-7.3 eBioscience
CD5 Biotin 53-7.3 BD
cKit APC-eFluor780 2B8 eBioscience
IFNγ PE-Cy7 XMG1.2 eBioscience
IgD APC 11-26c eBioscience
Ig λ FITC R26-46 BD
Ig λ Biotin R26-46 BD
IgM APC II/41 eBioscience
IgM PE-Cy7 II/41 eBioscience
IL-10 Alexa Fluor 488 JES5-16E3 eBioscience
IL-6 PE MP5-20F3 BD
Ig κ FITC 187.1 BD
PtC FITC
Streptavidin Brilliant Violet 711 BD
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ABSTrAcT
Dendritic cells (DCs) are sentinel cells regulating both immune homeostasis and immu-
nogenic responses. Ablation of Tnfaip3/A20, a negative regulator of the NF-κB pathway, 
in DCs (Tnfaip3CD11c-KO mice) induces DC activation. As a result, activation of T cells and 
B cells occurs leading to spontaneous germinal center (GC) formation and an autoim-
mune phenotype. In vitro Tnfaip3-deficient DCs are potent activators of naïve B cells that 
develop into IgG1- and IgA-producing plasma cells. We hypothesize that T cells might be 
dispensable for B cell-driven autoimmunity in Tnfaip3CD11c-KO mice.
Tnfaip3CD11c mice were crossed to Cd40lgKO mice to hamper communication between 
T cells and B cells and immune activation and tissue inflammation were examined. In 
10-week-old Tnfaip3CD11c-KO mice, splenic DCs harbor an activated phenotype as evi-
denced by higher CD40 surface expression, both on a WT and on a Cd40lgKO background. 
As expected, both follicular T helper (Tfh)-cells and GC B cells were reduced in CD40L-
deficient mice. Marginal zone B cells, but not follicular B cells, expressed GC-associated 
cytokine receptors in Tnfaip3CD11c-KOCd40lgKO mice. In 24-week-old Tnfaip3CD11c-KO mice, 
splenic IgG1+ plasma cells and memory B cells were highly abundant, together with 
elevated anti-dsDNA IgG1 in serum and IgG deposition in the kidneys. Importantly, 
Tnfaip3CD11c-KOCd40lgKO mice presented with kidney pathology, in which IgA was depos-
ited and serum anti-dsDNA IgM and IgA levels were enhanced.
These findings indicate that kidney pathology can occur in the absence of CD40L-de-
pendent communication between T cells and B cells in mice harboring Tnfaip3-deficient 
DCs. We conclude that therapies interfering with CD40-CD40L interaction may not fully 
prevent organ inflammation in autoimmune disorders.
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INTroDUcTIoN
Immune homeostasis is critically controlled by dendritic cells (DCs)1. In order to respond 
to pathogens, DCs are activated and induce an appropriate immune response to clear 
the infection. In autoimmunity, unfortunately, DCs are activated with deleterious con-
sequences2. For instance, artificial activation of DCs, by in vivo ablation of Tnfaip3/A20, 
a negative regulator of NF-κB signaling, resulted in T cell and B cell activation, antibody 
class switching, systemic inflammation and glomerulonephritis. When mice were 24 
weeks old, they developed an autoimmune phenotype resembling either inflammatory 
bowel disease3 or systemic lupus erythematosus (SLE)4.
SLE is a multifactorial disease in which multiple immune cells, such as DCs, T cells and 
B cells play a role5. The presence of antinuclear antibodies (ANA) in serum is generally 
considered a decisive diagnostic sign of SLE. These antibodies are produced by plasma 
cells, which develop from B cells that are either activated in germinal centers (GC) or 
by extrafollicular responses in a T cell-independent (TI) manner6. B-cell activation is 
initiated by engagement of specific antigens to the B-cell receptor (BCR), resulting in 
a T cell dependent or TI humoral response7. GC B cells are dependent on T cell help, 
whereby CD40L expression on activated T cells and their IL-21 production is crucial for 
communication with B cells8. Within the GC, T cell help promotes immunoglobulin (Ig) 
class switch, especially to IgG19 and IgG210. However, B cells can also be activated, differ-
entiate, and isotype-switch independent of antigen-specific T cell help, CD40L signaling, 
and IL-21 signaling to B cells. When B cells are activated in extrafollicular responses in a 
TI manner, antigen presenting cells such as DCs or macrophages can replace the func-
tion of T cells to instruct plasma cell formation11. Nevertheless, T cells do dramatically 
enhance the response, and this occurs via CD40L and IL-21 signals. 
Intriguingly, Tnfaip3-deficient bone marrow-derived DCs (BM-DCs), when cultured 
with naïve B cells, could induce plasma cell formation and IgG1 and IgA class switch in a 
TI manner4. This was partially dependent on the presence of IL-6, and not due to IL-21 or 
other familiar TI-cytokines, such as B lymphocyte stimulator protein (BLyS, also known 
as BAFF) or a proliferation-inducing ligand (APRIL)4.
It is currently unknown whether B cell activation in vivo in autoimmune Tnfaip3CD11c-KO 
mice is dependent on T cell help or directly induced by activated DCs. To determine 
whether T cell dependent contact was necessary, we hampered T cell communication 
with B cells by deletion of CD40L and crossed Tnfaip3CD11c-KO mice to CD40L-deficient 
mice12.




C57BL/6 Tnfaip3fl/flCd11ccre/+ mice4 were crossed with Cd40lgKO mice12 (The Jackson Labo-
ratory, Bar Harbor, ME, USA). Male and female mice were analyzed at 10 weeks or 24 
weeks of age. The cre-deficient littermates served as wild-type (WT) controls. Mice were 
bred and housed under specific pathogen-free conditions in the Erasmus MC experi-
mental animal facility. All experiments were approved by the animal ethical committee 
of the Erasmus MC (EMC3329).
Generation of bone marrow-derived dendritic cells (Bm-Dcs)
To obtain BM-DCs, BM cells were cultured for 9 days in DC culture medium (RPMI 1640 
containing GlutaMAX (Invitrogen, Waltham, MA, USA, with 5% FCS (Hyclone, South 
Logan, UT, USA), 50 µM 2-mercaptoethanol (Sigma-Aldrich Co., St. Louis, MO, USA) and 
50 µg/ml gentamycin (Invitrogen), with 20 ng/ml of granulocyte-macrophage colony-
stimulating factor (GM-CSF)13.
rNA Sequencing
Total RNA was extracted from BM-DCs as described14. Single-end reads were aligned to 
the mouse genome (UCSC Genome Browser mm9) using TopHat (Tophat version 2.0.8). 
Gene expression levels as fragments per kilobase of a transcript per million mapped 
reads (FPKMs) were calculated using Cufflinks15. RNA-Seq Data Analysis Differential gene 
expression assessment was done in the R environment (version 3.1.1) with CuffDiff16. 
Gene set enrichment analysis (GSEA)17 was performed using a pre-ranked list of all genes. 
The MySigDB collection “H: Hallmark Genes” was used to align for enrichment. From the 
top 3 most enriched gene sets results, we further specified cytokines and chemokines as 
published on www.genenames.org.
Tissue preparation
Spleens were taken from sacrificed mice. One half was stored in Tissue-Tek® O.C.T.TM com-
pound (Sakura Finetek Europe B.V., Alphen aan den Rijn, The Netherlands) and slowly 
frozen at -20 ºC. Cryo sections were cut using a CryoStarTM NX70 Cryostat (Thermo Fisher 
Scientific Inc., Waltham, MA, USA).
The other half was used to obtain single cell suspensions. Spleens were homogenized 
through a 100-μm cell strainer (Corning Inc., Corning, NY, USA) and collected in GibcoTM 
RPMI Medium 1640  (1 x) + GlutaMAXTM-1 (Thermo Fisher Scientific Inc., Waltham, MA, 
USA). Spleen red blood cells were lysed using osmotic lysis buffer (0.15 M NH4CL, 10 mM 
KHCO3, 0.1 mM EDTA, pH 7.1-7.4; sterile-filtered with 0.22 µm filter).
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Freshly isolated kidneys, liver, and pancreas were incubated 24 hrs on Roti-Histofix 4% 
(Carl-Roth, Karlsruhe, Germany) and then embedded in paraffin wax. Paraffin embedded 
tissue sections were stained with hematoxylin and eosin, using standard procedures.
Flow cytometry and cell sorting
Flow cytometric surface and intracellular staining procedures have been described 
previously18. Monoclonal antibodies used for flow cytometric analyses were (Target, 
Clone, Manufacturer): CD11b (M1/70, BD Biosciences), CD11c (N418, Invitrogen), CD19 
(1D3, BD Biosciences), CD21 (4E3, eBioscience), CD23 (B3B4, eBioscience), CD3e (17A2, 
eBioscience), CD4 (GK1.5, eBioscience), CD80 (16-10A1, eBioscience), CD86 (GL1, BD 
Biosciences), CD95 (Jo2, BD Biosciences), CXCR5 (2G8, BD Biosciences), GL7 (RUO, BD 
Biosciences), IgD (11-26c.2a, BD Biosciences), IgG1 (R19-15, BD Biosciences), IgM (II/41, 
eBioscience), MHC-II (M5/114.15.3, eBioscience), PD-1 (J43, BD Biosciences), The fol-
lowing monoclonal antibodies were used for cell sorting (Target, Clone, Manufacturer): 
CD19 (eBio1D3, eBioscience), CD21 (4E3, eBioscience), CD23 (B3B4, eBioscience), CD3e 
(145-2C11, BD Biosciences). Sorting was conducted using a BD FACSAriaTM II (BD Biosci-
ences, San Jose, CA, USA). Data analysis was performed in FlowJo version 9 Workspace 
(FlowJO LLC, Ashland, OR, USA).
rNA isolation and cDNA synthesis
Total RNA was isolated from sorted follicular (FO) B cells and marginal zone (MZ) B cells, 
using the RNeasy® Micro Kit (QIAGEN, Venlo, Netherlands) according to the manufactur-
er’s instructions. cDNA was synthesized using the RevertAid H Minus First Strand cDNA 
Synthesis Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). 11 µl of the isolated total 
RNA was used and 1 µl of random hexamer primer was added, then mixed, centrifuged 
and incubated for 5 min at 65 ºC. The mixture was chilled on ice, centrifuged and 4 µl of 
5x Reaction Buffer, 1 µl of RiboLock RNase Inhibitor (20U/µl), 2 µl 10 mM dNTP Mix and 
1 µl RevertAid H Minus Reverse Transcriptase (200U/µl) were added. After incubation for 
5 min at 25 ºC, the mixture was incubated for 60 min at 42 ºC. To terminate the reaction, 
the sample was heated to 70 ºC for 5 min. The cDNA was stored at -20 ºC until it was used 
in quantitative RT-PCR.
Quantitative rT-Pcr
Quantitative RT-PCR (real-time reverse-transcription PCR) analysis was performed using 
the SYBR® Select Master Mix Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA) and 
primers (Target, Forward, Reverse) for Fasl (F: GCAGAAGGAACTGGCAGAAC, R: TTAAAT-
GGGCCACACTCCTC), Il-4r (F: GAGTGGAGTCCTAGCATCACG, R: CAGTGGAAGGCGCTG-
TATC), Il-21 (F: CCATCAAACCCTGGAAACAA, R: TCACAGGAAGGGCATTTAGC) and Il-21r (F: 
AGTGCCCCAGCCTAAAGAAT, R: ACTGAGTATGCTGGGGTTGG) on an Applied BiosystemsTM 
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7300 Real Time PCR System (Thermo Fisher Scientific Inc., Waltham, MA, USA). Ubiquitin 
C (UBC) mRNA expression was used as housekeeping gene to normalize gene transcrip-
tion. Data were extracted from the linear range of amplification.
Immunoglobulin levels and autoreactivity assessment
Serum total immunoglobulin levels were assessed by ELISA, as previously described19. 
Briefly, goat-anti-mouse immunoglobulins were plated overnight. Wells were blocked 
and serum was incubated for 3 hrs at room temperature. Depending on the isotype of 
interest, anti-mouse biotin labeled against the isotype of interest was incubated and 
developed. The optical density (OD) was measured at 450 nm on a Microplate Reader 
(Bio-Rad, Hercules, CA, USA). Immunoglobulin autoreactivity assessment was assessed 
as previously described19.
Periodic Acid Schiff Diastase staining (PAS-D or PAS+ staining)
Three-μm-thick paraffin embedded kidney sections were stained with Periodic Acid 
Schiff (PAS; Sigma-Aldrich). Briefly, paraffin embedded sections were dewaxed and 
hydrated to water using Xylene (Sigma-Aldrich) and ethanol dilutions in MilliQ. One 
part human saliva (containing the enzyme diastase) was diluted 1:10 with MilliQ and 
incubated on slides for 30 min on room temperature. Slides were placed for 5 min in 
freshly prepared periodic acid solution (Sigma-Aldrich) and then in Schiff’s reagent for 5 
min and counterstained with Gill’s hematoxylin (Merck Millipore) for 2 sec. Lastly, slides 
were dehydrated using Xylene and mounted in Entallan (Merck Millipore).
Immunohistochemistry of cryosections
For immunohistochemistry, 6  µm acetone or 4  %  formalin fixed spleen sections were 
blocked in peroxidase blocking buffer (PBS, 0.67 % H2O2, 2 % NaN3) for 30 min at room 
temperature. Aspecific secondary antibody binding was prevented by blocking the sec-
tions in Blocking Buffer (1% Blocking Reagent (Roche Diagnostics GmbH, Mannheim, 
Germany) in PBS) containing 10% normal goat or donkey serum. Sections were stained 
with primary antibodies for 1  hr at room temperature, washed three times with PBS 
and incubated with alkaline phosphatase (AP) or peroxidase (PO) conjugated second-
ary antibodies for 30  min at room temperature. Used antibodies are listed (Target, 
clone, dilution, manufacturer, secondary antibody, dilution, manufacturer): CD21 
(Biotin, 1:100, Streptavidin PO, 1:50), MOMA1 (1:100, Bioceros, Goat anti-Rat AP, 1:50, 
Jackson Immunoresearch), GL7 (RUO, 1:50, eBioscience, Goat anti-Rat AP, 1:50, Jackson 
Immunoresearch) and IgD (11-26, 1:50, eBioscience, Goat anti-PE PO, 1:50, Rockland 
Immunochemichals). First the alkaline phosphatase was detected in 30 minutes using 
a mixture containing N-(4-Amino-2,5-diethoxyphenyl)benzamide (Fast Blue BB, Sigma-
Aldrich), 2 M HCl, 4 % NaNO2, Naphthol AS-MX phosphate (VWR International, Radnor, 
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PA, USA), N,N-dimethylformamide (DMF) (Sigma-Aldrich), Tris-HCl buffer (pH  8.5) and 
(-)-tetramisole hydrochloride (Sigma-Aldrich). The substrate was filtered using filtration 
paper. Subsequently, peroxidase was detected within 30 min with a mixture containing 
3-amino-9-ethylcarbazole (AEC) in DMF, 0.1 M NaAC (pH 4.6), 30% H2O2 (Merck Millipore, 
Darmstadt and double-filtered. Stained tissue sections were embedded in Kaiser’s 
Glycerol/Gelatin (Boom B.V., Meppel, The Netherlands). Micrographs were made using 
a Leica DM2000 microscope (Leica Microsystems GmbH, Wetzlar, Germany), a Leica 
DFC450 camera (Leica Microsystems GmbH, Wetzlar, Germany) and Leica Application 
(LAS) Software Version 4.5.0 (Leica Microsystems GmbH, Wetzlar, Germany).
Immunohistochemistry of Paraffin embedded sections
For immunohistochemical stainings on paraffin embedded sections, antigen retrieval 
was established using citrate buffer (Sigma Aldrich) pH 6.0 for 10 min in the microwave. 3 
μm-thick paraffin kidney sections were stained with biotinylated primary antibody against 
total Immunoglobulin Isotypes (Primary antibody target, dilution, manufacturer): IgA (Bio-
tin, 1:200, Southern Biotech), IgM (Biotin, 1:200, Southern Biotech) and IgG (Biotin, 1:200, 
Southern Biotech). After washing with PBS, slides were incubated for 1 hr with Avidin/Bioti-
nylated Enzyme Complex (ABC) from the anti-Rat ABC Peroxidase Kit (Vector Laboratories). 
10mg 3,3’-Diaminobenzene (DAB) (Sigma-Aldrich) was dissolved in Tris-HCl buffer (pH 7,6) 
with 12μl H2O2 to retrieve specific staining and slides were coated with Kaiser’s glycerol.
confocal microscopy
For confocal imaging, 12 μm-thick spleen cryostat sections were stained as explained 
above. Primary and secondary antibodies were (Target, clone, dilution, manufacturer, 
with respective secondary antibody target, dilution, manufacturer): B220 (RA3-6B2, 1:50, 
BD Biosciences, Donkey anti-Rat Cy5, 1:200, Jackson Immunoresearch), CD11c (N418, 
1:10, eBioscience, Goat anti-Hamster Cy3, 1:1000, Jackson Immunoresearch), CD3e (KT3, 
1:50, Bioceros, Donkey anti-Rat Cy3, 1:1000, Jackson Immunoresearch). Slides were 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI), mounted with VECTASHIELD® 
HardSetTM Antifade Mounting Medium (Vector Laboratries, Burlingame, CA, USA) and 
analyzed on a Zeiss LSM  510  META confocal microscope (Carl Zeiss AG, Oberkochen, 
Germany). Images were analyzed using ImageJ software (Rasband, W.S., ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA).
Statistics
Statistical significance of data was calculated using the non-parametric Mann-Whitney 
U test. P-values <0.05 were considered significant. All analyses were performed using 
Prism (GraphPad Software version 9, La Jolla, CA, USA). All data are presented as the 
mean with the standard error of the mean (SEM).
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reSUlTS
loss of Tnfaip3/A20 in Bm-Dcs increases the expression of cytokines involved 
in B cell activation.
As in vitro Tnfaip3/A20-deficient BM-DCs can directly activate B cells4, an unbiased tran-
scriptome analysis using mRNA-sequencing was performed14 to examine differences 
between Tnfaip3WT, Tnfaip3HZ, and Tnfaip3KO BM-DCs that could explain the TI B cell acti-
vating capacity. A large number of differentially expressed genes (DEG) were identified 
between Tnfaip3WT, Tnfaip3HZ, and Tnfaip3KO BM-DCs (Figure 1A). Gene set enrichment 
analysis (GSEA) revealed that several cytokine-signaling pathways are highly active in 
Tnfaip3KO BM-DCs, with the ‘TNF-α signaling via NF-κB’ pathway as the most enriched 
gene set in Tnfaip3KO BM-DCs compared to Tnfaip3WT BM-DCs (Figure 1B/c). This path-
way was also significantly enriched in Tnfaip3KO BM-DCs when compared to Tnfaip3HZ 
BM-DCs as well as in Tnfaip3HZ BM-DCs compared to Tnfaip3WT BM-DCs (Supplementary 
Figure 1A/B). mRNA expression of several cytokines and chemokines was increased 
in Tnfaip3KO BM-DCs compared to Tnfaip3WT BM-DCs (Figure 1D), including cytokines 
involved in activation of B cells and T cells, such as Il6, Il1b, and Il1a (Figure 1e). However, 
mRNA expression of some cytokines, including Tnf and Lta was reduced in Tnfaip3KO BM-
DCs compared to Tnfaip3WT BM-DCs (Figure 1F). Expression of TI cytokines regulating B 
cell activation and survival, such as APRIL, BAFF and TGFβ were not significantly altered 
in Tnfaip3KO BM-DCs (data not shown).
Taken together, cytokine signaling pathways were highly dependent on the expression 
of Tnfaip3 in BM-DCs and these pathways were inversely correlated with Tnfaip3 gene 
expression. Tnfaip3-deficient DCs harbored elevated mRNA expression of cytokines, 
such as IL-6, IL-1β and IL-1α that may directly influence B cell activation, particularly in 
the context of autoimmunity20, 21.
Splenic Dcs from Tnfaip3cD11c-KoCd40lgKo mice show enhanced expression of 
activation markers.
To test whether T cell help is needed for B cell activation in Tnfaip3CD11c-KO mice, 
CD40L-CD40 interaction between T cells and B cells was abrogated by crossing 
Tnfaip3CD11c-KO mice with Cd40lgKO mice. Spleens of 10-week-old Tnfaip3CD11c-KO mice and 
Tnfaip3CD11c-KOCd40lgKO mice showed splenomegaly in comparison to their respective WT 
controls and Tnfaip3CD11c-Hz mice (Supplementary Figure 1c). However, no differences in 
splenic cellularity (Supplementary Figure 1D) was seen, consistent with the previously 
demonstrated extramedullary hematopoiesis in Tnfaip3CD11c-KO mice4. Also, the number 
of splenic DCs (Supplementary Figure 1e/F) did not differ across the six genotypes. 
Splenic DCs of Tnfaip3CD11c-HZ and Tnfaip3CD11c-KO mice showed a slight increase of CD40 
expression, which reached significance for Tnfaip3CD11c-HZ mice, compared to WT mice 
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(Figure 2A/B). The expression of PD-L1, but not CD86, was moderately enhanced on 
DCs from Tnfaip3CD11c-KO mice compared to WT controls (Figure 2A/B). Remarkably, in the 
absence of CD40L, expression of CD40, CD86, and PD-L1 were significantly increased on 
DCs from Tnfaip3CD11c-KOCd40lgKO mice, compared to Cd40lgKO mice (Figure 2A/B).





Tnfaip3KO compared to Tnfaip3HZ
BM-DC
Number of signicantly 
down/up regulated genes
44 355








  INTERFERON-α RESPONSE
  INFLAMMATORY RESPONSE
  INTERFERON-γ RESPONSE








































































(Tnfaip3KO compared to Tnfaip3WT BM-DC)
-5 0 5 10
  E2F TARGETS
  MYC TARGETS v1
  G2M CHECKPOINT
  MTORC1 SIGNALING
  MYC TARGETS v2
  UNFOLDED PROTEIN RESPONSE
  DNA REPAIR
  OXIDATIVE PHOSPHORYLATION
  MITOTIC SPINDLE
  PI3K AKT MTOR SIGNALING























































GSEA enrichment (signed -log10 FDR q-value)
Figure 1: loss of Tnfaip3/A20 in Bm-Dcs increases the expression of cytokines involved in B cell ac-
tivation.
Bone marrow-derived DCs (BM-DCs) were analyzed by RNA Next generation sequencing (NGS). (A) The 
significant up and down-regulated gene numbers are listed according to Cuff diff-tools between Tnfaip3WT 
mice, Tnfaip3HZ mice and Tnfaip3KO BM-DCs. (B) Gene set enrichment analysis (GSEA) performed for the 
ranked list of significantly altered genes between BM-DCs from Tnfaip3CD11c-KO mice and Tnfaip3CD11c-WT mice. 
The top 10 results with a False Discovery Rate (FDR)<0.25 are shown. (c) The top result of the GSEA with ‘sig-
nal to noise’. (D) Using the three most enriched results (being “TNF-α SIGNALING VIA NF-κB”, “INTERFERON-γ 
RESPONSE” and “INFLAMMATORY RESPONSE”), we characterized all cytokines and chemokines and ex-
pressed the fold changes between Tnfaip3KO BM-DCs and Tnfaip3WT BM-DCs. (e-F) Quantification of the 
Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values of IL-6 (Il6), IL-1β (Il1b) and 
IL-1α (Il1a) (e) and TNF-α (Tnfa) and TNF-β (Lta) (F) between all BM-DC genotypes, as assessed directly from 
raw sequence data. NGS results are presented as mean values ± SEM of n = 4 mice per group.
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In short, in splenic DCs of Tnfaip3CD11c-KO mice, CD40L signals appear to restrain the 
expression of co-stimulatory molecules such as CD40, CD86, and PD-L1.
reduction of mZ B cells in Tnfaip3cD11c-Ko mice is restored by Cd40lg deletion.
In Tnfaip3CD11c-KO mice the numbers of CD4+ T cells and CD8+ T cells were not significantly 
affected (Figure 3A). However, the absence of CD40L signals is known to influence T cell 
and B cell homeostasis22. Both splenic CD8+ and CD4+ T cell numbers were reduced in 
10-week-old Cd40lgKO mice compared to WT mice (Figure 3A, see for gating strategy: 
Supplementary Figure 2A). Within the GC, follicular T-helper cells (Tfh-cells) are crucial 
for B cell activation and plasma cell formation, partly through CD40L-CD40 interaction23. 
The proportions of Tfh cells from total CD4+ T cells were reduced in spleens of Cd40lgKO 
mice compared to WT mice (Figure 3B, see for gating strategy: Supplementary Figure 
2A). The numbers of B cells were significantly decreased in Tnfaip3CD11c-KO mice as well 
as in Cd40lgKO mice compared to WT mice (Figure 3c, see for gating strategy: Supple-
mentary Figure 2B). The proportions of GC B cells were increased in Tnfaip3CD11c-KO mice 
compared to WT controls and Tnfaip3CD11c-HZ mice, but these were virtually absent in mice 
lacking Cd40lg (Figure 3c). Despite the lack of GC B cells in all three Tnfaip3 genotypes 
on the CD40lgKO background, substantial number of plasma cells were present (Figure 
3c, see for gating strategy: Supplementary Figure 2B).
Whereas the absence of the Tnfaip3 gene in DCs did not significantly affect the pro-
portions of follicular (FO) B cells in the spleen, marginal zone (MZ) B cell frequencies 
were dramatically reduced in Tnfaip3CD11c-KO mice compared to WT or Tnfaip3CD11c-HZ 
mice (Figure 3D/e). The percentages of FO B cells were slightly reduced in Cd40lgKO 
mice compared to WT controls and likewise in Tnfaip3CD11c-KOCd40lgKO mice compared to 
Tnfaip3CD11c-KO mice (Figure 3e). Intriguingly, the proportions of MZ B cells were increased 
in Tnfaip3CD11c-KOCd40lgKO mice compared to Tnfaip3CD11c-KO mice, to similar frequencies as 
observed in WT mice (Figure 3e).
Next, we used immunohistochemistry to examine the splenic architecture. In WT mice 
rings of MOMA1+ MZ macrophages were bordered by CD21+ FO B cells and MZ B cells 
on the inside and outside, respectively (Figure 3F). Similar staining patterns were ob-
served in spleens of Cd40lgKO mice. However, the architecture was completed distorted 
in Tnfaip3CD11c-KO mice, as previously described4 (Figure 3F), with only very few B cells 
and MZ macrophages. Strikingly, white pulp regions containing MZ macrophages, FO 
and MZ B cells were slightly reestablished in Tnfaip3CD11c-KOCd40lgKO mice, compared 
to Tnfaip3CD11c-KO mice, although these regions were still smaller than those in Cd40lgKO 
or WT mice (Figure 3F). In 24-week-old mice, the marked reduction in FO and MZ B 
cell was still apparent in Tnfaip3CD11c-KO mice, but less so in Tnfaip3CD11c-KOCd40lgKO mice 
(Supplementary Figure 2c).
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Taken together, in the absence of CD40L expression, mice harboring Tnfaip3-deficient 
DCs have strongly reduced Tfh-cell and GC B cell numbers. While young Tnfaip3CD11c-KO 
mice have very low MZ B cell proportions, these are considerably restored in the absence 
of CD40L, particularly in aging mice.
B cells from Tnfaip3cD11c-KoCd40lgKo mice have an activated phenotype and T 
cells show robust expression of B cell-activating cytokines.
We next examined the phenotype of FO and MZ B cells. Whereas deletion of Tnfaip3 
did not affect their phenotype, we found that both FO and MZ B cells from 10-week-
old Tnfaip3CD11c-KOCd40lgKO mice displayed enhanced surface expression of CD80, CD86 
and PD-L2 compared to Cd40lgKO mice (Figure 4A). While both FO B cells and MZ B cell 
expressed enhanced CD95 in Tnfaip3CD11c-KOCd40lgKO mice compared to Cd40lgKO mice, 
only MZ B cells displayed enhanced MHC-II expression, which however did not reach 
significance (Supplementary Figure 3A).
Since interleukin IL-21 and IL-4 direct GC B cell responses24, the expression of the IL-21 
receptor (IL-21R) and IL-4R was examined in purified splenic FO and MZ B cell fractions 
by RT-PCR (See for sorting strategy: Supplementary Figure 3B). Whereas no differences 



































































































Figure 2: Splenic Dcs from Tnfaip3cD11c-KoCd40lgKo mice show enhanced expression of activation 
markers.
Spleens of naïve 10-week-old Tnfaip3CD11cCd40lg mice were analyzed for DCs (CD11c+MHC-II+) (A-B) Quan-
tification of DC activation for CD40, CD86 and PD-L1 histograms (A) and bar-plot (B) using flow cytometry. 
Results are presented as mean values ± SEM of n = 2-5 mice per group. **P<0.01.
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observed in splenic MZ B cells from Tnfaip3CD11c-KOCd40lgKO mice compared to Cd40lgKO 
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Figure 3: reduction of mZ B cells in Tnfaip3cD11c-Ko mice is restored by Cd40lg deletion.
Naïve 10-week-old Tnfaip3CD11cCd40lg mice spleens were analyzed for T cells and B cells. (A-e) Quantifica-
tion of splenic CD8+ T cells (CD3+CD8+CD4-), CD4+ T cells (CD3+CD4+CD8-) (A), Follicular T-helper cells (Tfh-
cells; CD3+CD4+CXCR5+PD1hi) (B), B cells (B220+), Germinal center B cells (B220+CD138-CD95+IgD-), Plasma 
cells (B220-CD138+) (c) using flow cytometry. (D) Flow cytometric analysis of Follicular B cells (FO B cells; 
B220+CD23+, CD21/35int) and Marginal zone B cells (MZ B cells; B220+CD23-, CD21/35+) (e) Quantification of 
splenic FO B cell and MZ B cell proportions using flow cytometry. (F) Immunohistochemistry of spleens for 
MOMA1+ (Blue) macrophages and CD21+ (red) MZ B cells. Scale bars represent 200μm. Representative data 
is shown from one out of two independent experiments. Results are presented as mean values ± SEM of n = 
2-5 mice per group. *P<0.05, **P<0.01.
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We next investigated cytokine expression in splenic T cells. IL-21 mRNA expression in 
CD3+CD4+CD44+ effector CD4+ T-cells was apparently not affected by Tnfaip3 deletion 
(Figure 4B), but was decreased in Cd40lgKO mice and Tnfaip3CD11c-HZCd40lgKO mice com-
pared to their Cd40lgWT counterparts (Figure 4B). Interestingly, IL-21 mRNA expression 
in effector CD4+ T-cells appeared to be rescued in Tnfaip3CD11c-KOCd40lgKO mice compared 
to Cd40lgKO mice (Figure 4B). The splenic total CD4+ T cell population from Tnfaip3CD11c-KO 
mice contained elevated proportions of IL-4+ cells compared to Tnfaip3CD11c-HZ mice and 
WT mice, as determined by intracellular flow cytometry (Figure 4c). Likewise, the pro-
portions of IL-4+ CD4+ T cells from Tnfaip3CD11c-KOCd40lgKO mice were increased compared 
to Cd40lgKO mice (Figure 4c).
Other T cell-derived cytokines such as IFNγ, IL-6 and IL-17 can also promote B cell 
responses25, 26. The proportion of IFN-γ+ splenic CD4+ T cell did not differ within the three 
Tnfaip3 genotypes on the Cd40lgWT background, but were decreased in Cd40lgKO mice 
(Figure 4c). A minor significant increment of IFN-γ-expressing CD4+ T cells was seen in 
the spleen of Tnfaip3CD11c-KOCd40lgKO mice compared to Cd40lgKO mice (Figure 4c). The 
frequency of IL-6+ CD4+ T cells within Tnfaip3CD11c-KO mice was enhanced compared to 
Tnfaip3CD11c-HZ mice and WT mice (Figure 4c).
Interestingly, the most pronounced increase in IL-6+ CD4+ T cells was observed in 
Tnfaip3CD11c-KOCd40lgKO mice (Figure 4c). The proportions of IL-17+ CD4+ T cells were 
enhanced in Tnfaip3CD11c-KO mice and Tnfaip3CD11c-KOCd40lgKO mice (Figure 4c). The pro-
portions of IFN-γ+ CD8+ T cells did not significantly differ between the six genotypes 
(Figure 4D). A prominent increase in IL-6+ CD8+ T cells was seen in Tnfaip3CD11c-KOCd40lgKO 
mice compared to the other five groups of mice (Figure 4D).
In summary, in the absence of CD40L, FO B cells and MZ B cells from Tnfaip3CD11c-KO 
mice show increased expression of cell surface activation markers. Although the interac-
tion of T cells with B cells is hampered by the absence of CD40L, CD4+ and CD8+ T cells 
from Tnfaip3CD11c-KOCd40lgKO mice still produce B cell-activating cytokines, such as IL-21, 
IL-4, IFN-γ, IL-17 and IL-6.
Aged Tnfaip3cD11c-Ko mice do not develop Gc B cell clusters in the absence of 
cD40l.
As previously reported4, aged ~24-week-old Tnfaip3CD11c-HZ mice and Tnfaip3CD11c-KO 
mice harbor enlarged spleens in comparison to WT mice, largely due to extramedul-
lary hematopoiesis (Figure 5A). Likewise, spleens of Tnfaip3CD11c-HZCd40lgKO mice and 
Tnfaip3CD11c-KOCd40lgKO mice were enlarged compared to Cd40lgKO mice (Figure 5A). Simi-
lar to young mice, spleens of aged Tnfaip3CD11c-KO mice and Tnfaip3CD11c-KOCd40lgKO mice 
lacked normal lymphoid structures compared to Tnfaip3CD11c-HZ and Tnfaip3CD11c-WT mice 
on a WT or Cd40lgKO background (Figure 5B). The total numbers of CD4+ T cells were 
similar in spleens in all six genotypes of aged mice (Figure 5c). Within the splenic CD4+ T 
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cells, the proportions of Tfh-cells were increased in Tnfaip3CD11c-HZ mice compared to WT 
mice and Tnfaip3CD11c-KO mice, but were severely reduced in the three Tnfaip3 genotypes 
on the Cd40lgKO background (Figure 5D). Splenic B cell numbers were reduced in aged 
Tnfaip3CD11c-KO mice compared to WT or Tnfaip3CD11c-HZ mice, but did not differ between the 
three Tnfaip3 genotypes on the Cd40lgKO background (Figure 5e). Whereas the frequen-







































































































































































































































Figure 4: B cells from Tnfaip3cD11c-KoCd40lgKo mice have an activated phenotype and T cells show ro-
bust expression of B cell-activating cytokines.
Naïve 10-week-old Tnfaip3CD11cCd40lg mice spleens were analyzed for FO B cells (CD19+CD23+CD21/35int) 
and MZ B cells (CD19+CD23-CD21/35+). Since MZ B cells were virtually absent in Tnfaip3CD11c-KO mice, only 
FO B cells and MZ B cells from Tnfaip3CD11c-WT mice were compared with all three Cd40lgKO genotypes. (A) 
Histograms and bar-chart quantification of B cell activation markers CD80, CD86 and PD-L2. (B) Quantifica-
tion of cytokines IL-21 expression in sorted effector T cells (CD3+CD4+CD44+) using RT-PCR. (c) Enumeration 
of the proportions of intracellular IL-4+, IFN-γ+, IL-6+ and IL-17+ splenic CD4+ T cells using flow cytometry. 
(D) Quantification of the proportions intracellular IFN-γ+ and IL-6+ CD8+ T cells using flow cytometry. Data 
is shown from one experiment in (A-B) and pooled data from two experiments (c-D). Results are presented 
as mean values ± SEM of n = 2-7 mice per group. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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cells were virtually absent in aged Cd40lgKO and Tnfaip3CD11c-HZCd40lgKO mice (Figure 5F). 
Although B cells with a GC surface phenotype were detected in Tnfaip3CD11c-KOCd40lgKO 
mice (Figure 5F), GL7+ B cells were only present as isolated B cells and no GC B cell 
clusters could be observed (Figure 5G). The numbers of splenic plasma cells were el-
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Figure 5: Aged Tnfaip3cD11c-Ko mice do not develop Gc B cell clusters in the absence of cD40l.
Naïve 24-week-old Tnfaip3CD11cCd40lg mice spleens were analyzed. (A) Enumeration of splenic weight and 
cellularity. (B) Confocal histology of spleens for CD3+ (green); CD11c+ (red) and B220+ (white) cells. (c-F) 
Quantification of splenic CD4+ T cell numbers (CD3+CD4+) (c), proportions of splenic Follicular Th-cells 
(Tfh-cells; CD3+CD4+CXCR5+PD1hi) (D), B cell (B220+) numbers (e), and the proportions of splenic GC B cells 
(B220+CD138-CD95+IgD-) (F) using flow cytometry. (G) Immunohistochemistry of spleens for IgD+ (Pink) 
and GL7+ (Blue). (H-I) Quantification of splenic plasma cells (B220-CD138+) (H) and splenic memory IgG1+ 
memory B cells (B220+CD138-IgG1+(surface)) using flow cytometry. Results are pooled from 5-7 independent 
experiments and are presented as mean values ± SEM of n = 11-16 mice per group. Scale bars represent 
200μm. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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young mice, splenic plasma cell counts did not differ significantly between three Tnfaip3 
genotypes on the Cd40lgKO background (Figure 5H). IgG1+ memory B cells were sig-
nificantly increased in Tnfaip3CD11c-KO compared to Tnfaip3CD11c-HZ mice and Tnfaip3CD11c-WT 
mice (Figure 5I). However, only a minor increase was observed in Tnfaip3CD11c-KOCd40lgKO 
mice (Figure 5I).
Taken together, similar to young mice, aged Tnfaip3CD11c-KO mice develop splenomegaly 
irrespective of the presence of CD40L, with a disturbed splenic architecture. In aged 
Tnfaip3CD11c-KOCd40lgKO mice, GC B cell clusters were absent.
Aged Tnfaip3cD11c-KoCd40lgKo mice have Igm and IgA but not IgG1 auto-
antibodies.
Next, we used flow cytometry to asses IgM+, IgG1+ and IgA+ plasma cells in the spleens 
of the six groups of mice. On the Cd40lgWT background the proportions of plasma cells 
that were IgM+ were reduced in Tnfaip3CD11c-KO mice, which showed an increase in isotype 
switched plasma cells, in particular IgG1+ (Figure 6A). In contrast, the splenic plasma 
cells in all three Tnfaip3 genotypes on the Cd40lgKO background were mainly IgM+. The 
remaining (~10%) immunoglobulin positive plasma cells, likely IgG2b, IgG2c or IgG3-
positive plasma cells that can occur independently of T-cell interaction9, did not differ 
between the genotypes.
Autoreactive anti-dsDNA IgG1 and IgA, but not IgM, were increased in the serum of 
Tnfaip3CD11c-KO mice compared to WT and Tnfaip3CD11c-HZ controls (Figure 6B), as previously 
shown4. Anti-dsDNA IgM was increased in Tnfaip3CD11c-KOCd40lgKO mice, compared with 
Cd40lgKO and Tnfaip3CD11c-HZCd40lgKO mice (Figure 6B). The absence of CD40L abrogated 
anti-dsDNA IgG1 and reduced the levels of anti-dsDNA IgA in the serum of the three 
Tnfaip3 genotypes. Interestingly however, anti-dsDNA IgA in Tnfaip3CD11c-KOCd40lgKO mice 
was enhanced compared to Cd40lgKO mice (Figure 6B). Total IgM levels in serum were 
increased in Tnfaip3CD11c-HZ mice (Figure 6c). On Cd40lgKO background serum IgM was 
elevated in both Tnfaip3CD11c-HZCd40lgKO and Tnfaip3CD11c-KOCd40lgKO mice (Figure 6c). 
Serum total IgG1 and IgA was elevated in Tnfaip3CD11c-KO mice compared to WT mice and 
Tnfaip3CD11c-HZ mice, but was significantly lower in Tnfaip3CD11c-KOCd40lgKO mice (Figure 
6c).
Bone marrow (BM) of 24-week-old mice displayed non-significant increases 
in IgG1+ and IgA+ memory B-cells in Tnfaip3CD11c-KO mice, which were reduced in 
Tnfaip3CD11c-KOCd40lgKO mice (Supplementary Figure 4A). In contrast to spleen, BM 
plasma cells were reduced in Tnfaip3CD11c-KOCd40lgKO mice compared to Tnfaip3CD11c-KO 
mice (Supplementary Figure 4B). The proportions of IgM+ plasma cells in BM was low-
est in Tnfaip3CD11c-KO mice and Tnfaip3CD11c-KOCd40lgKO mice compared to the other four 
genotypes (Supplementary Figure 4c). The high proportions of bone marrow IgG1+ 





















































































































































Figure 6: Aged Tnfaip3cD11c-KoCd40lgKo mice have Igm and IgA but not IgG1 auto-antibodies.
Naïve 24-week-old Tnfaip3CD11cCd40lg mice serum were analyzed. (A) Quantification of IgM+ plasma cells 
(B220-CD138+IgM+), IgG1+ plasma cells (B220-CD138+IgG1+) and IgA+ plasma cells (B220-CD138+IgA+) using 
flow cytometry. (B) Quantification of serum autoreactive IgM, IgG1 and IgA immunoglobulins against ds-
DNA using ELISA. (c) Quantification of total serum IgM, IgG1 and total IgA using ELISA. Results are pooled 
from 2-5 independent experiments and are presented as mean values ± SEM of n = 11-16 mice per group. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Scale bars represent 200μm.










































Figure 7: Basement mem-
brane thickening and IgA 
deposition in kidneys of 
Tnfaip3cD11c-KoCd40lgKo mice.
Naïve 24-week-old Tn-
faip3CD11cCd40lg mice kidneys 
were analyzed. (A) Kidney 
paraffin slides were stained us-
ing Periodic Acid Schiff (PAS)+ 
staining (or PAS-diastase stain-
ing). (B) Kidney paraffin slides 
were stained for IgG-positivity 
using immunohistochemistry. 
(c) Kidney paraffin slides were 
stained for IgA-positivity using 
immunohistochemistry. Re-
sults are from 4 independent 
experiments. Scale bars repre-
sent 200μm.
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drastic reductions of these plasma cells on an CD40lgKO background (Supplementary 
Figure 4D/e). A relatively large population of non-IgM/IgG1/IgA plasma cells was seen 
in Tnfaip3CD11c-KOCd40lgKO mice (Figure 4F), likely expressing IgG2b, IgG2c or IgG3, given 
their CD40L-independence9.
In short, the absence of CD40L hampered the formation of IgG1+ plasma cells, leading 
to a lack of total IgG1 and autoreactive IgG1 in the serum of Tnfaip3CD11c-KOCd40lgKO mice. 
Interestingly, in these mice anti-dsDNA IgM was higher than in the Tnfaip3CD11c-KOCd40lgWT 
counterparts and anti-dsDNA IgA remained detectable.
Basement membrane thickening and IgA deposition in kidneys of Tnfaip3cD11c-
KoCd40lgKo mice.
Aged Tnfaip3CD11c-KO mice developed inflammatory infiltrates in livers and pancreas islets of 
Langerhans, which were still present in Tnfaip3CD11c-KOCd40lgKO mice but absent in control 
mice (Supplementary Figure 5A/B). As previously demonstrated4, aged Tnfaip3CD11c-KO 
mice developed membranoproliferative glomerulonephritis with increased glomerular 
cellularity and thickening of the basement membranes, compared with Tnfaip3CD11c-HZ 
mice and WT mice (Figure 7A). Interestingly, basement membrane thickening was also 
observed in kidneys of Tnfaip3CD11c-KOCd40lgKO mice, but not in Cd40lgKO controls (Figure 
7A).
Basement membrane thickening in kidneys in lupus glomerulonephritis patients 
develops due to immunoglobulin complex deposition27. Indeed, confirming previ-
ous results4, kidneys of Tnfaip3CD11c-KO mice showed IgG deposition in the glomeruli 
(Figure 7B). However, IgG staining was completely absent in kidneys from all three 
Tnfaip3CD11c genotypes on a Cd40lgKO background (Figure 7B). Interestingly however, 
positive glomerular IgA staining could be observed in 2 out of 5 Tnfaip3CD11c-KO mice and 
Tnfaip3CD11c-KOCd40lgKO mice, but was completely absent in the other genotypes (Figure 
7c).
In summary, basement membrane thickening in Tnfaip3CD11c-KO mice occurs in the ab-
sence of CD40L-derived signals and is independent of glomerular IgG deposition. Since 
IgA deposits were observed in the kidney glomeruli of Tnfaip3CD11c-KOCd40lgKO mice, these 
may well be involved in the induction of basement membrane thickening in the kidneys.
DIScUSSIoN
DCs critically control immune homeostasis1. Mice harboring activated DCs, through 
ablation of Tnfaip3/A20 develop autoimmunity, with increased T cell and B cell activa-
tion3, 4. In vitro B cells could be activated by Tnfaip3-deficient BM-DCs without T cell 
help4. In this study, we abrogated T-B cell communication through ablation of CD40L 
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to examine whether B cell activation could be provoked by Tnfaip3-deficient DCs in vivo 
without T cell help8. While IgG1 was drastically reduced in Tnfaip3CD11c-KO mice lacking 
CD40L-signaling, they still developed kidney pathology and (autoreactive) IgA and IgM. 
T-B cell communication appears therefore not necessary for autoimmune organ inflam-
mation in Tnfaip3CD11c-KO mice.
Using an unbiased approach, we first confirmed by GSEA17 that full or heterozygote 
loss of Tnfaip3 in BM-DCs caused activation, shown by the enrichment for several 
cytokine-signaling pathways, most prominently “TNF-α signaling via NF-κB”. The in vitro 
B cell response driven by Tnfaip3-deficient BM-DCs was facilitated by high IL-6 produc-
tion4. Tnfaip3-deficient BM-DCs harbored an increased expression of prominent T cell 
differentiating cytokines, such as IL-12 and IL-2328 as well as several TI cytokines, such 
as IL-629 and IL-1β30. It is puzzling that in our analyses the TI hallmark genes BAFF and 
APRIL11 were not significantly upregulated in Tnfaip3CD11c-KO BM-DCs, in contrast to pre-
vious publication4. In any case, these proteins were not involved in the in vitro B cell 
immunoglobulin production induced by Tnfaip3-deficient BM-DCs4.
As expected, Tnfaip3-deficient DCs in spleens of mice harbored an activated phe-
notype, shown by elevated CD40, CD86 and PD-L1 expression, which appeared to be 
further elevated when CD40L was absent. Most likely this is not a direct consequence 
of CD40L-CD40 interaction on DCs, as CD40 signaling in DCs is known to promote the 
expression of CD80/CD8631. It is conceivable that other signals, such as proinflammatory 
cytokines, promote the increased activation status of DCs.
GC formation critically depends on CD40L-CD40 interaction32, which we confirmed 
in both young and aged Cd40lgKO mice, as the number of both GC B cells and Tfh-cells 
were strongly decreased. Despite the absence of clusters of GC B cells and Tfh-cells in 
Tnfaip3CD11c-KOCd40lgKO mice, some B cells could still acquire a GL7+ GC B-cell phenotype. 
During TI immunizations, also in T cell-deficient mice, short-lived GC B cell responses 
can be induced33, 34. As we could not detect clusters of GC B cells in the spleens of 
Tnfaip3CD11c-KOCd40lgKO mice, the GL7+ B cell phenotype might be induced by sporadic in-
teraction of B cells and Tnfaip3-deficient DCs, promoting their TI activation. In particular 
MZ B cells are specialized in TI responses35. Strikingly, MZ B cells were almost absent in 
Tnfaip3CD11c-KO mice, but their proportions increased in Tnfaip3CD11c-KOCd40lgKO mice. These 
MZ B cells displayed an activated phenotype, and in contrast to FO B cells, receptors 
for IL-21 and IL-4 were detected36, 37. Elevated expression of IL-4 and IL-21 was seen in 
CD4+ T cells of Tnfaip3CD11c-KOCd40lgKO mice. Therefore, these cytokine signals can still be 
provided by T cells, thereby supporting activation of B cells, in particular of MZ B cells 
that express receptors for these cytokines.
Unexpectedly, in the absence of appropriate T-B cell communication, Tnfaip3CD11c-KO 
mice developed glomerulonephritis with glomerular basement membrane thickening. 
Anti-dsDNA IgG is well-known to cause kidney pathology by depositing in glomeruli 
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and forming immune complexes38. Indeed, IgG was present in kidneys of Tnfaip3CD11c-KO 
mice, but completely absent in the three Tnfaip3 genotypes lacking CD40L. Instead, 
IgA was detected in the glomeruli of a fraction of Tnfaip3CD11c-KOCd40lgKO mice, possibly 
contributing to glomerular membrane thickening, as indeed two out of five mice with 
IgA deposition had simultaneous glomerular membrane thickening present. Further 
research is required to identify the mechanisms involved in the kidney pathology in 
Tnfaip3CD11c-KOCd40lgKO mice, particularly in mice that lack IgA complex deposition in 
the glomeruli. In this context, some SLE patients with glomerulonephritis have high 
anti-dsDNA IgA titers present39, which may support the involvement of IgA in kidney 
pathology. IgA class switch can be induced by IL-640 and TGF-β41. As IL-6 expression 
was increased, but TGF-β mRNA expression was low in Tnfaip3-deficient BM-DCs 
(Figure 1 and previously demonstrated4, 14 it is conceivable that DC-derived IL-6 may 
play a prominent role in the induction of heavy chain class switch to IgA in our model. 
In support of this, in B cell cultures that were stimulated by Tnfaip3-deficient BM-DCs 
neutralization of IL-6 reduced IgA production by ~50%, indicating an important role for 
IL-6 in mediating increased Ig production when A20 is lacking in DCs. Nevertheless, IL-6 
can be produced by a variety of cells, including splenic CD4+ T cells, CD8+ T cells and B 
cells in Tnfaip3CD11c-KO and Tnfaip3CD11c-KOCd40lgKO mice. Therefore, the role of IL-6 in the 
pathology observed in Tnfaip3CD11c-KOCd40lgKO mice is an interesting topic of research 
in the future. IL-6 is already well recognized as a promising therapeutic target to treat 
autoimmune diseases42, 43. In addition, the increased production of IFN-γ and IL-17 by 
CD4+ T cells present in Tnfaip3CD11c-KOCd40lgKO mice, compared with Cd40lgKO mice, may 
contribute to the autoimmune pathology. Apart from IgA, anti-dsDNA IgM was enhanced 
in Tnfaip3CD11c-KOCd40lgKO mice. We also found total IgM depositions in the glomeruli of 
these mice, and not in Tnfaip3CD11c-KO mice (data not shown). It is unlikely that these are 
pathologic immunoglobulin depositions, since autoreactive IgM anti-dsDNA is shown 
to delay glomerulonephritis in lupus mice44.
In conclusion, T-B cell communication via CD40-CD40L interaction is not critical for 
B cell activation, Ig heavy chain class-switch, and autoimmune pathology including 
glomerulonephritis - possibly mediated by autoreactive IgA - in Tnfaip3CD11c-KO mice. In 
the context of therapies targeting CD40 or CD40L in human autoimmune diseases45, it is 
of relevance that glomerular nephritis can develop independently of IgG deposition and 
CD40L in mice. However, whether this mechanism also occurs in humans and whether 
this would involve IgA auto-antibodies remains unknown.
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TNF-α signaling via NF-κB
















GSEA: Tnfaip3WT compared to Tnfaip3HZ BM-DC
A
B
Supplementary Figure  1 
-8 -6 -4 -2 0 2 4 6
  E2F TARGETS
  G2M CHECKPOINT
  MYC TARGETS v1
  MYC TARGETS v2
  MITOTIC SPINDLE
  SPERMATOGENESIS







 EPITHELIAL MESENCHYMAL TRANSITION



































































































 MYC TARGETS v2
 DNA REPAIR
 UNFOLDED PROTEIN RESPONSE
 FATTY ACID METABOLISM
MITOTIC SPINDLE
 IL6 JAK STAT3 SIGNALING
 APICAL JUNCTION
 KRAS SIGNALING DN
































GSEA: Tnfaip3KO compared to Tnfaip3HZ BM-DC
-10 -8 -6 -4 -2 0 2 4 6
GSEA enrichment (signed -log10 FDR q-value)
GSEA enrichment (signed -log10 FDR q-value)
Supplementary Figure 1: Bm-Dcs and Dendritic cells are activated with loss of Tnfaip3/A20.
BM-derived dendritic cells (BM-DCs) were analyzed by RNA Next generation sequencing (NGS). (A-B) Gene 
set enrichment analysis (GSEA) performed for the ranked list of significantly altered genes between BM-
DCs from Tnfaip3CD11c-KO mice and Tnfaip3CD11c-HZ mice (A) and Tnfaip3CD11c-WT mice and Tnfaip3CD11c-HZ mice 
(B). Only the top results with a False Discovery Rate (FDR)<0.25 are shown. Enrichments plots for the Hall-
mark gene set TNFα signaling via NF-κB is also displayed. (c-F) Naïve 10-week-old Tnfaip3CD11cCd40lg mice 
spleens were analyzed for (c-D) Enumeration of splenic weight (c) and cellularity (D) using flow cytometry. 
(e-F) Gating strategy for splenic DCs (CD11c+MHC-II+) (e) and DC numbers (F) using flow cytometry. NGS 
data is from n=4 BM-DC cultures per genotype. Data in (c-F) shown from 2 independent experiments and 

















































































































Supplementary Figure 2: old Tnfaip3cD11c-Ko mice have restored mZ B-cells proportions and histology.
Gating strategy in naïve Tnfaip3CD11cCd40lg spleens to determine T-cells (A) and B-cells (B) mentioned in 
Figure 3 and Figure 5. (c) Naïve 24-week-old Tnfaip3CD11cCd40lg spleens were analyzed by immunohisto-
chemistry. (c) Immunohistochemistry of spleens for MOMA1+ (Blue) macrophages and CD21+ (red) MZ B-
cells. Scale bars represent 200μm.





























































































































































































Supplementary Figure 3: Follicular B-cells in Tnfaip3cD11c-Kocd40lgKo mice are also activated, but 
do not express Gc receptors.
Naïve 10-week-old Tnfaip3CD11cCd40lg mice spleens were analyzed for FO B-cells (CD19+CD23+, CD21/35int) 
and MZ B-cells (CD19+CD23-CD21/35+). (A) Histograms and barchart quantification of FO B-cell and MZ 
B-cell MHC-II and CD95 using flow cytometry. (B) Flow cytometry sorting gating strategy for both splenic 
FO B-cells and splenic MZ B-cells. (c) Sorted FO B-cells and MZ B-cells from spleens were analyzed using 
RT-PCR to quantify mRNA levels of Il21r and Il4r. Data is shown from one experiment. Results are presented 























































































































Supplementary Figure 4 
Supplementary Figure 4: Bone marrows of Tnfaip3cD11c-Ko mice have enhanced IgG1 B-cells, but not 
without cD40l signaling.
Analysis of Naïve 24-week-old Tnfaip3CD11cCd40lg mice serum and bone marrows. (A-F) Enumeration of 
proportions of IgG1+ Memory B-cells (B220+CD138-IgG1+) and IgA+ memory B-cells (B220+CD138-IgA+) 
(A), plasma cell (numbers B220+CD138+) (B) IgM+ plasma cells (B220-CD138+IgM+) (c), IgG1+ plasma cells 
(B220-CD138+IgG1+) (D), IgA+ plasma cells (B220-CD138+IgA+) (e) and other immunoglobulin-positive plas-
ma cells (B220-CD138+IgM-IgG1-IgA-) (F) using flow cytometry. Data is shown of n = 3 independent experi-
ments (in B) and 1 experiments (in A,C-F) and results are presented as mean values ± SEM of n = 2-9 mice 
per group. *P<0.05, **<P0.01.




























Liver Pancreas Supplementary Fig 5
Supplementary Figure 5: multiorgan inflammation in Tnfaip3cD11c-Ko mice occurs independently of 
T-cell help.
Naïve 24-week-old Tnfaip3CD11cCd40lg mice tissues were stained using Hematoxylin and Eosin. Representa-
tive Liver (A) and Pancreas (B) tissues are shown. Liver inflammatory infiltrates (black arrows), islets of Lang-
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ABSTrAcT
Background: Dendritic cells (DCs) are sentinel cells within the immune system that 
direct tolerogenic and immune conditions. Mice that lack Tnfaip3/A20, a negative 
regulator of NF-κB signaling, specifically in DCs (Tnfaip3CD11c-KO mice) have a lupus-like 
autoimmune phenotype characterized by autoantibodies and glomerulonephritis. 
Tnfaip3/A20-deficient DCs display spontaneous activation and thereby induce T and B 
cell activation. In vitro co-cultures of stimulated bone marrow-derived Tnfaip3CD11c-KO DCs 
with T cells display increased IL-17 production.
objective: We investigated the role of IL-23, a key cytokine for T helper 17 (Th17) cell 
maintenance and expansion, in the pathology of the lupus-like autoimmune phenotype 
of Tnfaip3 CD11c-KO mice.
methods: Tnfaip3CD11c-KO mice were crossed to Il23KO mice and in vivo Th subsets, B 
cell activation, levels of (auto-)antibodies and kidney inflammation were assessed in 
24-week-old mice.
results: Spleens of Tnfaip3CD11c-KO mice were enlarged, but additional loss of IL-23 result-
ed in a substantial reduction of spleen size, granulocytes and monocytes/macrophage 
counts. Although DCs from Il23KOTnfaip3CD11c-KO had a more activated phenotype than 
DCs from Il23WTTnfaip3CD11c-KO mice, their numbers in the spleen remained very low. In vivo 
Th17 cell differentiation was not enhanced in Tnfaip3CD11c-KO mice, compared to wild-type 
controls littermates. Loss of IL-23 did not significantly affect the numbers of Th17 cells in 
the spleen. Although splenic plasma cells were essentially not altered in Tnfaip3CD11c-KO 
mice, they were reduced by additional IL-23-deficiency. Total IgG1 or autoreactive IgG1 
was increased in the serum of both Il23KO and Il23WT Tnfaip3CD11c-KO mice. Only IgA was 
greatly reduced in Il23KOTnfaip3CD11c-KO mice compared to Il23WTTnfaip3CD11c-KO mice. 
Finally, IL-23-deficiency did not affect glomerulonephritis in Tnfaip3CD11-KO mice.
conclusion: These findings indicate that the lupus-like autoimmune pathology in 
Tnfaip3CD11c-KO mice is independent of the IL-23/IL-17 axis.
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INTroDUcTIoN
Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disorder 
in which multiple innate and adaptive immune cells, such as dendritic cells (DCs), T cells 
and B cells play an important role1. B lymphocytes are the primary effector cells in SLE 
pathogenesis2. As they become plasma cells, they produce autoreactive antibodies and 
thereby facilitate immune complexes that trigger kidney inflammation3. In addition, an 
imbalanced T-helper (Th) cell differentiation has been implicated in lupus pathology, 
because an increase of Th17 cells or their primary cytokine IL-17 was observed in pa-
tients compared to healthy controls and correlated with more disease activity4, 5. Further 
downstream, Th17 cells are known to facilitate differentiation of B cells into plasma 
cells and antibody production by secretion of cytokines6, 7. It has been demonstrated in 
mice that IL-17 is indispensable for the production of several autoantibodies and for the 
development of lupus nephritis8.
Differentiation and stabilization of Th17 cells is dependent on IL-239, which is pri-
marily produced by activated antigen presenting cells including DCs or monocytes/
macrophages10. IL-23R signaling is responsible for increasing RORγt expression and 
IL-17 via STAT311. Next to its function in survival and expansion of Th17 cells12, IL-23 is 
also involved in unlocking the full pathogenic potential of Th17 cells13. The observation 
that the addition of ustekinumab, a monoclonal antibody that inhibits IL-23 and IL-12, 
to standard-of-care treatment resulted in a better efficacy in clinical and laboratory 
parameters than placebo, supports further development of ustekinumab as a novel 
therapeutic strategy in SLE14, 15.
Ablation of the Tnfaip3 gene encoding A20, a negative regulator of the NF-κB signal-
ing pathway, specifically in DCs in vivo (in Tnfaip3CD11c-KO mice), resulted in T cell and B cell 
activation, antibody class switching, systemic inflammation, and glomerulonephritis, 
generating a phenotype resembling SLE16. Stimulated DCs lacking A20/Tnfaip3 pro-
duced high levels of IL-23 and promoted IL-17 production in in vitro co-cultures with 
T cells16. Moreover, we recently demonstrated that A20/Tnfaip3-deficient DCs induced 
Th17 cell differentiation via production of the pro-inflammatory cytokines IL-1β, IL-6 and 
IL-23 in vivo in a model of allergic airway inflammation17.
In this report, we investigated whether ablation of IL-23 would alter Th17 cell induction 
in Tnfaip3CD11c-KO mice in vivo. Th17 cells promote B cell proliferation and trigger antibody 
production and immunoglobulin (Ig) heavy chain class switch recombination in vivo7. 
Therefore, we wondered whether IL-23 abrogation would affect plasma cell differentia-
tion and Ig production and consequently renal pathology. We found that absence of 
IL-23 in Tnfaip3CD11c-KO mice reduced the splenic myeloid cell populations, while increas-
ing DC activation markers. Surprisingly, Th17 cells were not increased in 24-week-old 
Tnfaip3CD11c-KO mice, compared to Tnfaip3CD11c-WT mice. Moreover, the absence of IL-23 in 
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Tnfaip3CD11c-KO mice did not alter the numbers of Th17 cells or plasma cells in the spleen. 




Cd11c-cre+ transgenic Tnfaip3fl/fl mice16 were crossed with Il23p19-/- on a C57BL/6 
background18 to obtain Il23WT and Il23KO Tnfaip3CD11c-KO mice. Male and female mice were 
analyzed at 24-weeks of age and cre-deficient littermates were used as wild-type (WT) 
controls. Mice were bred and housed under specific pathogen-free conditions in the 
Erasmus MC experimental animal facility. All experiments were approved by the animal 
ethical committee of the Erasmus MC (EMC3329).
Tissue preparation
Spleens and bone marrow (BM) were taken from sacrificed mice to obtain single cell 
suspensions. One femur per mouse was crushed using a pestle and mortar and spleens 
were homogenized through a 100 μm cell strainer (Corning Inc., Corning, NY, USA) and 
collected in GibcoTM RPMI Medium 1640 (1 x) + GlutaMAXTM-1 (Thermo Fisher Scientific 
Inc., Waltham, MA, USA). Red blood cells were lysed using osmotic lysis buffer (0.15 M 
NH4CL, 10  mM KHCO3, 0.1  mM EDTA, pH  7.1  -  7.4; sterile-filtered with 0.22  µm filter). 
Viable cells were counted using Tryptan blue and a Buerker-Tuerk counting chamber 
(Paul Marienfeld GmbH & Co. KG, Lauda Königshofen, Germany). Freshly isolated kidneys 
were incubated on Roti-Histofix 4% (Carl-Roth, Karlsruhe, Germany) for 24 hrs and then 
embedded in paraffin wax.
Periodic Acid Schiff Diastase (PAS-D) staining
Three μm-thick paraffin-embedded kidney sections were stained according to the PAS-
D Staining protocol. Briefly, paraffin-embedded sections were dewaxed and hydrated 
to water using Xylene (Sigma-Aldrich) and ethanol dilutions in MilliQ. One part human 
saliva (containing the enzyme diastase) was diluted 1:10 with MilliQ and incubated on 
slides at room temperature for 30 min. Slides were placed in freshly prepared periodic 
acid solution for 5 min (Sigma-Aldrich) and subsequently in Schiff’s reagent for 5 min 
and counterstained with Gill’s hematoxylin (Merck Millipore) for 2 seconds. Finally, slides 
were dehydrated using Xylene and mounted in Entallan (Merck Millipore).
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Immunohistochemistry of cryosections
For immunohistochemistry, 6  µm acetone or 4  %  formalin-fixed spleen sections were 
blocked in peroxidase blocking buffer (PBS, 0.67 % H2O2, 2 % NaN3) at room temperature 
for 30 min. Blocking Buffer (1% Blocking Reagent (Roche Diagnostics GmbH, Mannheim, 
Germany) in PBS) containing 10% normal goat or donkey serum was used to prevent 
aspecific secondary antibody binding. Sections were stained with primary antibodies at 
room temperature for 1 hr, washed with PBS and incubated with alkaline phosphatase 
(AP) or peroxidase (PO) conjugated secondary antibodies at room temperature for 
30 min. Used antibodies were: anti-GL7 (clone RUO, 1:50, eBioscience) and anti-IgD-PE 
(clone 11-26, 1:50, eBioscience) with alkaline phosphatase (AP)-conjugated goat anti-rat 
(1:50, Jackson Immunoresearch) and peroxidase-labeled goat anti-PE, 1:50, Rockland 
Immunochemichals) as secondary antibody, respectively. AP was detected first dur-
ing 30 min using a mixture containing N-(4-Amino-2,5-diethoxyphenyl)benzamide 
(Fast  Blue  BB, Sigma-Aldrich), 2  M  HCl, 4  % NaNO2, Naphthol AS-MX phosphate (VWR 
International, Radnor, PA, USA), N,N-dimethylformamide (DMF) (Sigma-Aldrich), Tris-HCl 
buffer (pH  8.5) and (-)-tetramisole  hydrochloride (Sigma-Aldrich). The substrate was 
filtered using filtration paper. Secondly, peroxidase was detected within 30 min with a 
mixture containing 3-amino-9-ethylcarbazole (AEC) in DMF, 0.1 M NaAC (pH 4.6), 30% 
H2O2 (Merck Millipore, Darmstadt and double-filtered. Kaiser’s Glycerol/Gelatin (Boom 
B.V., Meppel, The Netherlands) was used to embed tissue sections and micrographs were 
made using a Leica DM2000 microscope (Leica Microsystems GmbH, Wetzlar, Germany), 
a Leica DFC450 camera (Leica Microsystems GmbH, Wetzlar, Germany) and Leica Ap-
plication (LAS) Software Version 4.5.0 (Leica Microsystems GmbH, Wetzlar, Germany).
confocal microscopy
For confocal imaging, 12 μm-thick spleen cryostat sections were stained as explained 
above. Primary and secondary antibodies were (Target, clone, dilution, manufacturer, 
with respective secondary antibody target, dilution, manufacturer): B220 (RA3-6B2, 
1:50, BD Biosciences, Donkey anti-Rat Cy5, 1:200, Jackson Immunoresearch), CD11c 
(N418, 1:10, eBioscience, Goat anti-Hamster Cy3, 1:1000, Jackson Immunoresearch), 
CD3e (KT3, 1:50, Bioceros, Donkey anti-Rat Cy3, 1:1000, Jackson Immunoresearch). 
Slides were counterstained with 4’,6-diamidino-2-phenylindole (DAPI), mounted with 
VECTASHIELD® HardSetTM Antifade Mounting Medium (Vector Laboratries, Burlingame, 
CA, USA) and analyzed on a Zeiss LSM  510  META confocal microscope (Carl Zeiss AG, 
Oberkochen, Germany). Images were analyzed using ImageJ software (Rasband, W.S., 
ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA).
chapter 7  | Autoimmunity in mice lacking A20 in DCs is IL-23 independent
170
Flow cytometry
Flow cytometry surface and intracellular staining procedures have been described 
previously19. Monoclonal antibodies used for flow cytometric analyses are listed in 
Supplementary Table S1A.
Immunoglobulin levels
For quantification of total immunoglobulin levels, Nunc Microwell plates (Life tech-
nologies, Carlsbad, CA, USA) were coated with 1 μg/ml goat-anti-mouse IgM, IgA, IgG1, 
IgG2b, IgG2c, or IgG3 (Southern Biotech, Birmingham, AL, USA) overnight at 4Co. Wells 
were blocked with 10% FCS (Capricorn Scientific, Ebsdorfergrund, Germany) in PBS 
(Thermo Scientific, Waltham, MA, USA) for 1 hr. Standards and serum were diluted in 
PBS and incubated at room temperature for 3 hrs. Depending on the isotype of interest, 
biotin labeled anti-mouse IgM, IgA, IgG1, IgG2b, IgG2c, or IgG3 (Southern Biotech) was 
incubated for 1 hr. Streptavidin-horseradish peroxidase (eBioscience) and 3,3’,5,5’-tet-
ramethylbenzidine substrate (eBioscience) was used to develop the ELISA and then 
optical density was measured at 450 nm on a Microplate Reader (Bio-Rad, Hercules, CA, 
USA). Ig autoreactivity assessment was assessed as previously described20.
Statistics
If the Kruskal-Wallis 1-way ANOVA test was significant, we further used the non-para-
metric Mann Whitney U test to determine significant differences between two groups. 
P-values <0.05 were considered significant. All analyses were performed using Prism 
(GraphPad Software version 9, La Jolla, CA, USA). All data are presented as mean values 
with the standard error of the mean (SEM).
reSUlTS
lack of Il-23 strongly reduces the numbers of neutrophils, monocytes/
macrophage and Dcs in Tnfaip3CD11c-KO mice.
To assess the effect of IL-23 abrogation on the phenotype of Tnfaip3CD11c-KO mice, 
we analyzed spleens of Tnfaip3CD11c-WT, Tnfaip3CD11c-HZ and Tnfaip3CD11c-KO mice that 
were either WT or KO for the IL-23 gene, at the age of 24 weeks. Spleens of the aged 
Tnfaip3CD11c-KO mice were enlarged, compared to Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice 
(Figure 1A), as previously described16. Also, spleens of Il23KOTnfaip3CD11c-KO mice were 
enlarged in comparison to Il23KO control mice, but they were significantly smaller than 
spleens of Il23WTTnfaip3CD11c-KO mice (Figure 1A). Despite the large size of the spleens in 
Il23KOTnfaip3CD11c-KOmice, their cellularity was drastically reduced compared to Il23KOTn-
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Figure 1: Il-23-deficiency strongly reduces myeloid cell populations in Tnfaip3CD11c-KO mice, but has 
moderate effects on lymphoid cells.
Spleens from 24-week-old naïve mice of the indicated genotypes were analyzed for myeloid and lym-
phoid cells. (A) Quantification of splenic weight and cellularity. (B) Enumeration of splenic neutrophils 
(CD45+CD11b+GR1+), Ly6Chi monocytes/macrophages (CD45+CD11b+GR1-Ly6Chi), Ly6Clo monocytes/
macrophages (CD45+CD11b+GR1-Ly6Clo), total DCs (CD45+CD11c+MHC-II+), cDC1s (CD45+CD11c+MHC-
II+CD11b-) and cDC2s (CD45+CD11c+MHC-II+CD11b+), using flow cytometry. (c) Quantification surface 
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The numbers of neutrophils were significantly increased in Il23WTTnfaip3CD11c-KO mice, 
compared to WT mice, Tnfaip3CD11c-HZ mice and Il23KOTnfaip3CD11c-KO mice (Figure 1B; see 
for gating strategy21: Supplementary Figure S1). Whereas absolute cell counts of Ly6Chi 
monocytes/macrophage were increased in Il23WTTnfaip3CD11c-KO mice, compared to Il23WT 
Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice, they did not differ for the Ly6Clo monocyte/mac-
rophage population (Figure 1B, see for gating strategy: Supplementary Figure S1). 
Both Ly6Chi and Ly6clo monocytes were reduced in Il23KOTnfaip3CD11c-KO mice compared to 
the other mouse groups (Figure 1B).
The absolute numbers of total DCs, as well as the cDC1 and cDC2 subsets (see for 
gating strategy: Supplementary Figure S1), were strongly reduced in the spleens of 
Il23WTTnfaip3CD11c-KO mice and even significantly further reduced in Il23KOTnfaip3CD11c-KO 
mice, compared to their Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ counterparts (Figure 1B). Next, 
we evaluated splenic DCs for the expression of the MHC class II and CD86 surface mark-
ers, which are associated with DC activation. Surface MHC-II was significantly increased 
in Il23KOTnfaip3CD11c-KO mice, compared to Il23WTTnfaip3CD11c-KO mice (Figure 1c). While 
CD86 expression was significantly reduced in Il23WTTnfaip3CD11c-KO mice, compared to 
Tnfaip3CD11c-WT andTnfaip3CD11c-HZ mice, it was significantly higher in Il23KOTnfaip3CD11c-KO 
mice compared to Il23KO mice and Il23WTTnfaip3CD11c-KO mice (Figure 1c).
In conclusion, the concomitant absence of IL-23 in Tnfaip3CD11c-KO mice resulted in sig-
nificantly reduced splenic cell counts, with lower numbers of neutrophils, monocytes/
macrophage and in particular DCs. The DCs in these Il23KOTnfaip3CD11c-KO mice had a more 
activated phenotype.
lack of Il-23 has moderate effects on lymphocyte cells in the spleen.
At 24 weeks of age, the numbers of splenic CD4+ T cells and CD8+ T cells did not differ 
between Tnfaip3CD11c-KO and Tnfaip3CD11c-WT mice on the Il23WT background (Figure 1D). 
However, they were moderately reduced in Il23KO Tnfaip3CD11c-KO mice, compared to 
Il23WTTnfaip3CD11c-KO mice (Figure 1D). Both TCRγd+ T cells and B cells were reduced in 
Tnfaip3CD11c-KO mice, irrespective of the Il23 genotype, when compared to the other four 
groups of mice (Figure 1D).
The very low absolute cell counts of the spleens of Tnfaip3CD11c-KOIl23KO mice, prompted 
us to investigated their architecture. We previously observed a disturbed splenic 
expression of MHC-II and CD86 on splenic DCs, using flow cytometry (left) and representative histogram 
overlays (right). (D) Quantification of splenic CD4+ T cells (CD3+CD4+CD8-), CD8+ Th cells (CD3+CD8+CD4-), 
TCRγd T cells (CD3+TCRγd+) and B cells (B220+CD138- ) using flow cytometry. (e) Confocal imaging of spleens 
for CD4 (Green), B220 (Blue) and CD11c (Red). Pooled data is shown from four independent experiments (in 
A/B/D) and a single experiment (in C/E). Results are presented as mean values ± SEM of n = 2-19 mice per 
group. Kruskal-Wallis test for multiple comparisons was performed and followed by a Mann-Whitney U test. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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architecture in Tnfaip3CD11c-KO mice in comparison to Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ 
mice16. Likewise, also on the Il23KO background the Tnfaip3CD11c-KO mice had spleens 
with a disturbed architecture: very few B220+ cells, and a few clusters of CD11c+ cells, 
without clearly separated B and T cell areas (Figure 1e). In a smaller magnification, im-
munohistochemical analyses revealed a drastic reduction of IgD+ B cells in the spleens 
of both Il23WT and Il23KO Tnfaip3CD11c-KO mice, compared to the Tnfaip3CD11c-WT counterparts 
(Supplementary Figure S2). Large regions were devoid of IgD+ B cells, most likely 
representing red pulp areas with myeloid cells. Nevertheless, the absence of IL-23 ap-
peared to result in a slight rescue of IgD+ B cells clusters in Tnfaip3CD11c-KO spleens. This 
would be consistent with the flow cytometry findings of reduced total numbers of cells, 
but similar numbers of B cells in the spleens of Il23KOTnfaip3CD11c-KO mice, compared with 
Il23WT Tnfaip3CD11c-KO mice.
In conclusion, despite the substantial reduction of spleen weight and total cell count 
in Il23KO Tnfaip3CD11c-KO mice compared to Il23WT Tnfaip3CD11c-KO mice, T cell numbers were 
only moderately reduced and B cell numbers were comparable between the two mouse 
groups.
Il-23-deficiency reduces the numbers of both Th17 and non-Th17 cycling T cells 
in Tnfaip3cD11c-Ko mice.
Because IL-23 plays a primary role in Th17-cell homeostasis and is important for the 
expansion of Th17 cells10, 22, we further investigated splenic CD4+ T-cell subsets.
Antigen-experienced CD44+ effector and memory CD4+ T cells in the spleen were 
highest in both Il23WT and Il23KO Tnfaip3CD11c-HZ mice (Figure 2A). This population was 
decreased in Il23KOTnfaip3CD11c-KO mice compared to Il23WTTnfaip3CD11c-KO mice. This was 
probably linked to the overall reduction of splenic CD4+ T cells in Il23KOTnfaip3CD11c-KO 
mice: when we calculated the proportions of antigen-experienced CD44+ effector and 
memory CD4+ T cells as a percentage of total CD4+ T cells, there was no detectable effect 
of the loss of IL-23 (Supplementary Figure S3A).
Loss of IL-23 also did not appear to affect the total numbers of RORγt+ Th17 cells in 
the spleen of Tnfaip3CD11c-KO mice (Figure 2B, 2c), although their proportions within the 
total CD4+ T cell population in the spleen were increased (Supplementary Figure S3B).
The numbers of cycling Ki67+ CD4+ T cells, non-Th17 cells and CD8+ T cells in the 
spleen of the six groups of mice essentially reflected the total numbers of cells in these 
populations (Figure 2D; see for proportions of Ki67+ cells within these populations: 
Supplementary Figure S3c). In contrast, a pattern emerged that both the absolute 
numbers and the proportions of Ki67+ RORyt+ Th17 cells were reduced in the three Il23KO 
genotypes, compared with the Il23WT counterparts (Figure 2D; Supplementary Figure 
S3c).
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The numbers of intracellular IL-17+, IFN-γ+ and IL-10+ splenic CD4+ T cells were 
significantly reduced in both Il23WT and Il23KO Tnfaip3CD11c-KO mice, compared to their 
Tnfaip3CD11c-WT or Tnfaip3CD11c-HZ counterparts (Figure 2e,2F,2G). However, as a proportion 
of CD4+ T cells, IL17+, IFNγ+ and IL-10+ cells were significantly higher in Il23KOTnfaip3CD11c-KO 
mice compared to Il23KOTnfaip3CD11c-WT or Il23KOTnfaip3CD11c-HZ controls (Supplementary 
Figure S3D, S3e, S3F).
Absence of IL-23 had limited effects on the numbers of antigen-experienced 
CD44+ effector and memory CD8+ T cells in the spleen of the three mouse genotypes. 
Although Il23KOTnfaip3CD11c-KO mice had lower absolute numbers of CD44+CD8+ T cells 
than Il23WTTnfaip3CD11c-KO mice (Figure 2H), their frequencies (as proportions of CD8+ T 
cells) were increased (Supplementary Figure S3G). In parallel, the absolute numbers of 
IFNγ+ CD8+ T cells tended to be lower in Il23KOTnfaip3CD11c-KO than in Il23WTTnfaip3CD11c-KO 
mice (Figure 2I), but their frequencies (as proportions of CD8+ T cells) were increased 
(Supplementary Figure S3H).
In conclusion, in Tnfaip3CD11c-KO mice the lack of IL-23 did not reduce the absolute 
numbers or proportions of RORγ+ or IL-17+ Th17 cells in the spleen. Nevertheless, in 
these mice the absolute numbers of cycling Ki67+Th17 cells, as well as the proportions of 
Ki67+ cells within the Th17 population was reduced in the spleen in the absence of IL-23. 
These findings suggest that an ongoing induction of Th17 cells can compensate for the 
absence of IL-23-driven expansion of Th17 cells in Il23KOTnfaip3CD11c-KOmice.
Il-23-deficiency reduces splenic plasma cells numbers and IgA serum levels in 
Tnfaip3cD11c-Ko mice.
Since Th17 cells are known to mediate B cell differentiation and Ig heavy chain class 
switch recombination7, we assessed the effects of Il23 gene deletion on germinal center 
(GC) B cells and plasma cells in the spleen at the age of 24 weeks. GC B-cell numbers 
were reduced in Tnfaip3CD11c-KO mice, irrespective of the presence of IL-23 (Figure 3A). 
However, as a proportion of B cells, splenic GC B cells were enhanced in Tnfaip3CD11c-KO 
mice and also in Il23KOTnfaip3CD11c-HZ mice, compared to Tnfaip3CD11c-WT mice and Il23KO 
mice respectively (Supplementary Figure 4A). Splenic plasma cell numbers were 
elevated in Il23WTTnfaip3CD11c-HZ mice in comparison to Il23WTTnfaip3CD11c-WT and Il23WTTn-
faip3CD11c-KO mice (Figure 3A). Importantly, whereas the effect of the absence of IL-23 
on Tnfaip3CD11c-WT and Tnfaip3CD11c-HZ mice was limited, plasma cells were very low in 
Il23KOTnfaip3CD11c-KO mice (Figure 3A). This pattern was similar for IgM+, IgG1+ and IgA+ 
plasma cell counts (Figure 3A). When we analyzed the Ig heavy chain class distribution 
in the plasma cells, we noticed that proportions of IgG1+ plasma cells were increased in 
Tnfaip3CD11c-KO mice, in particular in Il23KOTnfaip3CD11c-KO mice, compared to Tnfaip3CD11c-WT 
mice on an Il23WT or Il23KO background (Supplementary Figure 4B, see also pie-chart). 
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The remaining fraction of splenic plasma cells, expressing IgG2b, IgG2c and IgG3 ap-
peared to be increased in the absence of IL-23.
The total numbers of B220+ B-lineage cells in the bone marrow (BM) of Il23WTTn-
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Figure 2: Il-23-deficiency reduces the numbers of both Th17 and non-Th17 cycling T cells in Tn-
faip3cD11c-Ko mice.
Spleens from 24-week-old naïve mice of the indicated genotypes were analyzed for T cell populations. (A) 
Quantification of splenic antigen-experienced effector CD4+ T cells (CD3+CD4+CD44+) using flow cytometry. 
(B-c) Flow cytometry profiles of gated CD4+ T cells for surface CD44 and intracellular RORγt+ (B) and enumer-
ation of splenic Th17 cells (CD3+CD4+RORγt+)(c) using flow cytometry. (D) Quantification of Ki67+ proliferat-
ing CD4+ T cells (CD3+CD4+Ki67+), Th17 cells (CD3+CD4+Rorγt+Ki67+), Non-Th17 cells (CD3+CD4+Rorγt-Ki67+) 
and CD8+ T cells (CD3+CD8+Ki67+) (e-I) Quantification of IL-17+ CD4+ T cells (CD3+CD4+IL-17+) (e), IFNγ+ CD4+ 
T cells (CD3+CD4+IFNγ+) (F), IL-10+ CD4+ T cells (CD3+CD4+IL-10+) (G) antigen experienced effector CD8+ T 
cells (CD3+CD8+CD44+) (H) and IFNγ+ CD8+ T cells (CD3+CD8+IFNγ+) (I), using flow cytometry. Pooled data 
are shown from four independent experiments, except for panels D, E and G, which were from two indepen-
dent experiments. Results are presented as mean values ± SEM of n = 3-19 mice per group. Kruskal-Wallis 
test for multiple comparisons was performed and followed by a Mann-Whitney U test. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001.
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B cell defect (described in greater detail in chapter 5 of this thesis) and thus providing 
an explanation for the reduced numbers of B cells present in the spleen of these mice. 
Also, the absolute numbers of total plasma cells were highest in Il23WT Tnfaip3CD11c-HZ 
mice, but reduced in Il23WT and Il23KO Tnfaip3CD11c-KO mice compared to the other mouse 
groups (Figure 3B). All three Tnfaip3 genotypes had lower numbers of IgM+ plasma cells 
on the Il23KO than on the Il23WT background. IgM+ plasma cells were virtually absent in 
Il23KO Tnfaip3CD11c-KO mice (Figure 3B). In contrast, the complete absence of Tnfaip3/A20 
or IL-23 did not significantly affect the numbers of BM IgG1+ or IgA+ plasma cells. An 
IL-23-dependent rise was seen for BM IgG1+ and IgA+ BM plasma cells in Tnfaip3CD11c-HZ 
mice compared to the control mice (Figure 3B).
Altogether, regarding the Ig heavy chain class distribution in BM plasma cells, we 
observed a reduction of the proportions of IgM+ plasma cells in Il23WTTnfaip3CD11c-KO mice 
and a virtual absence of IgM+ plasma cells in Il23KOTnfaip3CD11c-KO mice (Supplementary 
Figure 4c, see also pie-chart). Concomitantly, the proportions of BM IgG1+ and IgA+ 
plasma cells were increased in Tnfaip3CD11c-KO mice compared to Tnfaip3CD11c-WT mice and 
Tnfaip3CD11c-HZ mice, irrespective of the presence of IL-23 (Supplementary Figure 4c, see 
also pie-chart).
Next, we assessed serum Ig levels and observed a differential effect of the absence 
of Tnfaip3/A20 on individual subclasses: IgM and Ig2b were unaffected, IgG1 and IgA 
were increased and IgG2c and IgG3 were decreased (Figure 3c). In Il23WTTnfaip3CD11c-HZ 
mice, we found that only IgA levels were increased. For most subclasses this pattern was 
largely unaffected by the absence of IL-23, except that levels of IgA were lower in all 
three Il23KO Tnfaip3 genotypes compared to their Il23WT equivalents (Figure 3c). Thus, in 
Il23KOTnfaip3CD11c-KO mice the levels of IgA in serum were in the normal range, similar to 
Il23WTTnfaip3CD11c-WT mice.
In summary, the absence of IL-23 resulted in strong reduction of IgM+, IgG1+ and IgA+ 
splenic plasma cells specifically in the group of Tnfaip3CD11c-KO mice. By contrast, in the BM 
the absence of IL-23 reduced the numbers of IgM+ plasma cells in all three Tnfaip3 geno-
types, but did not significantly affect IgG1+ and IgA+ plasma cell counts in Tnfaip3CD11c-KO 
mice. Serum IgG1 and IgA were the primary isotypes increased in Tnfaip3CD11c-KO mice, 
but additional loss of IL-23 in these mice only reduced serum IgA levels, leaving IgG1 
levels unaffected.
Il-23-deficiency does not affect autoreactive IgG1 levels or kidney 
glomerulonephritis in Tnfaip3cD11c-Ko mice.
Since aged Tnfaip3CD11c-KO mice expressed autoantibodies in vivo16, we analyzed the 
presence of autoreactive anti-dsDNA and anti-cardiolipin IgG1 in serum of 24-week-
old mice. Anti-dsDNA and anti-cardiolipin IgG1 was higher in Tnfaip3CD11c-KO mice 
than Tnfaip3CD11c-HZ or Tnfaip3CD11c-KO mice, regardless of IL-23-deficiency, although this 
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did not reach significance (Figure 4A, 4B). Since autoreactive immunoglobulins may 
cause tissue damage in glomeruli, we assessed histology of the kidney glomeruli in the 
six groups of mice. We previously reported that aged Tnfaip3CD11c-KO mice developed 
membranoproliferative glomerulonephritis with increased glomerular cellularity and 
thickening of the basement membranes16. Using PAS-D staining we confirmed that 
~80% of the Il23WTTnfaip3CD11c-KO mice had thicker glomerular basement membranes, 
compared to 0% and ~25% in Il23WTTnfaip3CD11c-WT and Il23WTTnfaip3CD11c-HZ mice re-
spectively (Figure 4c). Lack of IL-23 lead to similar basement membrane thickening in 
100% of Il23KO Tnfaip3CD11c-KO mice compared to 0% and ~40% in Il23KOTnfaip3CD11c-WT and 




























Il23WT Il23KO Il23WT Il23KOIl23WT Il23KO

















































































































































































































Il23WT Il23KO Il23WT Il23KO Il23WT Il23KOIl23WT Il23KO Il23WT Il23KO Il23WT Il23KO
Figure 3: Il-23-deficiency reduces splenic plasma cells numbers and IgA serum levels in Tnfaip3cD11c-
Ko mice.
Spleens and bone marrow (BM) from 24-week-old naïve mice of the indicated genotypes were analyzed for 
B-cell populations. (A-B) Quantification of GC B-cells (B220+CD138-IgD-CD95+), plasma cells (B220-CD138+), 
IgM+ plasma cells (B220-CD138+IgM+), IgG1+ plasma cells (B220-CD138+IgG1+) and IgA+ plasma cells B-cells 
(B220-CD138+IgA+) in spleens (A) and BM (B) (Total B-lineage cells in BM gated as B220+CD138-) using flow 
cytometry. (c) Serum concentrations of IgM, IgG1, IgG2b, IgG2c, IgG3 and IgA, determined by ELISA. Pooled 
data are shown from three independent experiments (panels A and B). Serum Ig levels are from two (IgM, 
IgG2b, IgG2c, IgG3) or four (IgG1, IgA) independent experiments. Results are presented as mean values ± 
SEM of n = 5-15 mice per group. Kruskal-Wallis test for multiple comparisons was performed and followed 
by a Mann-Whitney U test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Thus, lack of IL-23 did not abrogate the formation of IgG1 autoantibodies nor thicken-
ing of the glomerular basement membrane in Tnfaip3CD11c-KO mice.
DIScUSSIoN
Since the start of the millennium, the discovery of IL-23 and the primary acting cytokine 
IL-17 has redefined the understanding of autoimmune disorders22. In several autoim-
mune disorders such as psoriasis, inflammatory bowel disease (IBD) or SLE, common 
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Figure 4: Il-23-deficiency does not affect autoreactive IgG1 levels or kidney glomerulonephritis in 
Tnfaip3cD11c-Ko mice.
Serum of naïve 24-week-old mice of the indicated genotypes was analyzed for autoreactive IgG1 towards 
dsDNA (A) and cardiolipin (B) using ELISA. (c) PAS-D staining on paraffin-embedded kidneys. Scale bars 
represent 200μm. Representative histology images are shown from three independent experiments. Re-
sults are presented as mean values ± SEM of n = 2-10 mice per group.
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promising clinical results15, 23. Also, in lupus mouse models the role of IL-23/IL-17 is of 
importance24. We studied our Tnfaip3CD11c-KO lupus mouse model, in which Tnfaip3/A20, 
a negative regulator for NF-κB, is specifically deleted in DCs, leading to hyperactivated 
DCs16. As a result, activity of T and B cells is dysregulated and mice express autoantibod-
ies and develop lupus nephritis. BM-derived DCs from Tnfaip3CD11c-KO mice produced high 
IL-23 and induced Th17 cell differentiation in vitro16. In this report, we addressed the 
question whether loss of IL-23 in vivo would restore Th17 cell homeostasis and thereby 
alleviate the lupus phenotype. We found, however, that in vivo Th17 cell differentiation 
was not enhanced in 24-week-old Tnfaip3CD11c-KO mice, compared to Tnfaip3CD11c-WT mice. 
Moreover, loss of IL-23 expression did not significantly affect the numbers of Th17 cells 
in the spleen, serum levels of IgG1 or anti-dsDNA IgG1 or kidney glomerulonephritis. 
Taken together, these findings indicate that the autoimmune pathology in Tnfaip3CD11c-KO 
mice is independent of the IL-23/IL-17 axis.
While Tnfaip3CD11c-KO mice had enlarged spleens with various proliferating myeloid 
cells16, these were significantly reduced in the absence of IL-23. This was possibly due 
to survival signals to myeloid cells provided by IL-23, as shown during C. albicans infec-
tion25. Neutrophils were the myeloid cells that expanded most in Il23WTTnfaip3CD11c-KO 
mice. Although IL-23 deficiency may be associated with defects in granulopoiesis26, 27, no 
differences were seen between Il23WTand Il23KO mice of the Tnfaip3CD11c-WT or Tnfaip3CD11c-HZ 
genotype.
All conventional DC subsets, including the cDC2 subset known to primarily produce 
IL-2328 were reduced in number, both in Il23WT and Il23KO Tnfaip3CD11c-KO mice. Surprisingly, 
splenic DC activation status, as measured by surface MHC-II and CD86 expression was 
higher in Il23KO than Il23WT Tnfaip3CD11c-KO mice. In vitro, Tnfaip3/A20-deficient BM-derived 
DCs showed no differences for CD40, CD86 or MHC-II expression between IL-23WT and 
IL-23KO mice, indicating that IL-23 had no effect on their activation status in vitro. An 
autocrine effect of IL-23 on DCs has been suggested, influencing IL-12 production and 
improving antigen presentation in a skin reactivity test29, 30. Furthermore, human in vitro 
studies show that IL-23 promotes T cell proliferation, without affecting DC maturation31. 
In a naïve state only ~4% of CD11c+ DCs express IL-23R32. This did not differ across the six 
mouse groups in our study (T.D., unpublished. data), suggesting that the absence of this 
autocrine IL-23 effect is not a likely explanation for enhanced activation of DCs in Il23KOT-
nfaip3CD11c-KO mice. In contrast to previous findings16, we saw a reduction of splenic DCs at 
the age of 24 weeks in Il23WT Tnfaip3CD11c-KO mice, and even more so in Il23KOTnfaip3CD11c-KO 
mice. It may be argued that a higher activation status of this minor population of DCs is 
not likely to contribute to the systemic phenotype in Il23KOTnfaip3CD11c-KO mice. However, 
despite having such low DC counts, both Il23WT and Il23KOTnfaip3CD11c-KO mice still devel-
oped the lupus-like phenotype. This suggests that secondary activated cells that were 
in proximity to the DCs, such as T-cells or monocytes/macrophages contribute to the 
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phenotype, e.g. by elevated cytokine production such as the previously demonstrated 
IL-6 and TNF-α16.
In contrast to previously reported in vitro studies16, Tnfaip3CD11c-KO mice did not have 
increased RORγt+ Th17 cells or IL-17+ CD4+ T cells in vivo, compared to Tnfaip3CD11c-WT 
mice. It remains however unclear whether this originates from differences between in 
vivo and in vitro findings, or from differences between mouse facilities or microbiome. 
The latter would be supported by our analyses of the B cell compartment in the spleens 
of 24-week-old Tnfaip3CD11c-KO mice, showing reduced numbers of GC B cells and similar 
numbers of plasma cells compared to WT control mice, whereas Kool et al. reported 
that both cell populations were increased (although not significantly) in 25-week-old 
Tnfaip3CD11c-KO mice16. In this context, it is of note that another strain of C57Bl/6 mice 
with a DC-specific deficiency of Tnfaip3/A20, also based on CD11c-Cre-mediated gene 
targeting developed a phenotype characterized by IBD-associated arthritis33. This phe-
notype is quite different from the SLE-like phenotype in our Tnfaip3CD11c-KO mice16, which 
would support an important role of microbiome or other environmental factors on the 
in vivo immunological and pathological effects of Tnfaip3/A20 deletion.
We were surprised to see that whereas antigen-experienced effector/memory CD4+ 
T-cells were reduced in the spleens of Il23KOTnfaip3CD11c-KO mice, this was not observed 
for RORγt+ Th17 cells or IL-17+ CD4+ T cells. Rather, the proportions of RORγt+ Th17 
cells and IL-17+ CD4+ T cells appeared to rise in Il23KOTnfaip3CD11c-KO mice compared to 
Il23WTTnfaip3CD11c-KO mice. Two roles of IL-23 have been proposed, namely induction of T 
cell expansion and induction of T cell pathogenicity. Whereas initially IL-23 was regarded 
as an inducing factor for Th17 cells34, later studies show that primarily TGF-β and IL-6 are 
responsible for the induction and IL-23 is more important for survival and expansion of 
Th17 cells12. T cell proliferation was overall reduced in Il23KO mice, however, as a propor-
tion of CD4+ T cells, only the Th17 cell population - and not non-Th17 cells - showed a 
reduction in proliferation due to absence of IL-23. The limited effects of IL-23 on the size 
of the splenic Th17 population, together with a reduction of Ki67+ proliferating Th17 
cells, suggest an ongoing de novo induction of Th17 cells, or an increased migration of 
resting Th17 cells into the spleen. Both of these mechanisms may compensate for the 
absence of IL-23-driven expansion of Th17 cells in Il23KOTnfaip3CD11c-KOmice.
Another concept would be that IL-23 unlocks the full pathogenic potential of auto-
reactive T-cells, while only the TGF-β/IL-6 combination induces more suppressive IL-10+ 
T-cells13. Indeed, in our data a significant increase of the proportions – but not absolute 
numbers - of splenic IL-10+ T-cells was seen in Il23KOTnfaip3CD11c-KO mice, compared to 
Il23WTTnfaip3CD11c-KO mice, suggesting that relatively more immunosuppressive CD4+ T 
cells were present in the absence of IL-23. In our hands cytokine and transcription factor 
expression could unfortunately not reliably be combined to analyze on the single-cell 
level whether RORγt+ Th17 cells had altered IL-10 production. Regardless of these 
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suppressive IL-10+ Th-cells, however, autoantibody production or tissue inflammation 
assessed by basement membrane thickening in kidney glomeruli was unaltered in 
Tnfaip3CD11c-KO mice in absence of IL-23. Further experiments are necessary to determine 
whether other Th17-associated cytokines, such as IL-22 and GM-CSF, which is normally 
induced by IL-2335, are changed in Il23WT and Il23KOTnfaip3CD11c-KO mice.
The numbers of splenic IL-17+ or IFNγ+ Th cells was not different between Il23WT and 
Il23KOTnfaip3CD11c-KO mice. As a proportion, however, substantial increases in IFNγ+ Th cells 
were seen. This is not likely caused by IL-23-deficiency alone, because IL-23 has only 
a marginal effect on IFNγ expression36. Although IL-23 does not induce Th17 commit-
ment, it helps to maintain a Th17 phenotype37, which might explain why in its absence 
higher levels of Th1 cytokines are produced when DCs have an activated phenotype. 
Nevertheless, although it has been shown that plasticity of Th17 cells towards IFNγ+ Th1 
cells is dependent on IL-2338, we did not find evidence for such a role of IL-23 in our 
Tnfaip3CD11c-KO mice: IL-17+IFNγ+ Th cells were not decreased in Il23KO Tnfaip3CD11c-KO mice 
(T.D., unpublished data). Taken together, our findings suggests that the proportions of 
IFNγ+ CD4+ Th-cells in Il23KO Tnfaip3CD11c-KOmice may rise due to (i) de novo induction of 
Th1 cells over Th17 cells, possibly supported by IL-12 from Tnfaip3CD11c-KO DCs17 or to (ii) 
migration of IFNγ+ CD4+ Th-cells into the spleen or migration of IFNγ- CD4+ cells out of 
the spleen.
Th17 cells influence B-cell activation and Ig production by plasma cells into isotypes 
IgG1, IgG2a/c and IgG2b7. Since Th17 cells were not reduced in Il23KO Tnfaip3CD11c-KO mice 
compared to Il23WTTnfaip3CD11c-KO mice, it was expected that also serum Ig levels were 
essentially unaffected. This was indeed the case, except that IgA was substantially re-
duced. Given the low numbers of IgA+ plasma cells in the spleens of Tnfaip3CD11c-KO Il23KO 
mice, while the bone marrow plasma cells were unaffected, it might be possible that 
a major fraction of serum IgA in Tnfaip3CD11c-KO mice was produced in the spleen. How-
ever, IgA could also be derived from the intestine39, but we did not observe intestinal 
autoimmune inflammation in Il23WT or Il23KOTnfaip3CD11c-KO mice (T.D., unpublished data), 
despite a previous report of gut inflammation in another published Tnfaip3CD11c-KO mouse 
model33. Yet, lack of IL-23 did not appear to affect the autoimmune phenotype in that 
a similar basement membrane thickening was found in the kidney glomeruli of Il23WT 
and Il23KOTnfaip3CD11c-KO mice. Given the differential effects of the absence of Tnfaip3/A20 
or IL-23-deficiency on the individual subclasses, additional experiments are required to 
evaluate the autoreactivity of the individual Ig subclasses in the serum of Il23WT and 
Il23KOTnfaip3CD11c-KO mice. Likewise, it will be informative to investigate the presence and 
nature of immune complex depositions in the glomeruli in Il23WT and Il23KOTnfaip3CD11c-KO 
mice.
In conclusion, the absence of IL-23 resulted in a substantial reduction of granulo-
cytes and monocytes/macrophage in the spleens of Tnfaip3CD11c-KO mice. Although 
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splenic DCs from Il23KOTnfaip3CD11c-KO had a more activated phenotype than DCs from 
Il23WTTnfaip3CD11c-KO mice, their numbers remained very low. Deletion of the Tnfaip3 
gene in DCs did not enhance Th17 cell differentiation in vivo and further loss of IL-23 
did not affect the numbers of splenic Th17 cells. Despite a severe reduction of plasma 
cells in the spleen, the serum of Il23KOTnfaip3CD11c-KO mice contained autoreactive IgG1. 
Glomerular membrane thickening seen in Tnfaip3CD11c-KO mice was also unaffected by 
IL-23-deficiency. From these findings we conclude that the autoimmune pathology in 
Tnfaip3CD11c-KO mice is independent of the IL-23/IL-17 axis.
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A Supplementary Figure 1
Supplementary Figure 1: Gating strategy for the indicated myeloid cell fractions in the spleen of 













Supplementary Figure 2: Il-23-deficiency has no major effects on the splenic architecture in Tn-
faip3cD11c-Ko mice.
Spleens from naïve 24-week-old mice from the indicated genotypes were analyzed by immunohistochem-
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Supplementary Figure 3: effects of Il-23-deficiency on the proportions of T cell subsets, T cell prolif-
eration and cytokine production.
Spleens from naïve 24-week-old mice from the indicated genotypes were analyzed for T cell populations. 
(A-B) Quantification of proportions splenic effector CD4+ T-cells (CD3+CD4+CD44+)(A) and RORyt+ Th17 
cells (CD3+CD4+RORyt+) (B) using flow cytometry. (c) Quantification of proportions Ki67+ proliferating CD4+ 
T cells (CD3+CD4+Ki67+), Th17 cells (CD3+CD4+Rorγt+Ki67+), Non-Th17 cells (CD3+CD4+Rorγt- Ki67+) and 
CD8+ T cells (CD3+CD8+ Ki67+) (D-H) Proportion IL-17+ CD4+ T cells (CD3+CD4+IL-17+) (D) IFNγ+ CD4+ T cells 
(CD3+CD4+IFNγ+) (e) and IL-10+ CD4+ T cells (CD3+CD4+IL-10+)(F) and effector CD8+ T-cells (CD3+CD8+CD44+) 
(G) and IFNγ+ CD8+ T-cells (CD3+CD8+IFNγ+) (H) using flow cytometry. Pooled data are shown from four 
independent experiments, except for panels C,D and F, which are from two independent experiments. Re-
sults are presented as mean values ± SEM of n = 3-19 mice per group. Kruskal-Wallis test for multiple com-
parisons was performed, followed by a Mann-Whitney U test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.













































































































































Supplementary Figure 4: Splenic and Bm proportions of IgA+ and IgG1+ plasma cells are elevated 
regardless of Il-23 in Tnfaip3cD11c-Ko mice.
Naïve 24-week-old Tnfaip3CD11cIl23 mice spleens and BM were analyzed for B cell and plasma cell propor-
tions. (A) Quantification of proportion splenic GC B cells (B220+IgD-CD95+) using flow cytometry. (B-c) Enu-
meration of the proportion IgM+ plasma cells (B220-CD138+IgM+), IgG1+ plasma cells (B220-CD138+IgG1+) 
and IgA+ plasma cells (B220-CD138+IgA+) in spleen (B) and BM (c) using flow cytometry. Pie charts have 
been included of these proportions. Pooled data is shown from three independent experiments, except 
panels (B/c) which are from one experiment. Results are presented as mean values ± SEM of n = 2-15 
mice per group. Kruskal-Wallis test for multiple comparisons was used, followed by Mann-Whitney U test. 
*P<0.05, **P<0.01, ***P<0.001.
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Supplementary Table 1: Antibodies used for flow cytometry
Antibody conjugate clone company
B220 AF700 RA3-6B2 eBioscience
CD11b PercP-Cy5.5 M1/70 BD
CD11c BV786 HL3 BD
CD138 BV605 281-2 BD
CD19 APC-Cy7 1D3 BD
CD3e PE-CF594 145-2C11 BD
CD4 BV711 RM4-5 BD
CD44 Percp-Cy5.5 IM7 eBioscience
CD44 APC-cy7 IM7 BD
CD45 PE TxR I3/2.3 Abcam
CD62L APC-Cy7 MEL-14 BD
CD8a PE-Cy7 53-6.7 eBioscience
CD86 PE-Cy7 GL1 BD
Gr-1 PE-Cy7 D7 eBioscience
IFN-y ef450 XMG1.2 eBioscience
IgD APC 11-26c eBioscience
IgG1 Biotin A85-1 BD
IgG2a/b Biotin R2-40 BD
IgG3 Biotin R40-82 BD
IgM PE-Cy7 II/41 eBioscience
IL-10 Percp-EF710 JES5-16E3 eBioscience
IL17A AF700 TC11-18A10.1 BD
Ki67 eFluor 660 SolA15 eBioscience
MHC II AF700 I-Ad/I-Ed eBioscience
RORyt PE Q31-378 BD
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In this thesis we addressed the role of A20/Tnfaip3, a negative regulator of NF-κB 
signaling in dendritic cells (DCs) in immune regulation that is essential to prevent au-
toimmune disease. We examined a novel DNGR1-cre mediated targeted deletion of the 
Tnfaip3 gene in mice, which primarily affects cDC1s and studied their activation in the 
context of a spontaneous chronic autoimmune liver disease (chapter 3). In a house dust 
mite (HDM)-induced neutrophilic airway inflammation, based on LysM-cre-mediated 
deletion of A20/Tnfaip3 from myeloid cells, we examined the role of IL-17RA-signaling 
(chapter 4). We surprisingly found that IL-17RA-signaling played no detectable role in 
HDM-induced neutrophilic airway inflammation. In aged Tnfaip3CD11c-KO mice, which lack 
A20/Tnfaip3 expression essentially in all DCs, we noticed that splenic B cell numbers 
were significantly reduced. We therefore examined the developmental stages of B cells 
in these mice in detail in chapter 5 and found that B cell development in the bone 
marrow was hampered at the immature B cell stage in 6-week-old Tnfaip3CD11c-KO mice 
and at the pre-B cell stage in 24-week-old Tnfaip3CD11c-KO mice. It had been previously 
demonstrated that A20/Tnfaip3-deficient bone marrow-derived (BM)-DCs could directly 
activate B cells in vitro independent of T cell help. Using this model crossed onto a Cd40l-
gKO background, we examined whether this also occurred in vivo (chapter 6). Despite 
the crucial role of CD40L in T-B cell communication in acquiring germinal center (GC) 
B cells and IgG1 class-switched plasma cells, we still observed glomerular membrane 
thickening in Tnfaip3CD11c-KOCd40lgKO mice. We concluded that in these mice the kidney 
pathology was most likely mediated by autoreactive, T cell independent IgA, because 
IgA was deposited and serum anti-dsDNA IgM and IgA levels were enhanced. Finally, 
we aimed to investigate how IL-23 signaling affected Th17 and B cell populations in 
Tnfaip3CD11c-KO mice (chapter 7). We observed that the autoimmune phenotype in mice 
with dendritic cell-specific deletion of Tnfaip3/A20 was independent of the IL-23/IL-17 
axis.
In this chapter, we discuss the role of A20/Tnfaip3, primarily in DCs, but also other 
immune cells, to keep the immune system in balance and prevent autoimmunity. We 
translate our findings to patients and discuss the outlook of A20 research in autoim-
munity.
A STeP INTo THe PAST, eQUAlS A STeP INTo THe FUTUre: UNDerSTANDING 
Dc oNToGeNy
Nobel laureate Ralph Steinman’s discovery of DCs in the 1970’s boosted our knowledge 
of immune homeostasis1. DCs are orchestrators of the immune system from tolerance 
to immunity2. This delicate balance is maintained by the expression of tolerogenic or 
immunogenic co-stimulators and cytokines3, 4. Over the years various types of DCs were 
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discovered and this led to a confusing nomenclature of DC subsets in different organs 
and different species, and challenged the comparison of individual experimental stud-
ies. At one point in time, questions were asked whether DCs are truly any different from 
monocytes at all5. In 2014, when experiments described in this thesis were ongoing, a 
consensus was proposed on the basis of DC ontogeny, which corresponded well across 
different species6. Deciphering various transcription factors or cell-specific expression 
markers to isolate DC subsets became a ‘hot topic’, either by targeted deletion of those 
transcription factors7 or by genetic tracing using fluorescent reporters in mice8, 9. Promis-
ing results were found for cDC1s and pDCs, but to date, cDC2s have no single transcrip-
tion factor with exclusive control over their development. This is due to (i) key transcrip-
tion factors such as IRF4, which are also used by other myeloid or adaptive immune 
cells10 and (ii) the finding that cDC2s can also be derived from lymphoid progenitors 
during certain conditions11. An overview of the main pDC and cDC transcription factors 
is depicted in Figure 1. Very recent work identified a subdivision of cDC2s into cDC2A 
and cDC2B based on T-bet or RORγt expression, respectively, and divides them into 
anti-inflammatory and pro-inflammatory cDC2s12. Our work did not take these ongoing 
divisions of cDC subsets into account.
Our interest settled on loxP-Cre-mediated gene deletion, whereby the DNGR1-cre 
(Clec9a-cre) was shown to mostly affect cDC1s, and a smaller proportion cDC2s and 
moDCs in steady state8. By crossing our Tnfaip3DNGR1 mice with ROSA-EYFP mice we 
demonstrated, in parallel to the work of Schraml et al. in the kidney8, that primarily 
cDC1s (~95%) were affected in the liver (chapter 3). A proportion cDC2s and moDCs 
(~30-40%) also showed deletion, as evidenced by YFP expression, in steady state. 
Interestingly, during inflammation these proportions were reduced for cDC1s from 
~95% YFP-positivity to ~60% YFP-positivity. While Schraml et al did not report the 
exact percentages of YFP+ cells in DC subsets during L. monocytogenes inflammation, 
their CD11c+GR1- population had ~55% YFP-positivity and likely encompassed most 
DC subsets. Thus, during inflammation, there appears to be a positive selection for the 
YFP-negative (reflecting the Tnfaip3-sufficient) population of cDC1s in our study. What 
the origin of these cells are is yet unknown, but they could be derived from monocytes 
as they can express cDC markers in tumors13. In the time that the experiments described 
were ongoing, several novel cDC1 specific conditional cre transgenic mouse models 
became available such as XCR1-cre or Karma-cre14 that are superior to the DNGR1-cre 
mouse. Even during viral infection, these models remain specific for cDC114. The utiliza-
tion of these models would have given cleaner results in comparison to the DNGR1-cre 
mice when analyzing the systemic effects of activated cDC1s, as described in chapter 3. 
Nevertheless, in Tnfaip3DNGR1-KO mice cDC and moDC activation was associated with T cell 
activation, elevated IFN-γ production and plasma cell differentiation (Figure 2). Specifi-
cally, plasma cells were present that produced autoreactive IgA recognizing periportal 
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cytoplasmic liver antigens, possibly leading to inflammatory infiltrates in those areas. By 
administering anti-IL-6 antibodies in vivo, we blocked IL-6 for multiple weeks and found 
a simultaneous absence of Th17 cells (Thomas Koudstaal et al., unpublished data). Thus, 
lack of IL-6 and Th17 did not reduce the liver inflammation. We were unable to dem-
onstrate whether IFN-γ was responsible for the inflammation, which likely contributes 
to the pathology as IFN-γ transgenic mice on a liver specific promoter (serum amyloid 
P component) resembled our liver phenotype15. Evidence was obtained for an indis-
pensable role for cDC1s in a Batf3-/- mice in a primary biliary cirrhosis model (Reuveni/
Zigmund, pers. commun.), which would support our findings of liver pathology in the 
Tnfaip3DNGR1 model of activated cDC1s. Liver inflammation was previously demonstrated 
in the context of multiorgan inflammation by Kool et al in the SLE-like phenotype16 and 
by Xuan et al with CD11c-cre mediated deletion of Tnfaip317. Another group indepen-
Figure 1: Differential expression of transcription factors regulating Dc differentiation
From the common myeloid progenitor (CMP), stems off a granulocyte-monocyte progenitor (GMP) and 
macrophage-dendritic cell progenitor (MDP). The latter splits off into a common monocyte progenitor 
(CMoP) that may develop into monocytes or into the common DC progenitor (CDP). The CDP may give rise 
to pDCs or a precursor DC (pre-DC) for CD4+ or CD8+ DCs. ID2, inhibitor of DNA binding 2; BATF3, basic leu-
cine zipper transcription factor ATF-like 3; IRF, interferon-regulatory factor; Bcl6 or Bcl11a, B cell lymphoma 
6 or 11a; Runx1, Runt related transcription factor; Rbpj, Recombination signal binding protein for immuno-
globulin Kappa J Region; Klf4, Krueppel-like Factor; Mafb, MAF BZIP transcription factor B. From Murphy et 
al, Annu Rev Immunol, 20167.
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dently generated a similar Tnfaip3CD11c-KO mouse model that had an IBD phenotype18. We 
confi rmed that the Tnfaip3DNGR1-KO mice diff ered from these phenotypes, since we found 
no intestinal or kidney infl ammation. It is of note that cDC activation in the lungs of 
Tnfaip3DNGR1-KO mice, could result in a pulmonary hypertension phenotype (Koudstaal et 
al., manuscript submitted). Diff erences in phenotype between laboratories, using a simi-
lar Tnfaip3CD11c-KO model are likely caused by microbiome diff erences, although eff ects of 
genetic background or minor diff erences in the targeting construct cannot be excluded. 
How the microbiome aff ects genetic models deserves future attention, because they 
can cloud the conclusions of genetic murine studies.
A20/TNFAIP3, myeloID cellS AND TH17-Il-23 AXIS IN cHroNIc DISeASeS
Since the original discovery of the Th17 cell lineage in 200519, the Th17-IL-23 axis has 
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Figure 2: A summary of the Tnfaip3fl /fl  and Cre-LoxP models (DNGR1-cre (red), CD11c-cre (brown) and LysM-
cre (Green) applied in this thesis, as well as the studied organs. Additional crosses onto other backgrounds 
(Cd40lgKO, Il23KO and Il17raKO), which are described in the specifi c chapter blocks are indicated. “↑” means a 
signifi cant increase, “↓” means a signifi cant decrease and “=” means no signifi cant diff erences.
197
amples with deregulations in this axis20. Other chronic diseases such as COPD or asthma 
should deserve this attention too. Patients with severe asthma may have a neutrophilic 
infiltrate21 and elevated serum IL-17 levels22 in comparison to moderate asthma patients. 
In an HDM-driven mouse model of airway inflammation, our group demonstrated that 
myeloid deficiency of A20 lead to a neutrophilic rather than an eosinophilic airway 
infiltrate23. Since IL-17 levels coordinate neutrophil chemoattractants such as CXCL1 
from airway epithelial cells24, we hypothesized that HDM-induced neutrophil airway 
inflammation would be reduced in Tnfaip3LysM-KO mice when crossed onto an Il17raKO 
background (Figure 2). Surprisingly, this did not seem to be the case (chapter 4). 
An equal extent of neutrophilic airway infiltration was seen in the broncho-alveolar 
lavage (BAL) fluid in HDM-exposed Il17raWT and Il17raKO Tnfaip3LysM-KO mice. Although 
IL-17Ra-signaling was absent, chemokines such as CXCL1, CXCL2 and CXCL12 were still 
formed, possibly due to high unaltered levels of IL-1β and IL-6. The clinical relevance of 
A20 in asthma patients was recently highlighted by reports of reduced TNFAIP3 mRNA 
and protein levels, isolated from PBMCs from asthmatic children compared to healthy 
controls25. DCs also showed a non-significant reduction of TNFAIP3 mRNA levels in 
asthmatic children25.
Increased numbers of Th17 cells were present in spleens and inguinal lymph nodes of 
Tnfaip3LysM-KO mice26 and these mice were originally demonstrated to have paw inflam-
mation resembling arthritis. Although the arthritis was independent of T or B cells26, 
myeloid cells such as monocytes27 or neutrophils28 can also produce IL-17. We thus 
wanted to examine the role of IL-17Rα signaling on arthritis. Surprisingly, despite having 
no IL-17Rα-signaling, there was equal paw inflammation in Tnfaip3LysM-KOIl17raKO mice 
(Supplementary Figure chapter 4, Figure 2), which was explained in a subsequent 
paper by evidence that IL-1β is the responsible cytokine29. A novel function for A20 was 
deciphered: it regulates the inflammasome NLRP3 and secondary IL-1β release from 
myeloid cells29. The effect of A20 on the inflammasome was confirmed in a few families 
around the world that had a loss-of-function mutation in A20. These patients have a rare 
disease called “A20 Haploinsufficiency”30 and their PBMCs have elevated inflammasome 
activation, NLRP3 and IL-1β protein and mRNA production30, 31. Phenotypes ranged from 
autoinflammatory diseases such as Behςets disease30 to autoimmune disorders32. 
In the same Tnfaip3LysM-KO mouse, another role of A20 was discovered: A20-deficiency 
in IFN-γ-stimulated bone marrow derived macrophages (BM-DM), resulted in higher 
STAT1 mRNA transcription in comparison to STAT3 mRNA transcription, indicating that 
A20 may regulate STAT gene transcription ratios33. Understanding the potent molecular 
functions of A20 is still of high interest, illustrated by two recent papers that studied the 
functional domains of A20. The Zinc Finger (ZF) 7 domain was most important to prevent 
a spontaneous autoimmune psoriatic-arthritis/like phenotype34, 35, whereas abrogat-
ing the ZF4 or OTU domain of A20 surprisingly did not reveal any phenotype36, 37. The 
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psoriatic-arthritis like symptoms were dependent on T cells, IL-17 and TNFα35. Although 
DC co-stimulatory molecules were not assessed (except for MHC-II), this does suggest 
their involvement to activate the adaptive immune system.
In vitro, it was shown that A20-deficient BM-DCs16, produce high levels of IL-23 and IL-6 
(Vroman et al23 and this thesis, chapter 6), and could elicit IL-17 production from naïve 
T cells. We wondered whether in vivo Th17 cells could be reduced, and consecutive B 
cell activation as well, since Th17 cells can stimulate immunoglobulin production38. We 
thus crossed Tnfaip3CD11c-KO mice to Il23KO mice and analyzed the resulting phenotype 
(chapter 7, Figure 2). We surprisingly did not see a reduction of Th17 cells or IL-17+ 
CD4+ T-cells in the spleen when we abrogated IL-23 in Tnfaip3CD11c-KO mice. This corre-
sponds with the literature that IL-23 is mostly important for maintenance of Th17 cells 
and inducing its pathogenicity, but that IL-6 and TGF-β cause Th17 cell induction39. Since 
Th17 cells influence plasma cell class switch by cytokines38, we also assessed serum im-
munoglobulins. We found no differences in Tnfaip3CD11c-KO mice concerning serum IgM, 
IgG2b, IgG2c or IgG3 in absence of IL-23. IgA which was elevated in Tnfaip3CD11c-KO mice 
was lowered in Tnfaip3CD11c-KOIl23KO mice. The increase of total IgG1 levels in the serum 
of Tnfaip3CD11c-KO mice was independent of IL-23, nor was the amount of autoreactive 
IgG1 and kidney glomerulonephritis. We therefore concluded that the SLE-phenotype 
in Tnfaip3CD11c-KO mice acts independently from the IL-23/Th17 axis. These findings are in 
contrast to studies that show a crucial role of IL-23 in other SLE models, such as the lupus 
prone MRL.Faslpr mice40, 41. Therefore, distinct immunological mechanisms may lead to 
a similar SLE phenotype: in the lpr mice there is a greater dependency on the Th17/
IL-23 axis. In our model, future studies to identify the primary responsible cytokine may 
include blocking IL-6, TNF-α or IFN-γ since these were elevated in Tnfaip3CD11c-KO mice in 
vivo16-18.
A20/TNFAIP3 AND DIrecT AcTIVATIoN oF B cellS By DcS, INDePeNDeNTly 
From T cellS
The most classic route of adaptive immune cell activation is by antigen presenting cells 
(APCs), via T cells, which in turn activate B cells. However, a direct interaction between 
APCs and B cells is also described42, whereby DCs are shown to interact directly with B 
cells and present antigen to them43. Our group was able to demonstrate in vitro that 
BM-DCs from Tnfaip3CD11c-KO mice in combination with only naïve B cells, stimulated plas-
mablast and plasma cell formation leading to IgA and IgG1 release16. Interestingly, char-
acteristic T cell independent activators of plasma cells such as BAFF and APRIL44, were 
not necessary in this in vitro activation of plasma cells16. Only IL-6 was found to stimulate 
IgA release16. Using mRNA sequencing, we compared Tnfaip3KO, Tnfaip3HZ and Tnfaip3WT 
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BM-DCs23 for a comprehensive genome-wide identification of differentially transcribed 
genes including candidate factors that may orchestrated B cell activation by DCs (chap-
ter 6). However, even by gene-set enrichment analysis (GSEA), we did not find new 
targets except IL-6, IL-1α and IL-1β. Factors such as BAFF and APRIL were not significantly 
differentially expressed in our analysis. We proceeded to analyze whether activated DCs 
in Tnfaip3CD11c-KO mice could also activate B cells in vivo and could direct class-switched 
plasma cells without T cell help by crossing these mice onto a Cd40lgKO background 
(chapter 6, Figure 2). GC B cells are dependent on CD40 ligand interaction45. However, 
while Tnfaip3CD11c-KOCd40lgKO displayed a detectable elevation of GC-like B cells on flow 
cytometry in comparison to Cd40lgKO mice, GC structures containing these cells could not 
be visualized using immunohistochemistry (chapter 6). These findings indicating that 
these GC-like B cells were most likely activated B cells, rather than true GC B cells. While 
some studies provided evidence that GC B cells can be formed without T cell help46, 47, 
these were short-lived GC B cells that did not allow the immunoglobulin variable regions 
to undergo somatic hypermutation. Interestingly, despite having no regular GC B cells, 
we did see equal number of plasma cells in double KO mice, compared to Tnfaip3CD11c-KO 
mice, suggesting that extrafollicular B cell activation was likely responsible for plasma 
cell formation. Within lupus models, the short-lived plasmablasts are the main source of 
autoantibodies48, 49, which derive from extrafollicular loci instead of long-lived plasma 
cells that originate from germinal centers. In these extrafollicular loci, DCs are in close 
proximity to autoantibody-positive B cells and are thought to provide survival signals to 
them49. In accordance, it has been reported that constitutive DC depletion in MRL.Faslpr 
mice reduced plasma blast numbers, autoantibodies and glomerulonephritis50. Interest-
ingly, despite the absence of T-B cell communication, IgG formation or glomerular IgG 
deposition, we still found glomerulonephritis in Cd40lgKOTnfaip3CD11c-KO mice. Possibly, 
autoreactive IgA contributed to the basement membrane thickening, as IgA deposi-
tions were detected in ~40% of the double KO mice. This knowledge is valuable, since 
therapies that inhibit T-B cell communication in patients with SLE, may not be sufficient 
to prevent end-stage renal disease.
A20/TNFAIP3, DcS AND B-cell DeVeloPmeNT IN THe BoNe mArrow
The function of DCs in the lymph nodes, the splenic compartment and mucosa are 
pronounced and well-studied, but what could the roles of DCs be in the bone marrow 
(BM)? BM-resident DCs have been identified and are known to resemble cDC2s, but si-
multaneously differ from splenic cDC2s in their chemokines and chemokine receptors51. 
They are thought to provide survival signals to mature B cells in the BM52. Could DCs that 
are resident in the BM influence the BM environment and thereby also affect developing 
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B cells or play a role in their development? And what will be the effects of DCs in the BM 
on the functionality of developing B cells later in their life once they have left the BM? 
We specifically asked these questions, because we found reduced numbers of mature B 
cells in the spleen, but also in BM of 24-week-old Tnfaip3CD11c-KO mice.
In young 6-week-old mice we therefore analyzed the different stages of B cell develop-
ment in BM and found a disorder around the small pre-B cell stage in chapter 5 (Figure 
2). Using an in vitro co-culture with IL-7, we identified that the CD19negative BM fraction 
from Tnfaip3CD11c-KO mice could negatively influence development of B cells that were 
derived from both WT or from Tnfaip3CD11c-KO mice. This implies that there is a non-cell in-
trinsic defect in B cell differentiation in these mice. Using several washing steps, we also 
hypothesize that cytokines are not likely responsible for defects in B cell differentiation. 
We however cannot exclude that during the in vitro study, new cytokines were produced 
that hampered B cell development. Future experiments may be conducted to explore 
the presence of any elevated inhibitory cytokines in such IL-7-driven co-cultures, includ-
ing IFN α/β/γ, IL-1 α/β, IL-4 or TGF-β, or stromal cell chemokines such as CXCL1253 that 
are known to influence B cell development. It is attractive to speculate that local DCs in 
the BM of Tnfaip3CD11c-KO mice have critical effects on B cell differentiation in the BM. It 
would be informative to assess activation markers and cytokines on BM-resident DCs in 
Tnfaip3CD11c-KO mice.
Since BM is a compartment that is difficult to access in humans, relatively little is known 
about possible defects in B cell development in autoimmune patients. A small cohort of 
SLE patients, however, revealed reduced BM CD20+ B cells54, which may parallel our find-
ings of reduced mature B cells in the BM of Tnfaip3CD11c-KO mice. Unstimulated peripheral 
B cells from MS patients and stimulated B cells from SLE patients had elevated CD80/
CD86 expression in comparison to healthy donor B cells55, 56. This also corresponds to our 
in vitro findings in chapter 5 where peripheral mature B cells from Tnfaip3CD11c-KO mice 
expressed higher levels of CD80/CD86 on different stimuli. In an SLE cohort, it was found 
that more apoptotic cells were present in the BM, together with elevated numbers of T 
cells, macrophages and pDCs, thus reflecting a more pro-inflammatory environment54. 
Signs of a type 1 IFN-rich environment in the BM of SLE patients have been found57 and 
it was recently shown that transitional B cells in SLE patients indeed have a type 1, and 
also a type 2 IFN-stimulated signature derived from the BM environment58. All in all, 
understanding of abnormal BM and B cell development in SLE patients may contribute 
to knowledge that is important for the future development of new therapies for this 
autoimmune disease.
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coNclUSIoNS AND FUTUre DIrecTIoNS
Immune cell activation may tip the balance from tolerance to autoimmunity. In all our 
murine studies we deleted A20/TNFAIP3, a negative regulator of NF-ĸB signaling, to lean 
different immune cells towards activation (Figure 2). How relevant is A20 deficiency 
in humans? Besides a very rare disorder, haploinsufficiency of A20 (HA20)30, it is more 
reasonable that subtle defects in A20 expression levels or its induction is affected than 
general A20 deficiency. One TNFAIP3 missense mutation near the OTU domain with the 
most subtle effect on function (T108A/I207L), was seen in Australian families from Maori 
ancestry59. The allele variation was also identified in Denovisan archaic human species, 
but not present in Neanderthals, which lived in the same Siberian cave, suggesting that 
this allele arose after Denovisan and Neanderthal lineage divergence more than 170,000 
years ago59. What could be the advantage of this allele? A heightened immune response 
with e.g. release of TNF-α or CXCL2 could be seen in stimulated PBMCs from these 
families versus controls. Using a humanized mouse model with CRISPR-Cas9 genome 
editing, the authors elegantly demonstrate that the T108A/I207L mutation increases 
survival by 1.8x in male mice compared to WT mice when exposed to coxsackie virus 
infection59. Mice with more severe missense mutations, one of which was based on the 
HA20 phenotype in humans30, never died of this coxsackie virus infection. But this came 
at a price: a range of subclinical spontaneous tissue inflammation was detectable in one 
variation, whereas fatal intestinal inflammation was seen in another. Thus, protection 
from foreign invaders may be more efficient, at the price of suffering from responses e.g. 
to microbes that should be tolerated.
One of A20’s functions is thus to create a balanced immune system, which is primar-
ily important in DCs. We were most interested to study the role of A20/Tnfaip3 in DCs. 
Given the division of labor it is important to study DC subsets specifically, and not as a 
whole population. We have made a first step using the DNGR1-cre model to decipher 
the role of A20/Tnfaip3-depletion primarily in the cDC1 subset. However, more specific 
cre models such as the XCR1-cre or Karma-cre can be used in future experiments to 
ablate A20 in only cDC1s, since the DNGR1-cre model also targets a proportion cDC2s 
and moDCs. When translating findings from murine studies to patients, it is crucial to 
consider this subdivision of DCs. Although human DCs have been properly classified60, 
to date only a few studies on cDC changes in autoimmune patients have been reported. 
The Tnfaip3CD11c-KO model demonstrated the consequence of active DCs, but it raised 
several more questions. When we crossed Tnfaip3CD11c-KO mice to Cd40lgKO mice, we saw 
no class switched IgG, but we did find autoreactive IgA and also IgA depositions in the 
kidneys. Two clinical diseases are known with similar findings: X-linked Hyper-IgM syn-
drome patients lack CD40LG and therefore have drastically reduced class-switched im-
munoglobulins, including reduced levels of IgA61. IgA nephropathy is characterized by a 
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dominance of IgA that leads to deposition in the kidney glomeruli, in contrast to IgG62. 
Although the pathogenesis of these two disorders is different, it appears that they may 
merge in our Cd40lgKOTnfaip3CD11c-KO mice, because we did find IgA depositions in the kid-
ney glomeruli without IgG immunoglobulins present. There are case reports available 
of IgA nephropathy and SLE occurring in the same patients62, 63. Several clinical trials are 
currently performed with anti-CD40L or anti-CD40 biologicals in SLE64, whereby clinical 
activity scores are improved over placebo controls that also include kidney function 
parameters. Our findings, however, suggest that in a diseased state with activated DCs, 
such inhibitors may still result in unexpected outcomes of kidney glomerulonephritis.
The Th17-IL23-axis was contra intuitively not of importance in our model of Tnfaip3-
deficiency in DCs and other myeloid cells, concerning endpoints of kidney glomerulone-
phritis (chapter 7, Figure 2), paw inflammation and neutrophilic airway inflammation 
(chapter 4, Figure 2). Ustekinumab, the biological anti-p40 subunit against both 
IL-23 and IL-12 has been approved for diseases such as Crohn’s disease, psoriasis and 
psoriatic arthritis. It is still under investigation for SLE, although promising results have 
been reported65. Ustekinumab does not seem to be effective in RA66. There are no ongo-
ing clinical trials in asthma, which reflects our findings of similar neutrophilic airway 
inflammation with or without IL-17RA-signaling in a HDM-induced airway inflammation 
model in Tnfaip3LysM-KO mice. It has been demonstrated in one case study, however, that 
Ustekinumab also relieved an asthmatic patient of her chronic airway medication, while 
she was treated for psoriasis67, suggesting that Th17 responses could be underlying 
asthma pathogenesis in some patients. Further investigations are needed to characterize 
the group of asthma patients that may benefit from IL-17 blockade, before ustekinumab 
may be tested in clinical trials for a subgroup of therapeutically refractive patients.
In conclusion, our studies have shown that activated DCs lie at the initiation phase of 
the autoimmune response, with extensive secondary consequences. Blocking an inter-
mediate cytokine sometimes may not inhibit a primary endpoint such as kidney glo-
merulonephritis, because activated DCs can activate multiple cells prior to the release of 
the cytokine in question. Future autoimmunity treatments could be focused on inhibit-
ing NF-κB activation. However, these treatment strategies need to be designed carefully 
as they might reduce acute inflammation, while causing long-lasting side effects. For 
example, interference with NF-κB in enterocytes prevented systemic inflammation in an 
intestinal-ischemia reperfusion model, but led to apoptotic mucosal damage as well68, 
since NF-κB acts as an anti-apoptotic factor. For that reason, NF-κB blockade has already 
been an attractive candidate in cancer therapy NF-κB69. While IKK inhibitors pose toxic-
ity issues, a lot of research is conducted to pharmacologically modulate ubiquitination 
and degradation of NF-κB components69, thus nearing the functions of A20. Another 
therapeutic option in accordance to our findings, would be to treat autoimmunity with 
tolerogenic DCs. To date, two studies with the induction of tolerogenic DCs with an 
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AMPK activator and an AhR antagonist showed promising results in SLE70. Perhaps the 
induction of tolerogenic-DCs holds a future in the treatment or prevention of autoim-
mune diseases, and should thus be investigated.
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Our immune system consists of a complex network of multiple players. These serve to 
keep foreign pathogens away, while tolerating our own proteins or harmless organ-
isms. In other words, the immune system requires a balance between immunity on one 
hand, and tolerance on the other hand. Excessive activation can tip the balance into 
the domain of autoimmune disorders. Typical autoimmune disorders are rheumatoid 
arthritis, inflammatory bowel disease (IBD), psoriasis and systemic lupus erythematosus 
(SLE). It is estimated that within Europe and USA 6-7% of the population has a diagnosed 
autoimmune disorder. Studying the pathogenesis of autoimmune disorders has been an 
ongoing quest, as many immune cells take part in it.
Genome-wide association studies (GWAS) reveal a wide range of genes that could be 
implicated in autoimmune disorders. One of these genes, TNFAIP3 (A20), is associated to 
multiple autoimmune disorders and is a protein that inhibits the NF-κB pathway that is 
essential for the activation and survival of many immune cells. In simple terms, A20/TN-
FAIP3 is one of the most important brake-mechanism protein on immune cell activation.
A unique immune cell, discovered in the 1970s by Nobel laureate Ralph Steinman, 
termed dendritic cells, is the prime orchestrator of the balance of the immune system. By 
genetic engineering in mice, the Tnfaip3 gene could specifically be removed from DCs, 
which resulted in their activation. This led to activation of several other primary immune 
cells such as T cells and B cells, and a phenotype that resembled human autoimmune 
diseases. Our group saw a phenotype resembling SLE, while another research group 
documented a phenotype of inflammatory bowel disease.
In chapter 2 we highlight all mouse models known to date in which a targeted dele-
tion of the Tnfaip3 gene was performed in different immune cells that are known to be 
involved in autoimmune disorders. We summarize small DNA mutations (single nucleo-
tide polymorphisms (SNPs)) in the human A20/TNFAIP3 locus that have functional and 
therapeutic consequences for autoimmune patients.
While the population of DCs became more defined over the course of the last 10 years, 
we utilized a specific Cre-LoxP model (Dngr1-cre) to delete the A20/Tnfaip3 gene from 
the conventional type 1 DC (cDC1s) (chapter 3). We found that cDC1s were also acti-
vated in these mice, and that by the age of ~31 weeks they developed autoimmune liver 
inflammation. T cells and B cells were activated, which resulted in antibody producing 
cells (plasma cells) that made auto-antibodies of the IgA isotype to components of liver 
cells.
Another highlight in autoimmune research was the unraveling of the Th17/IL-23 axis, 
which is important in autoimmune diseases such as arthritis, IBD and psoriasis, but also 
in other chronic diseases such as asthma. In a house dust mite (HDM)-driven model of 
airway inflammation, our group demonstrated previously that deficiency of Tnfaip3/A20 
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in myeloid cells lead to neutrophilic rather than eosinophilic airway infiltration, which 
condition might resemble therapy-resistant asthma patients. We determined whether 
neutrophilic infiltrates would be reduced in the absence of IL-17 receptor A (IL-17RA) sig-
naling (chapter 4), because IL-17 is known to control neutrophil attractants such as the 
CXCL1 chemokine production by airway epithelial cells. Surprisingly, this did not seem 
to be the case, as other cytokines including IL-1β, IL-23 and GM-CSF, which also have 
the capacity to induce neutrophilic-attracting chemokines, were still produced. We also 
determined whether the arthritis-like phenotype in mice that lack Tnfaip3 in myeloid 
cells was reduced in the absence of IL-17RA-signaling (chapter 4). The paw inflamma-
tion seen in these aged mice was not dependent on IL-17, but was later demonstrated 
by another group to be mostly driven by IL-1β.
When studying Tnfaip3CD11c-KO mice, that developed an SLE-like phenotype, we noticed 
a reduction of B cells in the spleens of aged mice. This could be explained by a develop-
ment disorder of B cells in the bone marrow. We thus examined all developmental stages 
of B cells in young and aged mice in chapter 5. We found that B cell development in the 
bone marrow was hampered at the immature B cell stage in 6-week-old Tnfaip3CD11c-KO 
mice and at the pre-B cell stage in 24-week-old Tnfaip3CD11c-KO mice. The developmental 
disorder might well explain the reduced numbers of mature B cells in the periphery of 
aged Tnfaip3CD11c-KO mice. Using in vitro studies, we determined that systemic effects of 
DC activation leading to changes in the cytokine milieu in bone marrow was most likely 
not responsible for the observed defect in B cell development. Rather, the observed 
age-dependent developmental arrest of B-lineage cells most likely reflected changes 
in non-B cells, most likely A20/Tnfaip3-deficient DCs in the bone marrow. This indicated 
that activated DCs in a different compartment than spleen, such as bone marrow, could 
also hamper B cell development and perhaps their function. Interestingly, B cells that 
reached the periphery were more easily activated compared to B cells from healthy mice.
Antibody producing plasma cells are derived from B cells. The normal route of B cell 
activation is as follows: DCs activate T cells, and they in turn activate B cells. However, in 
certain circumstances DCs can also directly activate B cells without the help of T cells. It 
had been previously demonstrated that A20/Tnfaip3-deficient bone marrow DCs could 
activate B cells in in vitro, independently of T cell help. In chapter 6, we determined 
whether T cell-independent activation of B cells also occurs in a mice in vivo, if we would 
disable T-B cell communication by abrogating CD40L expression in mice lacking A20 
in dendritic cells. CD40L is an essential protein expressed on activated T cells that is 
essential for their capacity to support B cell activation. Although T-B cell communica-
tion was required to achieve germinal centers and IgG1 antibody production, we found 
that antibodies of the IgA subclass could still be formed. Kidney glomerular basement 
membrane thickening was also seen, despite the absence of IgG induction, possibly 
facilitated by IgA depositions that we could demonstrate in the kidneys of a consider-
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able fraction of CD40L-deficient mice with CD11c-Cre-driven deletion of the A20/Tnfaip3 
gene.
Since Th17 cells are so important in autoimmunity, and their development is facili-
tated by IL-23, we wondered how Th17 cell homeostasis would be affected if we induce 
IL-23-deficiency in mice with abrogated Tnfaip3 expression from DCs (chapter 7). 
Surprisingly, Th17 cell homeostasis was not altered in absence of IL-23. Levels of im-
munoglobulins, autoreactive immunoglobulins and kidney glomerular changes were 
also unaltered in these mice. We thus concluded that the SLE phenotype seen in mice 
with Tnfaip3-deficient DCs was independent of the Th17/IL-23 axis.
Taken together, DCs maintain the balance between tolerance to autoimmunity. The 
A20/Tnfaip3 protein in DCs helps in keeping the balance: loss of this protein tips the im-
mune system into a state of autoimmunity. By utilizing several genetic mouse models of 
targeted A20/Tnfaip3 deletion from specific DC subsets, we have seen that the absence 
of A20/Tnfaip3 can result in different autoimmune phenotypes, e.g. an autoimmune 
liver phenotype or SLE. In more detail, the SLE phenotype is quite robust, because de-
spite inhibiting the Th17/IL-23 axis or T-B cell communication, the mice still developed 
a disease phenotype with characteristics of SLE. This highlights that future of therapies 
may need to be targeted to the start of an autoimmune reaction, for example at the level 
of DCs, because at a later point in disease development many other immune players and 
cytokines are involved, perhaps irreversibly. Those future therapies will be crucial to help 




Ons immuunsystem bestaat uit een complex netwerk van verschillende immunologische 
spelers. Zij werken samen om vreemde lichamen zoals virussen en bacteriën te weren, 
terwijl ze andere eiwitten of organismen welke ongevaarlijk zijn moeten tolereren. Met 
andere woorden: ons immuunsysteem heeft een balans nodig tussen immuniteit aan de 
ene kant en tolerantie aan de andere kant. Te veel activatie van het immuunsysteem leidt 
tot gezondheidsproblemen op het gebied van auto-immuunziekten, waarin lichaamsei-
gen eiwitten worden aangevallen. Karakteristieke auto-immuunziekten zijn reumatoïde 
artritis, inflammatoire darm aandoeningen (IBD), psoriasis en systemische lupus erytho-
matodes (SLE). Naar schatting heeft 6 à 7% van de Europese en Amerikaanse bevolking 
een auto-immuun aandoening. Onderzoek naar het ontstaan van auto-immuunziekten 
is een zoektocht die al tientallen jaren speelt vanwege de complexiteit van de vele im-
muuncellen die er aan deelnemen.
Door genetisch onderzoek via genoombrede associatie studies zijn vele genen ge-
vonden die betrokken kunnen zijn bij auto-immuun aandoeningen. Één van die genen 
is TNFAIP3 (ook bekend als A20), welke geassocieerd is met verscheidene auto-immuun 
ziekten. Het is een eiwit dat de NF-κB signaleringsroute remt, die zeer belangrijk is voor 
cel activatie en overleving. Eenvoudig gezegd: TNFAIP3/A20 is één van de belangrijkste 
regulatoren die als rem functioneert in immuuncel activatie.
Eén unieke immuuncel, de dendritische cel (DC), ontdekt in de jaren ‘70 door Nobel-
prijswinnaar Ralph Steinman, is de dirigent van het immuunsysteem. Door middel van 
extra signalen op het celoppervlak (co-stimulatoire en co-inhibitoire moleculen) kan 
de DC bepalen of een volgende immuuncel, de T cel, geactiveerd wordt. Met behulp 
van genetische muismodellen is het mogelijk om Tnfaip3/A20 specifiek weg te halen 
in een enkel celtype, bijvoorbeeld de DC. Dit leidt dan tot spontane activatie van deze 
DCs. Als je deze muizen, die A20/Tnfaip3 missen uit DCs (deze zijn Tnfaip3CD11c-KO muizen 
genoemd), oud laat worden treedt activatie op van andere immuuncellen, zoals T en B 
cellen. Als gevolg daarvan ontwikkelen deze dieren een ziektebeeld dat grote overeen-
komsten vertoont met autoimmuunziekten bij de mens. Onze groep heeft aangetoond 
dat Tnfaip3CD11c-KO muizen SLE-achtige verschijnselen ontwikkelen, terwijl een andere 
onderzoeksgroep heeft laten zien dat vergelijkbare muizen een IBD ziektebeeld kunnen 
ontwikkelen. In Hoofdstuk 2 geven we een overzicht van de nu bekende muismodellen 
waarin A20/Tnfaip3 specifiek is verwijderd uit verschillende immunologische cellen die 
een rol spelen bij autoimmuun reacties. We noemen ook de kleine DNA variaties (de zgn. 
enkel-nucleotide polymorfismen of SNPs) die bij patiënten worden gevonden en een 
mogelijke verklaring kunnen zijn voor functionele veranderingen in hun immuunsys-
teem en mogelijk therapeutische consequenties hebben.
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Doordat de populatie van DCs steeds beter gedefinieerd werd in de laatste 10 jaar, 
werd ook steeds duidelijker dat er verschillende DC typen waren. Onze interesse viel op 
een nieuw genetisch model om A20/Tnfaip3 specifiek te verwijderen uit een subtype 
van DCs, de zgn. conventioneel type 1 dendritische cel (cDC1) (Hoofdstuk 3). We zagen 
in deze Tnfaip3Dngr1-KO muizen dat de cDC1s inderdaad geactiveerd raakten en dat rond 
de leeftijd van 31 weken deze muizen een autoimmuun leverontsteking hadden ontwik-
keld. T cellen en B cellen waren geactiveerd en er waren antistof producerende cellen 
(plasma cellen) aantoonbaar, die antistoffen van het IgA isotype tegen lichaamseigen 
levereiwitten produceerden.
Nog een belangrijke ontwikkeling in het onderzoek over auto-immuun ziekten 
was de ontdekking van de Th17 cel, die de belangrijke signaalstof, het IL-17 cytokine, 
produceert. De zgn. Th17/IL-23 as van inflammatoire cytokinen en de Th17 cel bleek 
betrokken te zijn bij auto-immuun ziekten zoals reuma, IBD en psoriasis, maar ook bij 
andere chronische aandoeningen zoals astma. In een huisstofmijt-geïnduceerd model 
van luchtwegontsteking in muizen met myeloïde cel-specifieke deficiëntie van A20/
Tnfaip3 (Tnfaip3LysM-KO) heeft onze groep eerder aangetoond dat muizen een neutrofiel 
infiltraat in de longen ontwikkelden in tegenstelling tot een eosinofiel infiltraat. Een der-
gelijk ziekteprofiel met een neutrofiel infiltraat in de longen vertoont overeenkomsten 
met het immunologisch profiel van patiënten met moeilijk te behandelen astma. We 
vroegen ons af of de aantrekking en opeenhoping van neutrofielen zou afnemen als we 
de signaalstof IL-17 zouden wegnemen, aangezien IL-17 betrokken is bij de productie 
van stoffen die neutrofielen aantrekken zoals het CXCL1 chemokine dat door de cellen 
van de luchtwegwand wordt geproduceerd onder invloed van IL-17 (Hoofdstuk 4). In 
tegenstelling tot onze verwachting bleek dit niet het geval te zijn, aangezien andere 
cytokinen zoals IL-1β, IL-23 en GM-CSF nog steeds geproduceerd werden en deze ook in 
luchtwandcellen de productie van chemokinen die neutrofielen aantrekken kunnen sti-
muleren. We hebben in deze myeloid-specifieke Tnfaip3-deficiënte Tnfaip3LysM-KO muizen 
ook gekeken naar een reuma-achtig ziektebeeld dat door een andere onderzoeksgroep 
was beschreven, en onderzocht of dergelijke ziekteverschijnselen zouden afnemen in 
afwezigheid van IL-17 receptor signalering. Dit bleek ook niet het geval te zijn. Later 
werd aangetoond in een ander onderzoek dat cytokine IL-1β hoofdverantwoordelijk is 
voor het reuma-achtig beeld in myeloid-specifieke Tnfaip3-deficiënte muizen.
Tijdens het bestuderen van de muis welke dendritische cel-specifiek Tnfaip3-deficient 
is (Tnfaip3CD11c-KO muizen) en een SLE-achtig beeld ontwikkeld, viel het ons op dat de 
B cellen aanzienlijk verminderd waren in de milt. Omdat deze bevinding wijst op een 
defect in de aanmaak van B cellen in het beenmerg hebben we in hoofdstuk 5 de 
ontwikkeling van B cellen onderzocht in zowel jonge als oudere Tnfaip3CD11c-KO muizen. 
Er bleek een leeftijdsafhankelijke B cel ontwikkelingsstoornis te zijn, gekenmerkt door 
een sterke blokkade op het immature B cel en het eerdere pre-B cel stadium in, respec-
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tievelijk, 6 en 24 weken oude Tnfaip3CD11c-KO muizen. Deze stoornis is een aannemelijke 
verklaring voor de afname van B cellen in perifere lymphoïde organen zoals de milt op 
oudere leeftijd. Door laboratoriumproeven in een beenmerg celkweek systeem hebben 
we kunnen aantonen dat circulerende signaalstoffen waarschijnlijk niet de afwijking in 
B cel ontwikkeling probleem induceren, maar dat Tnfaip3-deficiëntie DCs in het been-
merg zelf waarschijnlijk deze afwijkingen in de B cel ontwikkeling veroorzaken. Een 
andere interessante bevinding was dat volgroeide B cellen die het beenmerg verlaten, 
wel gemakkelijker geactiveerd raken op eenzelfde stimulus dan B cellen uit een normale 
gezonde muis. Onze proeven laten zien dat de geactiveerde DCs in ons muis model 
ook in een ander orgaan dan de milt, zoals dus in het beenmerg, B cel ontwikkeling kan 
verstoren en mogelijk hun uiteindelijke functie kan beïnvloeden.
Normaalgesproken verloopt de activatie van B cellen via antigeen presenterende cel-
len zoals DCs, die T cellen activeren, die vervolgens hulp bieden aan B cellen in nauwe 
B-T cel interactie. Er is echter aangetoond dat Tnfaip3-deficiënte DCs, zonder de hulp van 
T cellen, in een celkweeksysteem (in vitro) B cellen konden activeren. In hoofdstuk 6, 
vroegen we ons af of deze directe activatie van B cellen door Tnfaip3-deficiënte DCs ook 
in de muis (in vivo) plaatsvindt. Om dit te onderzoeken hebben we T en B cel communi-
catie geblokkeerd door genetisch tevens CD40L weg te halen (een eiwit dat door de T 
cel na activatie op het celoppervlak wordt gezet en dat belangrijk is voor functionele T-B 
cel interactie). Deze T-B cel communicatie bleek essentieel te zijn voor het ontwikkelen 
van kiemcentrum B cellen, een subgroep van B cellen die zich bevinden in kiemcentra 
waar B cellen na activatie een interactie aangaan met T cellen om vervolgens verder te 
kunnen uitrijpen o.a. tot antistof-producerende plasma cellen. In de afwezigheid van 
CD40L werd er geen IgG1 gevormd, maar vonden we dat een andere antistof, IgA, wel 
gevormd kon worden. Het circulerende IgA in het serum bevatte ook reactiviteit tegen 
lichaamseigen stoffen. Structurele veranderingen in de glomeruli – dit zijn de kluwens 
van haarvaatjes die belangrijk zijn voor de bloedfiltratie in de nier – die passen bij een 
SLE beeld, werden nog steeds aangetroffen ondanks de afwezigheid van IgG.
Omdat Th17 cellen zo belangrijk zijn in auto-immuunziekten en hun ontwikkeling 
ondersteund wordt door IL-23, vroegen we ons af of de auto-immuun afwijkingen in 
Tnfaip3CD11c-KO muizen zouden verminderen in de afwezigheid van IL-23 (Hoofdstuk 7). 
In tegenstelling tot de verwachting, was de ontwikkeling van Th17 cellen niet verstoord 
in afwezigheid van IL-23. Ook het niveau van antistoffen, ook die tegen lichaamseigen 
eiwitten zoals dubbelstrengs DNA in het serum en afwijkingen in de nieren was bij de 
IL-23-deficiënte Tnfaip3CD11c-KO niet veranderd ten opzichte van Tnfaip3CD11c-KO die wel 
IL-23 konden maken. We concludeerden dus dat het SLE fenotype in deze Tnfaip3CD11c-KO 
muizen onafhankelijk was van de Th17/IL-23 as.
Samenvattend is de DC belangrijk om een goede balans tussen tolerantie en immuni-
teit te bewaren. Het Tnfaip3/A20 eiwit in DCs speelt hierin een cruciale rol, want als DCs 
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dit eiwit missen slaat het immuun systeem teveel door richting auto-immuniteit. Door 
gebruik te maken van verschillende genetische muismodellen waarbij we heel specifiek 
bepaalde DC subgroepen deficiënt konden maken voor Tnfaip3/A20, zagen we dat 
deze muizen verschillende auto-immuun ziektebeelden ontwikkelden. Deze varieerden 
van auto-immuun leverontsteking tot een algehele immuunontsteking die duidelijke 
overeenkomsten had met SLE. Dit SLE beeld bleek robuust: ook als we T-B cel interactie 
of de Th17/IL-23 as blokkeerden waren er nog steeds diverse kenmerken van SLE meet-
baar. Deze bevindingen benadrukken dat de toekomstige therapie ontwikkeling voor 
auto-immuunziekten gericht zou moeten zijn op ingrijpen in een vroeg stadium van het 
ziekteproces, zoals op het niveau van DCs. In een later stadium van de ziekte zijn er veel 
andere immuuncellen en signaalstoffen betrokken, waardoor het moeilijker wordt een 
afdoende effect van de behandeling te verkrijgen. Het is dus belangrijk om de DCs te 
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